BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Oettle H, Neuhaus P, Hochhaus A, Hartmann JT, Gellert K, Ridwelski K, Niedergethmann M, Zülke C, Fahlke J, Arning MB, Sinn M, Hinke A, Riess H. Adjuvant Chemotherapy With Gemcitabine and Long-term Outcomes Among Patients With Resected Pancreatic Cancer: The CONKO-001 Randomized Trial. JAMA 2013;310:1473. [DOI: 10.1001/jama.2013.279201] [Cited by in Crossref: 923] [Cited by in F6Publishing: 708] [Article Influence: 115.4] [Reference Citation Analysis]
Number Citing Articles
1 Nitta T, Fujii K, Kataoka J, Tominaga T, Kawasaki H, Ishibashi T. A case of long-term 24-month survival in pancreatic anaplastic carcinoma (giant cell type) after S1 postoperative adjuvant chemotherapy. Int J Surg Case Rep 2016;23:134-7. [PMID: 27111877 DOI: 10.1016/j.ijscr.2016.04.013] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
2 Riva F, Dronov OI, Khomenko DI, Huguet F, Louvet C, Mariani P, Stern MH, Lantz O, Proudhon C, Pierga JY. Clinical applications of circulating tumor DNA and circulating tumor cells in pancreatic cancer. Mol Oncol. 2016;10:481-493. [PMID: 26856794 DOI: 10.1016/j.molonc.2016.01.006] [Cited by in Crossref: 48] [Cited by in F6Publishing: 37] [Article Influence: 9.6] [Reference Citation Analysis]
3 Väyrynen SA, Zhang J, Yuan C, Väyrynen JP, Dias Costa A, Williams H, Morales-Oyarvide V, Lau MC, Rubinson DA, Dunne RF, Kozak MM, Wang W, Agostini-Vulaj D, Drage MG, Brais L, Reilly E, Rahma O, Clancy T, Wang J, Linehan DC, Aguirre AJ, Fuchs CS, Coussens LM, Chang DT, Koong AC, Hezel AF, Ogino S, Nowak JA, Wolpin BM. Composition, Spatial Characteristics, and Prognostic Significance of Myeloid Cell Infiltration in Pancreatic Cancer. Clin Cancer Res 2021;27:1069-81. [PMID: 33262135 DOI: 10.1158/1078-0432.CCR-20-3141] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
4 Denbo JW, Fleming JB. Definition and Management of Borderline Resectable Pancreatic Cancer. Surg Clin North Am 2016;96:1337-50. [PMID: 27865281 DOI: 10.1016/j.suc.2016.07.008] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
5 Ahn DH, Williams TM, Goldstein DA, El-Rayes B, Bekaii-Saab T. Adjuvant therapy for pancreas cancer in an era of value based cancer care. Cancer Treat Rev 2016;42:10-7. [PMID: 26620819 DOI: 10.1016/j.ctrv.2015.11.004] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 2.3] [Reference Citation Analysis]
6 Korkeila EA. Advanced pancreatic cancer - how to choose an adequate treatment option. World J Gastroenterol 2015;21:10709-13. [PMID: 26478662 DOI: 10.3748/wjg.v21.i38.10709] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
7 Alzhrani R, Alsaab HO, Vanamal K, Bhise K, Tatiparti K, Barari A, Sau S, Iyer AK. Overcoming the Tumor Microenvironmental Barriers of Pancreatic Ductal Adenocarcinomas for Achieving Better Treatment Outcomes. Adv Ther (Weinh) 2021;4:2000262. [PMID: 34212073 DOI: 10.1002/adtp.202000262] [Reference Citation Analysis]
8 Lee YS, Lee JC, Yang SY, Kim J, Hwang JH. Neoadjuvant therapy versus upfront surgery in resectable pancreatic cancer according to intention-to-treat and per-protocol analysis: A systematic review and meta-analysis. Sci Rep 2019;9:15662. [PMID: 31666626 DOI: 10.1038/s41598-019-52167-9] [Cited by in Crossref: 10] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
9 Wolfe AR, Wald P, Webb A, Sebastian N, Walston S, Robb R, Chen W, Vedaie M, Dillhoff M, Frankel WL, Kwon W, Jang JY, Williams TM. A microRNA-based signature predicts local-regional failure and overall survival after pancreatic cancer resection. Oncotarget 2020;11:913-23. [PMID: 32206188 DOI: 10.18632/oncotarget.27496] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
10 Kurahara H, Shinchi H, Ohtsuka T, Miyasaka Y, Matsunaga T, Noshiro H, Adachi T, Eguchi S, Imamura N, Nanashima A, Sakamoto K, Nagano H, Ohta M, Inomata M, Chikamoto A, Baba H, Watanabe Y, Nishihara K, Yasunaga M, Okuda K, Natsugoe S, Nakamura M. Significance of neoadjuvant therapy for borderline resectable pancreatic cancer: a multicenter retrospective study. Langenbecks Arch Surg 2019;404:167-74. [DOI: 10.1007/s00423-019-01754-5] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 5.0] [Reference Citation Analysis]
11 Lim SA, Kim J, Jeon S, Shin MH, Kwon J, Kim TJ, Im K, Han Y, Kwon W, Kim SW, Yee C, Kim SJ, Jang JY, Lee KM. Defective Localization With Impaired Tumor Cytotoxicity Contributes to the Immune Escape of NK Cells in Pancreatic Cancer Patients. Front Immunol. 2019;10:496. [PMID: 31024520 DOI: 10.3389/fimmu.2019.00496] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 9.0] [Reference Citation Analysis]
12 Liedtke KR, Freund E, Hermes M, Oswald S, Heidecke CD, Partecke LI, Bekeschus S. Gas Plasma-Conditioned Ringer's Lactate Enhances the Cytotoxic Activity of Cisplatin and Gemcitabine in Pancreatic Cancer In Vitro and In Ovo. Cancers (Basel) 2020;12:E123. [PMID: 31906595 DOI: 10.3390/cancers12010123] [Cited by in Crossref: 13] [Cited by in F6Publishing: 7] [Article Influence: 13.0] [Reference Citation Analysis]
13 Matsumoto I, Tanaka M, Shirakawa S, Shinzeki M, Toyama H, Asari S, Goto T, Yamashita H, Ishida J, Ajiki T, Fukumoto T, Shimokawa M, Ku Y. Postoperative Serum Albumin Level is a Marker of Incomplete Adjuvant Chemotherapy in Patients with Pancreatic Ductal Adenocarcinoma. Ann Surg Oncol 2015;22:2408-15. [PMID: 25487967 DOI: 10.1245/s10434-014-4280-7] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 2.6] [Reference Citation Analysis]
14 Akita H, Takahashi H, Asukai K, Tomokuni A, Wada H, Marukawa S, Yamasaki T, Yanagimoto Y, Takahashi Y, Sugimura K, Yamamoto K, Nishimura J, Yasui M, Omori T, Miyata H, Ochi A, Kagawa A, Soh Y, Taniguchi Y, Ohue M, Yano M, Sakon M. The utility of nutritional supportive care with an eicosapentaenoic acid (EPA)-enriched nutrition agent during pre-operative chemoradiotherapy for pancreatic cancer: Prospective randomized control study.Clin Nutr ESPEN. 2019;33:148-153. [PMID: 31451252 DOI: 10.1016/j.clnesp.2019.06.003] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 3.5] [Reference Citation Analysis]
15 Sawicka E, Mirończuk A, Wojtukiewicz MZ, Sierko E. Chemoradiotherapy for locally advanced pancreatic cancer patients: is it still an open question? Contemp Oncol (Pozn) 2016;20:102-8. [PMID: 27358587 DOI: 10.5114/wo.2016.60066] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
16 Jang WI, Kim MS, Kang SH, Jo AJ, Kim YJ, Tchoe HJ, Park CM, Kim HJ, Choi JA, Choi HJ, Paik EK, Seo YS, Yoo HJ, Kang JK, Han CJ, Kim SB, Ko MJ. Association between metformin use and mortality in patients with type 2 diabetes mellitus and localized resectable pancreatic cancer: a nationwide population-based study in korea. Oncotarget. 2017;8:9587-9596. [PMID: 28077783 DOI: 10.18632/oncotarget.14525] [Cited by in Crossref: 26] [Cited by in F6Publishing: 25] [Article Influence: 8.7] [Reference Citation Analysis]
17 Butler JR, Ahmad SA, Katz MH, Cioffi JL, Zyromski NJ. A systematic review of the role of periadventitial dissection of the superior mesenteric artery in affecting margin status after pancreatoduodenectomy for pancreatic adenocarcinoma. HPB (Oxford) 2016;18:305-11. [PMID: 27037198 DOI: 10.1016/j.hpb.2015.11.009] [Cited by in Crossref: 32] [Cited by in F6Publishing: 22] [Article Influence: 6.4] [Reference Citation Analysis]
18 Tung S, Davis LE, Hallet J, Mavros MN, Mahar AL, Bubis LD, Hammad A, Zhao H, Earle CC, Barbera L, Coburn NG, Siqqidui M, Li Q, Elmi M, Shin E, Hsieh E, Goyert N; Pancreas Cancer Population Outcomes Research Group. Population-Level Symptom Assessment Following Pancreaticoduodenectomy for Adenocarcinoma. JAMA Surg 2019;154:e193348. [PMID: 31483457 DOI: 10.1001/jamasurg.2019.3348] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 4.0] [Reference Citation Analysis]
19 Dong Q, Li C, Che X, Qu J, Fan Y, Li X, Li Y, Wang Q, Liu Y, Yang X, Qu X. MicroRNA-891b is an independent prognostic factor of pancreatic cancer by targeting Cbl-b to suppress the growth of pancreatic cancer cells. Oncotarget 2016;7:82338-53. [PMID: 27494897 DOI: 10.18632/oncotarget.11001] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 4.7] [Reference Citation Analysis]
20 Samawi HH, Yin Y, Lim HJ, Cheung WY. Primary Care Versus Oncology-Based Surveillance Following Adjuvant Chemotherapy in Resected Pancreatic Cancer. J Gastrointest Canc 2018;49:429-36. [DOI: 10.1007/s12029-017-9988-8] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
21 Lee JC, Ahn S, Paik KH, Kim HW, Kang J, Kim J, Hwang JH. Clinical impact of neoadjuvant treatment in resectable pancreatic cancer: a systematic review and meta-analysis protocol. BMJ Open 2016;6:e010491. [PMID: 27016245 DOI: 10.1136/bmjopen-2015-010491] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
22 Siebenhüner AR, Seifert H, Bachmann H, Seifert B, Winder T, Feilchenfeldt J, Breitenstein S, Clavien PA, Stupp R, Knuth A, Pestalozzi B, Samaras P. Adjuvant treatment of resectable biliary tract cancer with cisplatin plus gemcitabine: A prospective single center phase II study. BMC Cancer 2018;18:72. [PMID: 29325521 DOI: 10.1186/s12885-017-3967-0] [Cited by in Crossref: 14] [Cited by in F6Publishing: 8] [Article Influence: 4.7] [Reference Citation Analysis]
23 Freund E, Miebach L, Stope MB, Bekeschus S. Hypochlorous acid selectively promotes toxicity and the expression of danger signals in human abdominal cancer cells. Oncol Rep 2021;45:71. [PMID: 33760187 DOI: 10.3892/or.2021.8022] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
24 Zhu X, Li F, Ju X, Cao F, Cao Y, Fang F, Qing S, Shen Y, Jia Z, Zhang H. Prognostic role of stereotactic body radiation therapy for elderly patients with advanced and medically inoperable pancreatic cancer. Cancer Med 2017;6:2263-70. [PMID: 28834410 DOI: 10.1002/cam4.1164] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 3.0] [Reference Citation Analysis]
25 Hyde AJ, Nassabein R, AlShareef A, Armstrong D, Babak S, Berry S, Bossé D, Chen E, Colwell B, Essery C, Goel R, Goodwin R, Gray S, Hammad N, Jeyakuymar A, Jonker D, Karanicolas P, Lamond N, Letourneau R, Michael J, Patil N, Powell E, Ramjeesingh R, Saliba W, Singh R, Snow S, Stuckless T, Tadros S, Tehfé M, Thana M, Thirlwell M, Vickers M, Virik K, Welch S, Asmis T. Eastern Canadian Gastrointestinal Cancer Consensus Conference 2018. Curr Oncol 2019;26:e665-81. [PMID: 31708660 DOI: 10.3747/co.26.5193] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
26 Regine WF, Winter K, Abrams RA, Safran H, Kessel IL, Chen Y, Fugazzi JA, Donnelly ED, DiPetrillo TA, Narayan S, Plastaras JP, Gaur R, Delouya G, Suh JH, Meyer JE, Haddock MG, Didolkar MS, Padula GDA, Johnson D, Hoffman JP, Crane CH. Postresection CA19-9 and margin status as predictors of recurrence after adjuvant treatment for pancreatic carcinoma: Analysis of NRG oncology RTOG trial 9704. Adv Radiat Oncol 2018;3:154-62. [PMID: 29904740 DOI: 10.1016/j.adro.2018.01.003] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
27 de Geus SWL, Kasumova GG, Eskander MF, Ng SC, Kent TS, James Moser A, Vahrmeijer AL, Callery MP, Tseng JF. Is Neoadjuvant Therapy Sufficient in Resected Pancreatic Cancer Patients? A National Study. J Gastrointest Surg 2018;22:214-25. [PMID: 29235000 DOI: 10.1007/s11605-017-3541-8] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 3.5] [Reference Citation Analysis]
28 Barnes CA, Aldakkak M, Clarke CN, Christians KK, Bucklan D, Holt M, Tolat P, Ritch PS, George B, Hall WA, Erickson BA, Evans DB, Tsai S. Value of Pretreatment 18F-fluorodeoxyglucose Positron Emission Tomography in Patients With Localized Pancreatic Cancer Treated With Neoadjuvant Therapy. Front Oncol. 2020;10:500. [PMID: 32363161 DOI: 10.3389/fonc.2020.00500] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
29 Cui J, Guo Y, Wu H, Xiong J, Peng T. Everolimus regulates the activity of gemcitabine-resistant pancreatic cancer cells by targeting the Warburg effect via PI3K/AKT/mTOR signaling. Mol Med 2021;27:38. [PMID: 33849427 DOI: 10.1186/s10020-021-00300-8] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
30 Zhu F, Wang H, Guirguis A, Ashamalla H. The Value of Total Lymph Nodes Examined and Number of Positive Lymph Nodes in Determining the Role of Adjuvant Radiation in Pancreatic Cancer Patients. Pancreas 2020;49:435-41. [PMID: 32132517 DOI: 10.1097/MPA.0000000000001512] [Reference Citation Analysis]
31 Tomihara H, Yamada D, Eguchi H, Iwagami Y, Noda T, Asaoka T, Wada H, Kawamoto K, Gotoh K, Takeda Y, Tanemura M, Mori M, Doki Y. MicroRNA-181b-5p, ETS1, and the c-Met pathway exacerbate the prognosis of pancreatic ductal adenocarcinoma after radiation therapy. Cancer Sci 2017;108:398-407. [PMID: 28064436 DOI: 10.1111/cas.13159] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 5.0] [Reference Citation Analysis]
32 Lidsky ME, Sun Z, Nussbaum DP, Adam MA, Speicher PJ, Blazer DG 3rd. Going the Extra Mile: Improved Survival for Pancreatic Cancer Patients Traveling to High-volume Centers. Ann Surg 2017;266:333-8. [PMID: 27429020 DOI: 10.1097/SLA.0000000000001924] [Cited by in Crossref: 73] [Cited by in F6Publishing: 27] [Article Influence: 18.3] [Reference Citation Analysis]
33 Goel N, Reddy SS. Randomized Clinical Trials in Pancreatic Cancer. Surg Oncol Clin N Am 2017;26:767-90. [PMID: 28923230 DOI: 10.1016/j.soc.2017.05.005] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
34 Kruger S, Haas M, Burger PJ, Ormanns S, Modest DP, Westphalen CB, Michl M, Kleespies A, Angele MK, Hartwig W, Bruns CJ, Niyazi M, Roeder F, Kirchner T, Werner J, Heinemann V, Boeck S. Isolated pulmonary metastases define a favorable subgroup in metastatic pancreatic cancer. Pancreatology 2016;16:593-8. [PMID: 27067420 DOI: 10.1016/j.pan.2016.03.016] [Cited by in Crossref: 36] [Cited by in F6Publishing: 23] [Article Influence: 7.2] [Reference Citation Analysis]
35 Li X, Xu F, He Y, Li Y, Hou J, Yang G, Zhou S. A Hierarchical Structured Ultrafine Fiber Device for Preventing Postoperative Recurrence and Metastasis of Breast Cancer. Adv Funct Mater 2020;30:2004851. [DOI: 10.1002/adfm.202004851] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
36 Bakens MJAM, Lemmens VEPP, de Hingh IHJT. Socio-economic status influences the likelihood of undergoing surgical treatment for pancreatic cancer in the Netherlands. HPB (Oxford) 2017;19:443-8. [PMID: 28223043 DOI: 10.1016/j.hpb.2017.01.010] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.8] [Reference Citation Analysis]
37 Kim HW, Lee JC, Lee J, Kim JW, Kim J, Hwang JH. Early versus delayed initiation of adjuvant treatment for pancreatic cancer. PLoS One 2017;12:e0173960. [PMID: 28301556 DOI: 10.1371/journal.pone.0173960] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 2.5] [Reference Citation Analysis]
38 Taboada AGM, Lominchar PL, Roman LM, García-Alfonso P, Martin AJM, Rodriguez JAB, Pascual JMA. Advances in neoadjuvant therapy for resectable pancreatic cancer over the past two decades. Ann Hepatobiliary Pancreat Surg 2021;25:179-91. [PMID: 34053920 DOI: 10.14701/ahbps.2021.25.2.179] [Reference Citation Analysis]
39 Roland CL, Katz MH, Tzeng CW, Lin H, Varadhachary GR, Shroff R, Javle M, Fogelman D, Wolff RA, Vauthey JN, Crane CH, Lee JE, Fleming JB. The Addition of Postoperative Chemotherapy is Associated with Improved Survival in Patients with Pancreatic Cancer Treated with Preoperative Therapy. Ann Surg Oncol. 2015;22 Suppl 3:S1221-S1228. [PMID: 26350371 DOI: 10.1245/s10434-015-4854-z] [Cited by in Crossref: 29] [Cited by in F6Publishing: 24] [Article Influence: 4.8] [Reference Citation Analysis]
40 Borazanci E, Sckolnik S, Amini A. Neo-adjuvant therapy for pancreatic cancer: hope for the future. Expert Rev Gastroenterol Hepatol 2019;13:579-89. [PMID: 30979348 DOI: 10.1080/17474124.2019.1607294] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
41 Hasegawa S, Nagano H, Konno M, Eguchi H, Tomokuni A, Tomimaru Y, Wada H, Hama N, Kawamoto K, Kobayashi S, Marubashi S, Nishida N, Koseki J, Gotoh N, Ohno S, Yabuta N, Nojima H, Mori M, Doki Y, Ishii H. Cyclin G2: A novel independent prognostic marker in pancreatic cancer. Oncol Lett 2015;10:2986-90. [PMID: 26722276 DOI: 10.3892/ol.2015.3667] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 2.2] [Reference Citation Analysis]
42 Nakamura M, Sugimoto H, Ogata T, Hiraoka K, Yoda H, Sang M, Sang M, Zhu Y, Yu M, Shimozato O, Ozaki T. Improvement of gemcitabine sensitivity of p53-mutated pancreatic cancer MiaPaCa-2 cells by RUNX2 depletion-mediated augmentation of TAp73-dependent cell death. Oncogenesis 2016;5:e233. [PMID: 27294865 DOI: 10.1038/oncsis.2016.40] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
43 Abbassi R, Schmid RM. Evolving Treatment Paradigms for Pancreatic Cancer. Visc Med 2019;35:362-72. [PMID: 31934585 DOI: 10.1159/000503797] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
44 Tee MC, Kendrick ML, Farnell MB. Laparoscopic Pancreaticoduodenectomy: Is It an Effective Procedure for Pancreatic Ductal Adenocarcinoma? Adv Surg 2015;49:143-56. [PMID: 26299496 DOI: 10.1016/j.yasu.2015.03.003] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
45 Murakami Y, Uemura K, Hashimoto Y, Kondo N, Nakagawa N, Takahashi S, Shintakuya R, Sueda T. Survival effects of adjuvant gemcitabine plus S-1 chemotherapy on pancreatic carcinoma stratified by preoperative resectability status: Adjuvant GS for Pancreatic Carcinoma. J Surg Oncol 2016;113:405-12. [DOI: 10.1002/jso.24156] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 2.8] [Reference Citation Analysis]
46 Uesaka K, Boku N, Fukutomi A, Okamura Y, Konishi M, Matsumoto I, Kaneoka Y, Shimizu Y, Nakamori S, Sakamoto H, Morinaga S, Kainuma O, Imai K, Sata N, Hishinuma S, Ojima H, Yamaguchi R, Hirano S, Sudo T, Ohashi Y; JASPAC 01 Study Group. Adjuvant chemotherapy of S-1 versus gemcitabine for resected pancreatic cancer: a phase 3, open-label, randomised, non-inferiority trial (JASPAC 01). Lancet. 2016;388:248-257. [PMID: 27265347 DOI: 10.1016/s0140-6736(16)30583-9] [Cited by in Crossref: 460] [Cited by in F6Publishing: 154] [Article Influence: 92.0] [Reference Citation Analysis]
47 Baugh KA, Tran Cao HS, van Buren G 2nd, Silberfein EJ, Hsu C, Chai C, Barakat O, Fisher WE, Massarweh NN. Understaging of clinical stage I pancreatic cancer and the impact of multimodality therapy. Surgery 2019;165:307-14. [PMID: 30243481 DOI: 10.1016/j.surg.2018.08.003] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 4.0] [Reference Citation Analysis]
48 Liu Z, Luo G, Guo M, Jin K, Xiao Z, Liu L, Liu C, Xu J, Ni Q, Long J, Yu X. Lymph node status predicts the benefit of adjuvant chemoradiotherapy for patients with resected pancreatic cancer. Pancreatology 2015;15:253-8. [DOI: 10.1016/j.pan.2015.03.012] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 2.3] [Reference Citation Analysis]
49 Shin SH, Kim SC, Song KB, Hwang DW, Lee JH, Park KM, Lee YJ. Chronologic changes in clinical and survival features of pancreatic ductal adenocarcinoma since 2000: A single-center experience with 2,029 patients. Surgery 2018;164:432-42. [PMID: 29884479 DOI: 10.1016/j.surg.2018.04.017] [Cited by in Crossref: 15] [Cited by in F6Publishing: 7] [Article Influence: 5.0] [Reference Citation Analysis]
50 Yang A, O'Reilly EM. Novel directions in neoadjuvant therapy for pancreas adenocarcinoma. Expert Rev Gastroenterol Hepatol 2015;9:585-601. [PMID: 25686370 DOI: 10.1586/17474124.2015.1012496] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
51 Long M, Zhan M, Xu S, Yang R, Chen W, Zhang S, Shi Y, He Q, Mohan M, Liu Q, Wang J. miR-92b-3p acts as a tumor suppressor by targeting Gabra3 in pancreatic cancer. Mol Cancer 2017;16:167. [PMID: 29078789 DOI: 10.1186/s12943-017-0723-7] [Cited by in Crossref: 53] [Cited by in F6Publishing: 51] [Article Influence: 13.3] [Reference Citation Analysis]
52 Yamada D, Eguchi H, Asaoka T, Tomihara H, Noda T, Wada H, Kawamoto K, Gotoh K, Takeda Y, Tanemura M, Mori M, Doki Y. The basal nutritional state of PDAC patients is the dominant factor for completing adjuvant chemotherapy. Surg Today 2017;47:1361-71. [PMID: 28421348 DOI: 10.1007/s00595-017-1522-x] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 2.8] [Reference Citation Analysis]
53 Cassinotto C, Sa-Cunha A, Trillaud H. Radiological evaluation of response to neoadjuvant treatment in pancreatic cancer. Diagn Interv Imaging 2016;97:1225-32. [PMID: 27692675 DOI: 10.1016/j.diii.2016.07.011] [Cited by in Crossref: 21] [Cited by in F6Publishing: 17] [Article Influence: 4.2] [Reference Citation Analysis]
54 Fenocchio E, Depetris I, Campanella D, Garetto L, Schianca FC, Galizia D, Grignani G, Aglietta M, Leone F. Successful treatment of gemcitabine-induced acute interstitial pneumonia with imatinib mesylate: a case report. BMC Cancer. 2016;16:793. [PMID: 27733144 DOI: 10.1186/s12885-016-2833-9] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.2] [Reference Citation Analysis]
55 Stein SM, James ES, Deng Y, Cong X, Kortmansky JS, Li J, Staugaard C, Indukala D, Boustani AM, Patel V, Cha CH, Salem RR, Chang B, Hochster HS, Lacy J. Final analysis of a phase II study of modified FOLFIRINOX in locally advanced and metastatic pancreatic cancer. Br J Cancer. 2016;114:737-743. [PMID: 27022826 DOI: 10.1038/bjc.2016.45] [Cited by in Crossref: 99] [Cited by in F6Publishing: 81] [Article Influence: 19.8] [Reference Citation Analysis]
56 Li J, Li Z, Kan H, Sun Z, Xing J, Cheng Y, Bai C. CA19-9 elevation as an indication to start salvage treatment in surveillance after pancreatic cancer resection. Pancreatology. 2019;19:302-306. [PMID: 30737189 DOI: 10.1016/j.pan.2019.01.023] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 3.5] [Reference Citation Analysis]
57 Choi JG, Nipp RD, Tramontano A, Ali A, Zhan T, Pandharipande P, Dowling EC, Ferrone CR, Hong TS, Schrag D, Fernandez-Del Castillo C, Ryan DP, Kong CY, Hur C. Neoadjuvant FOLFIRINOX for Patients with Borderline Resectable or Locally Advanced Pancreatic Cancer: Results of a Decision Analysis. Oncologist 2019;24:945-54. [PMID: 30559125 DOI: 10.1634/theoncologist.2018-0114] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
58 Luu AM, Braumann C, Belyaev O, Janot-Matuschek M, Rudolf H, Praktiknjo M, Uhl W. Long-term survival after pancreaticoduodenectomy in patients with ductal adenocarcinoma of the pancreatic head. Hepatobiliary Pancreat Dis Int 2021;20:271-8. [PMID: 33349608 DOI: 10.1016/j.hbpd.2020.12.006] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
59 Izumo W, Higuchi R, Furukawa T, Yazawa T, Uemura S, Shiihara M, Yamamoto M. Evaluation of preoperative prognostic factors in patients with resectable pancreatic ductal adenocarcinoma. Scandinavian Journal of Gastroenterology 2019;54:780-6. [DOI: 10.1080/00365521.2019.1624816] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
60 Balboni B, El Hassouni B, Honeywell RJ, Sarkisjan D, Giovannetti E, Poore J, Heaton C, Peterson C, Benaim E, Lee YB, Kim DJ, Peters GJ. RX-3117 (fluorocyclopentenyl cytosine): a novel specific antimetabolite for selective cancer treatment. Expert Opin Investig Drugs 2019;28:311-22. [PMID: 30879349 DOI: 10.1080/13543784.2019.1583742] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 5.5] [Reference Citation Analysis]
61 Hsieh MC, Chang WW, Yu HH, Lu CY, Chang CL, Chow JM, Chen SU, Cheng Y, Wu SY. Adjuvant radiotherapy and chemotherapy improve survival in patients with pancreatic adenocarcinoma receiving surgery: adjuvant chemotherapy alone is insufficient in the era of intensity modulation radiation therapy. Cancer Med. 2018;7:2328-2338. [PMID: 29665327 DOI: 10.1002/cam4.1479] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 4.0] [Reference Citation Analysis]
62 Tran TB, Maker VK, Maker AV. Impact of Immunotherapy after Resection of Pancreatic Cancer. J Am Coll Surg 2019;229:19-27.e1. [PMID: 30742911 DOI: 10.1016/j.jamcollsurg.2019.01.016] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
63 Sen N, Falk S, Abrams R. Role of Chemoradiotherapy in the Adjuvant and Neoadjuvant Settings for Resectable Pancreatic Cancer. Clinical Oncology 2014;26:551-9. [DOI: 10.1016/j.clon.2014.06.003] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 2.3] [Reference Citation Analysis]
64 Liu H, Zenati MS, Rieser CJ, Al-Abbas A, Lee KK, Singhi AD, Bahary N, Hogg ME, Zeh HJ 3rd, Zureikat AH. CA19-9 Change During Neoadjuvant Therapy May Guide the Need for Additional Adjuvant Therapy Following Resected Pancreatic Cancer. Ann Surg Oncol. 2020;27:3950-3960. [PMID: 32318949 DOI: 10.1245/s10434-020-08468-9] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 6.0] [Reference Citation Analysis]
65 Miura JT, Krepline AN, George B, Ritch PS, Erickson BA, Johnston FM, Oshima K, Christians KK, Evans DB, Tsai S. Use of neoadjuvant therapy in patients 75 years of age and older with pancreatic cancer. Surgery 2015;158:1545-55. [PMID: 26243342 DOI: 10.1016/j.surg.2015.06.017] [Cited by in Crossref: 30] [Cited by in F6Publishing: 16] [Article Influence: 5.0] [Reference Citation Analysis]
66 Nakamura T, Asano T, Okamura K, Tsuchikawa T, Murakami S, Kurashima Y, Ebihara Y, Noji T, Nakanishi Y, Tanaka K, Shichinohe T, Hirano S. A Preoperative Prognostic Scoring System to Predict Prognosis for Resectable Pancreatic Cancer: Who Will Benefit from Upfront Surgery? J Gastrointest Surg 2019;23:990-6. [PMID: 30242645 DOI: 10.1007/s11605-018-3972-x] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
67 Nassour I, Adam MA, Kowalsky S, Al Masri S, Bahary N, Singhi AD, Lee K, Zureikat A, Paniccia A. Neoadjuvant therapy versus upfront surgery for early-stage left-sided pancreatic adenocarcinoma: A propensity-matched analysis from a national cohort of distal pancreatectomies. J Surg Oncol 2021;123:245-51. [PMID: 33103242 DOI: 10.1002/jso.26267] [Reference Citation Analysis]
68 Christians KK, Heimler JW, George B, Ritch PS, Erickson BA, Johnston F, Tolat PP, Foley WD, Evans DB, Tsai S. Survival of patients with resectable pancreatic cancer who received neoadjuvant therapy. Surgery. 2016;159:893-900. [PMID: 26602840 DOI: 10.1016/j.surg.2015.09.018] [Cited by in Crossref: 86] [Cited by in F6Publishing: 62] [Article Influence: 17.2] [Reference Citation Analysis]
69 Jones CM, Radhakrishna G, Aitken K, Bridgewater J, Corrie P, Eatock M, Goody R, Ghaneh P, Good J, Grose D, Holyoake D, Hunt A, Jamieson NB, Palmer DH, Soonawalla Z, Valle JW, Hawkins MA, Mukherjee S. Considerations for the treatment of pancreatic cancer during the COVID-19 pandemic: the UK consensus position. Br J Cancer 2020;123:709-13. [PMID: 32641867 DOI: 10.1038/s41416-020-0980-x] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 8.0] [Reference Citation Analysis]
70 Ibrahim AM, Wang YH. Viro-immune therapy: A new strategy for treatment of pancreatic cancer. World J Gastroenterol. 2016;22:748-763. [PMID: 26811622 DOI: 10.3748/wjg.v22.i2.748] [Cited by in CrossRef: 9] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
71 Terasaki F, Fukami Y, Maeda A, Takayama Y, Takahashi T, Uji M, Kaneoka Y. Comparison of end-to-end anastomosis and interposition graft during pancreatoduodenectomy with portal vein reconstruction for pancreatic ductal adenocarcinoma. Langenbecks Arch Surg 2019;404:191-201. [DOI: 10.1007/s00423-019-01749-2] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 6.0] [Reference Citation Analysis]
72 Parmar A, Chaves-Porras J, Saluja R, Perry K, Rahmadian AP, Santos SD, Ko YJ, Berry S, Doherty M, Chan KKW. Adjuvant treatment for resected pancreatic adenocarcinoma: A systematic review and network meta-analysis. Crit Rev Oncol Hematol. 2020;145:102817. [PMID: 31955005 DOI: 10.1016/j.critrevonc.2019.102817] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 3.5] [Reference Citation Analysis]
73 Adamska A, Domenichini A, Falasca M. Pancreatic Ductal Adenocarcinoma: Current and Evolving Therapies. Int J Mol Sci. 2017;18. [PMID: 28640192 DOI: 10.3390/ijms18071338] [Cited by in Crossref: 210] [Cited by in F6Publishing: 173] [Article Influence: 52.5] [Reference Citation Analysis]
74 Guo SW, Shen J, Gao JH, Shi XH, Gao SZ, Wang H, Li B, Yuan WL, Lin L, Jin G. A preoperative risk model for early recurrence after radical resection may facilitate initial treatment decisions concerning the use of neoadjuvant therapy for patients with pancreatic ductal adenocarcinoma. Surgery 2020;168:1003-14. [PMID: 32321665 DOI: 10.1016/j.surg.2020.02.013] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 6.0] [Reference Citation Analysis]
75 Sak ZHA, Süzergöz F, Kasumov VT, Gürol AO. Anticancer Properties of Fluorinated Aminophenylhydrazines on A549 Lung Carcinoma Cell Line. Iran J Public Health 2021;50:550-6. [PMID: 34178802 DOI: 10.18502/ijph.v50i3.5596] [Reference Citation Analysis]
76 Garrido-Laguna I, Hidalgo M. Pancreatic cancer: from state-of-the-art treatments to promising novel therapies. Nat Rev Clin Oncol. 2015;12:319-334. [PMID: 25824606 DOI: 10.1038/nrclinonc.2015.53] [Cited by in Crossref: 350] [Cited by in F6Publishing: 296] [Article Influence: 58.3] [Reference Citation Analysis]
77 Lee PY, Shyr BU, Shyr BS, Chen SC, Shyr YM, Wang SE. Surgical and survival outcomes after robotic and open pancreaticoduodenectomy with positive margins. J Chin Med Assoc 2021;84:698-703. [PMID: 34050108 DOI: 10.1097/JCMA.0000000000000558] [Reference Citation Analysis]
78 Elander NO, Aughton K, Ghaneh P, Neoptolemos JP, Palmer DH, Cox TF, Campbell F, Costello E, Halloran CM, Mackey JR, Scarfe AG, Valle JW, McDonald AC, Carter R, Tebbutt NC, Goldstein D, Shannon J, Dervenis C, Glimelius B, Deakin M, Charnley RM, Anthoney A, Lerch MM, Mayerle J, Oláh A, Büchler MW, Greenhalf W; European Study Group for Pancreatic Cancer. Intratumoural expression of deoxycytidylate deaminase or ribonuceotide reductase subunit M1 expression are not related to survival in patients with resected pancreatic cancer given adjuvant chemotherapy. Br J Cancer 2018;118:1084-8. [PMID: 29523831 DOI: 10.1038/s41416-018-0005-1] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.7] [Reference Citation Analysis]
79 Kamarajah SK, White SA, Naffouje SA, Salti GI, Dahdaleh F. Adjuvant Chemotherapy Associated with Survival Benefit Following Neoadjuvant Chemotherapy and Pancreatectomy for Pancreatic Ductal Adenocarcinoma: A Population-Based Cohort Study. Ann Surg Oncol 2021. [PMID: 33786676 DOI: 10.1245/s10434-021-09823-0] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
80 Schwarz L, Vernerey D, Bachet JB, Tuech JJ, Portales F, Michel P, Cunha AS. Resectable pancreatic adenocarcinoma neo-adjuvant FOLF(IRIN)OX-based chemotherapy - a multicenter, non-comparative, randomized, phase II trial (PANACHE01-PRODIGE48 study). BMC Cancer 2018;18:762. [PMID: 30041614 DOI: 10.1186/s12885-018-4663-4] [Cited by in Crossref: 35] [Cited by in F6Publishing: 28] [Article Influence: 11.7] [Reference Citation Analysis]
81 Okada K, Uemura K, Kondo N, Sumiyoshi T, Seo S, Otsuka H, Serikawa M, Ishii Y, Tsuboi T, Murakami Y, Takahashi S. Preoperative risk factors for para-aortic lymph node positivity in pancreatic cancer. Pancreatology 2021;21:606-12. [PMID: 33648880 DOI: 10.1016/j.pan.2021.01.022] [Reference Citation Analysis]
82 Parekh HD, Starr J, George TJ Jr. The Multidisciplinary Approach to Localized Pancreatic Adenocarcinoma. Curr Treat Options Oncol 2017;18:73. [PMID: 29143898 DOI: 10.1007/s11864-017-0515-8] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
83 Chawla A. Contemporary trials evaluating neoadjuvant therapy for resectable pancreatic cancer. J Surg Oncol 2021;123:1423-31. [PMID: 33831254 DOI: 10.1002/jso.26393] [Reference Citation Analysis]
84 Springfeld C, Jäger D, Büchler MW, Strobel O, Hackert T, Palmer DH, Neoptolemos JP. Chemotherapy for pancreatic cancer. Presse Med 2019;48:e159-74. [PMID: 30879894 DOI: 10.1016/j.lpm.2019.02.025] [Cited by in Crossref: 42] [Cited by in F6Publishing: 27] [Article Influence: 21.0] [Reference Citation Analysis]
85 Wei L, Lin Q, Lu Y, Li G, Huang L, Fu Z, Chen R, Zhou Q. Cancer-associated fibroblasts-mediated ATF4 expression promotes malignancy and gemcitabine resistance in pancreatic cancer via the TGF-β1/SMAD2/3 pathway and ABCC1 transactivation. Cell Death Dis 2021;12:334. [PMID: 33782384 DOI: 10.1038/s41419-021-03574-2] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
86 Motoi F, Satoi S, Honda G, Wada K, Shinchi H, Matsumoto I, Sho M, Tsuchida A, Unno M; Study Group of Preoperative therapy for Pancreatic cancer (PREP). A single-arm, phase II trial of neoadjuvant gemcitabine and S1 in patients with resectable and borderline resectable pancreatic adenocarcinoma: PREP-01 study. J Gastroenterol 2019;54:194-203. [PMID: 30182219 DOI: 10.1007/s00535-018-1506-7] [Cited by in Crossref: 26] [Cited by in F6Publishing: 19] [Article Influence: 8.7] [Reference Citation Analysis]
87 Hashimoto D, Arima K, Nakagawa S, Negoro Y, Hirata T, Hirota M, Inomata M, Fukuzawa K, Ohga T, Saeki H, Oki E, Yamashita YI, Chikamoto A, Baba H, Maehara Y. Pancreatic cancer arising from the remnant pancreas after pancreatectomy: a multicenter retrospective study by the Kyushu Study Group of Clinical Cancer. J Gastroenterol 2019;54:437-48. [PMID: 30515563 DOI: 10.1007/s00535-018-01535-9] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
88 Matsumoto I, Murakami Y, Shinzeki M, Asari S, Goto T, Tani M, Motoi F, Uemura K, Sho M, Satoi S. Proposed preoperative risk factors for early recurrence in patients with resectable pancreatic ductal adenocarcinoma after surgical resection: A multi-center retrospective study. Pancreatology. 2015;15:674-680. [PMID: 26467797 DOI: 10.1016/j.pan.2015.09.008] [Cited by in Crossref: 47] [Cited by in F6Publishing: 39] [Article Influence: 7.8] [Reference Citation Analysis]
89 Saeed H, Hnoosh D, Huang B, Durbin EB, McGrath PC, Desimone P, Maynard E, Anthony LB, Dineen SP, Hosein PJ, Tzeng CW. Defining the optimal timing of adjuvant therapy for resected pancreatic adenocarcinoma: A statewide cancer registry analysis. J Surg Oncol 2016;114:451-5. [PMID: 27238300 DOI: 10.1002/jso.24314] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.4] [Reference Citation Analysis]
90 Yamada D, Eguchi H, Iwagami Y, Asaoka T, Noda T, Kawamoto K, Gotoh K, Kobayashi S, Mori M, Doki Y. The investigation of the survival time after recurrence in patients with pancreatic ductal adenocarcinoma for individualization of adjuvant chemotherapy. Surg Today 2018;48:952-62. [PMID: 29770847 DOI: 10.1007/s00595-018-1674-3] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
91 Ye M, Zhang Q, Chen Y, Fu Q, Li X, Bai X, Liang T. Neoadjuvant chemotherapy for primary resectable pancreatic cancer: a systematic review and meta-analysis. HPB (Oxford) 2020;22:821-32. [PMID: 32001139 DOI: 10.1016/j.hpb.2020.01.001] [Cited by in Crossref: 14] [Cited by in F6Publishing: 9] [Article Influence: 14.0] [Reference Citation Analysis]
92 Weberpals J, Jansen L, Silversmit G, Verbeeck J, van der Geest L, Vissers PA, Zadnik V, Brenner H. Comparative performance of a modified landmark approach when no time of treatment data are available within oncological databases: exemplary cohort study among resected pancreatic cancer patients. Clin Epidemiol 2018;10:1109-25. [PMID: 30214315 DOI: 10.2147/CLEP.S160973] [Cited by in Crossref: 5] [Article Influence: 1.7] [Reference Citation Analysis]
93 Motoi F, Kosuge T, Ueno H, Yamaue H, Satoi S, Sho M, Honda G, Matsumoto I, Wada K, Furuse J, Matsuyama Y, Unno M;  Study Group of Preoperative Therapy for Pancreatic Cancer (Prep) and Japanese Study Group of Adjuvant Therapy for Pancreatic cancer (JSAP). Randomized phase II/III trial of neoadjuvant chemotherapy with gemcitabine and S-1 vs upfront surgery for resectable pancreatic cancer (Prep-02/JSAP05). Jpn J Clin Oncol. 2019;49:190-194. [PMID: 30608598 DOI: 10.1093/jjco/hyy190] [Cited by in Crossref: 80] [Cited by in F6Publishing: 87] [Article Influence: 40.0] [Reference Citation Analysis]
94 Postlewait LM, Ethun CG, Kooby DA, Sarmiento JM, Chen Z, Staley CA 3rd, Brutcher E, Adsay V, El-Rayes B, Maithel SK. Combination gemcitabine/cisplatin therapy and ERCC1 expression for resected pancreatic adenocarcinoma: Results of a Phase II prospective trial. J Surg Oncol 2016;114:336-41. [PMID: 27501338 DOI: 10.1002/jso.24317] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 1.4] [Reference Citation Analysis]
95 Zhi X, Chen W, Xue F, Liang C, Chen BW, Zhou Y, Wen L, Hu L, Shen J, Bai X, Liang T. OSI-027 inhibits pancreatic ductal adenocarcinoma cell proliferation and enhances the therapeutic effect of gemcitabine both in vitro and in vivo. Oncotarget 2015;6:26230-41. [PMID: 26213847 DOI: 10.18632/oncotarget.4579] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
96 Demir IE, Jäger C, Schlitter AM, Konukiewitz B, Stecher L, Schorn S, Tieftrunk E, Scheufele F, Calavrezos L, Schirren R, Esposito I, Weichert W, Friess H, Ceyhan GO. R0 Versus R1 Resection Matters after Pancreaticoduodenectomy, and Less after Distal or Total Pancreatectomy for Pancreatic Cancer. Ann Surg 2018;268:1058-68. [PMID: 28692477 DOI: 10.1097/SLA.0000000000002345] [Cited by in Crossref: 53] [Cited by in F6Publishing: 24] [Article Influence: 26.5] [Reference Citation Analysis]
97 Lavu H, Yeo CJ. Pancreatic ductal adenocarcinoma treatment--the past, present, and future. Semin Oncol. 2015;42:4-7. [PMID: 25726047 DOI: 10.1053/j.seminoncol.2014.12.001] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
98 Joglekar S, Asghar A, Mott SL, Johnson BE, Button AM, Clark E, Mezhir JJ. Sarcopenia is an independent predictor of complications following pancreatectomy for adenocarcinoma. J Surg Oncol. 2015;111:771-775. [PMID: 25556324 DOI: 10.1002/jso.23862] [Cited by in Crossref: 155] [Cited by in F6Publishing: 120] [Article Influence: 22.1] [Reference Citation Analysis]
99 Abudalou M, Vega EA, Dhingra R, Holzwanger E, Krishnan S, Kondratiev S, Niakosari A, Conrad C, Stallwood CG. Solid pseudopapillary neoplasm-diagnostic approach and post-surgical follow up: Three case reports and review of literature. World J Clin Cases 2021;9:1682-95. [PMID: 33728313 DOI: 10.12998/wjcc.v9.i7.1682] [Reference Citation Analysis]
100 Kyrochristos ID, Glantzounis GK, Ziogas DE, Gizas I, Schizas D, Lykoudis EG, Felekouras E, Machairas A, Katsios C, Liakakos T, Cho WC, Roukos DH. From Clinical Standards to Translating Next-Generation Sequencing Research into Patient Care Improvement for Hepatobiliary and Pancreatic Cancers. Int J Mol Sci 2017;18:E180. [PMID: 28106782 DOI: 10.3390/ijms18010180] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
101 Mirkin KA, Hollenbeak CS, Gusani NJ, Wong J. Trends in utilization of neoadjuvant therapy and short-term outcomes in resected pancreatic cancer. The American Journal of Surgery 2017;214:80-8. [DOI: 10.1016/j.amjsurg.2016.08.015] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 3.3] [Reference Citation Analysis]
102 Wu AA, Jaffee E, Lee V. Current Status of Immunotherapies for Treating Pancreatic Cancer. Curr Oncol Rep 2019;21:60. [PMID: 31101991 DOI: 10.1007/s11912-019-0811-5] [Cited by in Crossref: 23] [Cited by in F6Publishing: 16] [Article Influence: 11.5] [Reference Citation Analysis]
103 Salvia R, Casciani F, Sereni E, Bassi C. Pancreatic cancer – What's next? Presse Med 2019;48:e187-97. [PMID: 30878338 DOI: 10.1016/j.lpm.2019.02.031] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
104 Zijlstra M, Bernards N, de Hingh IH, van de Wouw AJ, Goey SH, Jacobs EM, Lemmens VE, Creemers GJ. Does long-term survival exist in pancreatic adenocarcinoma? Acta Oncol 2016;55:259-64. [PMID: 26559995 DOI: 10.3109/0284186X.2015.1096020] [Cited by in Crossref: 17] [Cited by in F6Publishing: 10] [Article Influence: 2.8] [Reference Citation Analysis]
105 Nakano Y, Kitago M, Shinoda M, Abe Y, Yagi H, Hibi T, Takeuchi A, Aiura K, Itano O, Kitagawa Y. Clinical predictive factors of long-term survival after curative resection of pancreatic cancer: a retrospective study. Cancer Med 2017;6:2278-86. [PMID: 28925039 DOI: 10.1002/cam4.1178] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 2.3] [Reference Citation Analysis]
106 Ishido K, Hakamada K, Kimura N, Miura T, Wakiya T. Essential updates 2018/2019: Current topics in the surgical treatment of pancreatic ductal adenocarcinoma. Ann Gastroenterol Surg 2021;5:7-23. [PMID: 33532676 DOI: 10.1002/ags3.12379] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
107 Takahashi H, Yamada D, Asukai K, Wada H, Hasegawa S, Hara H, Shinno N, Ushigome H, Haraguchi N, Sugimura K, Yamamoto K, Nishimura J, Yasui M, Omori T, Miyata H, Ohue M, Yano M, Sakon M, Ishikawa O. Clinical implications of the serum CA19-9 level in "biological borderline resectability" and "biological downstaging" in the setting of preoperative chemoradiation therapy for pancreatic cancer. Pancreatology 2020;20:919-28. [PMID: 32563596 DOI: 10.1016/j.pan.2020.05.020] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 6.0] [Reference Citation Analysis]
108 Connor AA, Denroche RE, Jang GH, Timms L, Kalimuthu SN, Selander I, McPherson T, Wilson GW, Chan-Seng-Yue MA, Borozan I, Ferretti V, Grant RC, Lungu IM, Costello E, Greenhalf W, Palmer D, Ghaneh P, Neoptolemos JP, Buchler M, Petersen G, Thayer S, Hollingsworth MA, Sherker A, Durocher D, Dhani N, Hedley D, Serra S, Pollett A, Roehrl MHA, Bavi P, Bartlett JMS, Cleary S, Wilson JM, Alexandrov LB, Moore M, Wouters BG, McPherson JD, Notta F, Stein LD, Gallinger S. Association of Distinct Mutational Signatures With Correlates of Increased Immune Activity in Pancreatic Ductal Adenocarcinoma. JAMA Oncol 2017;3:774-83. [PMID: 27768182 DOI: 10.1001/jamaoncol.2016.3916] [Cited by in Crossref: 137] [Cited by in F6Publishing: 102] [Article Influence: 34.3] [Reference Citation Analysis]
109 Sinn M, Sinn BV, Striefler JK, Lindner JL, Stieler JM, Lohneis P, Bischoff S, Bläker H, Pelzer U, Bahra M. SPARC expression in resected pancreatic cancer patients treated with gemcitabine: results from the CONKO-001 study. Ann Oncol. 2014;25:1025-1032. [PMID: 24562449 DOI: 10.1093/annonc/mdu084] [Cited by in Crossref: 54] [Cited by in F6Publishing: 51] [Article Influence: 7.7] [Reference Citation Analysis]
110 Ghaneh P, Hanson R, Titman A, Lancaster G, Plumpton C, Lloyd-Williams H, Yeo ST, Edwards RT, Johnson C, Abu Hilal M, Higginson AP, Armstrong T, Smith A, Scarsbrook A, McKay C, Carter R, Sutcliffe RP, Bramhall S, Kocher HM, Cunningham D, Pereira SP, Davidson B, Chang D, Khan S, Zealley I, Sarker D, Al Sarireh B, Charnley R, Lobo D, Nicolson M, Halloran C, Raraty M, Sutton R, Vinjamuri S, Evans J, Campbell F, Deeks J, Sanghera B, Wong WL, Neoptolemos JP. PET-PANC: multicentre prospective diagnostic accuracy and health economic analysis study of the impact of combined modality 18fluorine-2-fluoro-2-deoxy-d-glucose positron emission tomography with computed tomography scanning in the diagnosis and management of pancreatic cancer. Health Technol Assess 2018;22:1-114. [PMID: 29402376 DOI: 10.3310/hta22070] [Cited by in Crossref: 41] [Cited by in F6Publishing: 28] [Article Influence: 20.5] [Reference Citation Analysis]
111 Diab M, Azmi A, Mohammad R, Philip PA. Pharmacotherapeutic strategies for treating pancreatic cancer: advances and challenges. Expert Opin Pharmacother 2019;20:535-46. [PMID: 30592647 DOI: 10.1080/14656566.2018.1561869] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 4.0] [Reference Citation Analysis]
112 O’neill L, Reynolds S, Sheill G, Guinan E, Mockler D, Geoghegan J, Conlon K, Reynolds JV, Hussey J. Physical function in patients with resectable cancer of the pancreas and liver–a systematic review. J Cancer Surviv 2020;14:527-44. [DOI: 10.1007/s11764-020-00875-x] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
113 Lohneis P, Sinn M, Bischoff S, Jühling A, Pelzer U, Wislocka L, Bahra M, Sinn BV, Denkert C, Oettle H, Bläker H, Riess H, Jöhrens K, Striefler JK. Cytotoxic tumour-infiltrating T lymphocytes influence outcome in resected pancreatic ductal adenocarcinoma. Eur J Cancer 2017;83:290-301. [PMID: 28772128 DOI: 10.1016/j.ejca.2017.06.016] [Cited by in Crossref: 38] [Cited by in F6Publishing: 35] [Article Influence: 9.5] [Reference Citation Analysis]
114 Terasaki F, Sugiura T, Okamura Y, Ito T, Yamamoto Y, Ashida R, Ohgi K, Uesaka K. Oncological benefit of metformin in patients with pancreatic ductal adenocarcinoma and comorbid diabetes mellitus. Langenbecks Arch Surg 2020;405:313-24. [PMID: 32367394 DOI: 10.1007/s00423-020-01874-3] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
115 Arnachellum RP, Cariou M, Nousbaum JB, Jezequel J, Le Reste JY, Robaszkiewicz M. Pancreatic Adenocarcinoma in the Finistère Area, France, Between 2002 and 2011 (1002 Cases): Population Characteristics, Treatment and Survival. Pancreas 2016;45:953-60. [PMID: 26765965 DOI: 10.1097/MPA.0000000000000594] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
116 Ahmed SA, Atta H, Hassan RA. The utility of Multi-Detector Computed Tomography criteria after neoadjuvant therapy in Borderline Resectable Pancreatic cancer: Prospective, bi-institutional study. Eur J Radiol 2021;139:109685. [PMID: 33819805 DOI: 10.1016/j.ejrad.2021.109685] [Reference Citation Analysis]
117 Hashimoto D, Chikamoto A, Masuda T, Nakagawa S, Imai K, Yamashita YI, Reber HA, Baba H. Pancreatic Cancer Arising From the Remnant Pancreas: Is It a Local Recurrence or New Primary Lesion? Pancreas 2017;46:1083-90. [PMID: 28902776 DOI: 10.1097/MPA.0000000000000897] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
118 Altman AM, Wirth K, Marmor S, Lou E, Chang K, Hui JYC, Tuttle TM, Jensen EH, Denbo JW. Completion of Adjuvant Chemotherapy After Upfront Surgical Resection for Pancreatic Cancer Is Uncommon Yet Associated With Improved Survival. Ann Surg Oncol. 2019;26:4108-4116. [PMID: 31313044 DOI: 10.1245/s10434-019-07602-6] [Cited by in Crossref: 31] [Cited by in F6Publishing: 21] [Article Influence: 15.5] [Reference Citation Analysis]
119 Yoshii Y, Matsumoto H, Yoshimoto M, Oe Y, Zhang MR, Nagatsu K, Sugyo A, Tsuji AB, Higashi T. 64Cu-Intraperitoneal Radioimmunotherapy: A Novel Approach for Adjuvant Treatment in a Clinically Relevant Preclinical Model of Pancreatic Cancer. J Nucl Med 2019;60:1437-43. [PMID: 30850497 DOI: 10.2967/jnumed.118.225045] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 5.5] [Reference Citation Analysis]
120 Rosumeck N, Timmermann L, Klein F, Bahra M, Stintzig S, Malinka T, Pelzer U. Induction Chemotherapy for Primarily Unresectable Locally Advanced Pancreatic Adenocarcinoma-Who Will Benefit from a Secondary Resection? Medicina (Kaunas) 2021;57:77. [PMID: 33477505 DOI: 10.3390/medicina57010077] [Reference Citation Analysis]
121 Torgeson A, Garrido-Laguna I, Tao R, Cannon GM, Scaife CL, Lloyd S. Value of surgical resection and timing of therapy in patients with pancreatic cancer at high risk for positive margins. ESMO Open 2018;3:e000282. [PMID: 29387477 DOI: 10.1136/esmoopen-2017-000282] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 4.3] [Reference Citation Analysis]
122 Fisher AV, Abbott DE, Venkatesh M, Leverson GE, Campbell-flohr SA, Ronnekleiv-kelly SM, Greenberg CC, Winslow ER, Weber SM. The Impact of Hospital Neoadjuvant Therapy Utilization on Survival Outcomes for Pancreatic Cancer. Ann Surg Oncol 2018;25:2661-8. [DOI: 10.1245/s10434-018-6650-z] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
123 Sugimoto M, Farnell MB, Nagorney DM, Kendrick ML, Truty MJ, Smoot RL, Chari ST, Moynagh MR, Petersen GM, Carter RE, Takahashi N. Decreased Skeletal Muscle Volume Is a Predictive Factor for Poorer Survival in Patients Undergoing Surgical Resection for Pancreatic Ductal Adenocarcinoma. J Gastrointest Surg. 2018;22:831-839. [PMID: 29392613 DOI: 10.1007/s11605-018-3695-z] [Cited by in Crossref: 17] [Cited by in F6Publishing: 13] [Article Influence: 5.7] [Reference Citation Analysis]
124 Min EK, Chong JU, Hwang HK, Pae SJ, Kang CM, Lee WJ. Negative oncologic impact of poor postoperative pain control in left-sided pancreatic cancer. World J Gastroenterol 2017;23:676-86. [PMID: 28216975 DOI: 10.3748/wjg.v23.i4.676] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
125 Katayama ES, Hue JJ, Bajor DL, Ocuin LM, Ammori JB, Hardacre JM, Winter JM. A comprehensive analysis of clinical trials in pancreatic cancer: what is coming down the pike? Oncotarget 2020;11:3489-501. [PMID: 33014285 DOI: 10.18632/oncotarget.27727] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 6.0] [Reference Citation Analysis]
126 Xia G, Wang H, Song Z, Meng Q, Huang X, Huang X. Gambogic acid sensitizes gemcitabine efficacy in pancreatic cancer by reducing the expression of ribonucleotide reductase subunit-M2 (RRM2). J Exp Clin Cancer Res 2017;36:107. [PMID: 28797284 DOI: 10.1186/s13046-017-0579-0] [Cited by in Crossref: 33] [Cited by in F6Publishing: 30] [Article Influence: 8.3] [Reference Citation Analysis]
127 Kagedan DJ, Raju RS, Dixon ME, Shin E, Li Q, Liu N, Elmi M, El-Sedfy A, Paszat L, Kiss A, Earle CC, Mittmann N, Coburn NG. The association of adjuvant therapy with survival at the population level following pancreatic adenocarcinoma resection. HPB (Oxford) 2016;18:339-47. [PMID: 27037203 DOI: 10.1016/j.hpb.2015.12.005] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
128 Urey C, Andersson B, Ansari D, Sasor A, Said-Hilmersson K, Nilsson J, Andersson R. Low MUC4 expression is associated with survival benefit in patients with resectable pancreatic cancer receiving adjuvant gemcitabine. Scand J Gastroenterol 2017;52:595-600. [PMID: 28270046 DOI: 10.1080/00365521.2017.1290134] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
129 Ozaki K, Hayashi H, Ikuta Y, Masuda T, Akaboshi S, Ogata K, Matumoto K, Ogawa K, Kamio T, Baba H, Takamori H. Conversion surgery for initially unresectable pancreatic ductal adenocarcinoma with synchronous liver metastasis after treatment with FOLFIRINOX. Clin J Gastroenterol 2019;12:603-8. [PMID: 30993652 DOI: 10.1007/s12328-019-00965-z] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
130 Yin N, Yu H, Zhang X, Lv X. Enhancement of Pancreatic Cancer Therapy Efficacy by Type-1 Matrix Metalloproteinase-Functionalized Nanoparticles for the Selective Delivery of Gemcitabine and Erlotinib. Drug Des Devel Ther 2020;14:4465-75. [PMID: 33122890 DOI: 10.2147/DDDT.S270303] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
131 Zhou X, Lu Z, Wang T, Huang Z, Zhu W, Miao Y. Plasma miRNAs in diagnosis and prognosis of pancreatic cancer: A miRNA expression analysis. Gene. 2018;673:181-193. [PMID: 29913239 DOI: 10.1016/j.gene.2018.06.037] [Cited by in Crossref: 45] [Cited by in F6Publishing: 43] [Article Influence: 15.0] [Reference Citation Analysis]
132 Sandhu V, Bowitz Lothe IM, Labori KJ, Lingjærde OC, Buanes T, Dalsgaard AM, Skrede ML, Hamfjord J, Haaland T, Eide TJ, Børresen-Dale AL, Ikdahl T, Kure EH. Molecular signatures of mRNAs and miRNAs as prognostic biomarkers in pancreatobiliary and intestinal types of periampullary adenocarcinomas. Mol Oncol 2015;9:758-71. [PMID: 25579086 DOI: 10.1016/j.molonc.2014.12.002] [Cited by in Crossref: 24] [Cited by in F6Publishing: 20] [Article Influence: 3.4] [Reference Citation Analysis]
133 Xu JB, Jiang B, Chen Y, Qi FZ, Zhang JH, Yuan H. Optimal adjuvant chemotherapy for resected pancreatic adenocarcinoma: a systematic review and network meta-analysis. Oncotarget 2017;8:81419-29. [PMID: 29113401 DOI: 10.18632/oncotarget.19082] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 2.5] [Reference Citation Analysis]
134 Zhang M, Fang R, Mou Y, Chen R, Xu X, Zhang R, Yan J, Jin W, Ajoodhea H. LDP vs ODP for pancreatic adenocarcinoma: a case matched study from a single-institution. BMC Gastroenterol 2015;15:182. [PMID: 26695506 DOI: 10.1186/s12876-015-0411-2] [Cited by in Crossref: 23] [Cited by in F6Publishing: 20] [Article Influence: 3.8] [Reference Citation Analysis]
135 Chen K, Tong Q, Yan JF, Huang CJ, Pan Y, Zhang RC, Chen QL, Zheng XY, Cai XY, Wang Y, Wang XF. Laparoscopic versus open distal pancreatectomy for pancreatic ductal adenocarcinoma: a single-center propensity score matching study. Updates Surg 2020;72:387-97. [PMID: 32266660 DOI: 10.1007/s13304-020-00742-5] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
136 Khorana AA, Mangu PB, Berlin J, Engebretson A, Hong TS, Maitra A, Mohile SG, Mumber M, Schulick R, Shapiro M, Urba S, Zeh HJ, Katz MH. Potentially Curable Pancreatic Cancer: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol. 2016;34:2541-2556. [PMID: 27247221 DOI: 10.1200/jco.2016.67.5553] [Cited by in Crossref: 195] [Cited by in F6Publishing: 67] [Article Influence: 39.0] [Reference Citation Analysis]
137 Walston S, Salloum J, Grieco C, Wuthrick E, Diaz DA, Barney C, Manilchuk A, Schmidt C, Dillhoff M, Pawlik TM, Williams TM. Identifying Clinical Factors Which Predict for Early Failure Patterns Following Resection for Pancreatic Adenocarcinoma in Patients Who Received Adjuvant Chemotherapy Without Chemoradiation. Am J Clin Oncol 2018;41:1185-92. [PMID: 29727311 DOI: 10.1097/COC.0000000000000452] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 3.5] [Reference Citation Analysis]
138 Motoi F, Murakami Y, Okada KI, Matsumoto I, Uemura K, Satoi S, Sho M, Honda G, Fukumoto T, Yanagimoto H, Kinoshita S, Kurata M, Aoki S, Mizuma M, Yamaue H, Unno M; Multicenter Study Group of Pancreatobiliary Surgery (MSG-PBS). Sustained Elevation of Postoperative Serum Level of Carbohydrate Antigen 19-9 is High-Risk Stigmata for Primary Hepatic Recurrence in Patients with Curatively Resected Pancreatic Adenocarcinoma. World J Surg 2019;43:634-41. [PMID: 30298281 DOI: 10.1007/s00268-018-4814-4] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 5.0] [Reference Citation Analysis]
139 Jiraskova L, Ryska A, Duintjer Tebbens EJ, Hornychova H, Cecka F, Staud F, Cerveny L. Are ENT1/ENT1, NOTCH3, and miR-21 Reliable Prognostic Biomarkers in Patients with Resected Pancreatic Adenocarcinoma Treated with Adjuvant Gemcitabine Monotherapy? Cancers (Basel) 2019;11:E1621. [PMID: 31652721 DOI: 10.3390/cancers11111621] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
140 Bergquist JR, Puig CA, Shubert CR, Groeschl RT, Habermann EB, Kendrick ML, Nagorney DM, Smoot RL, Farnell MB, Truty MJ. Carbohydrate Antigen 19-9 Elevation in Anatomically Resectable, Early Stage Pancreatic Cancer Is Independently Associated with Decreased Overall Survival and an Indication for Neoadjuvant Therapy: A National Cancer Database Study. Journal of the American College of Surgeons 2016;223:52-65. [DOI: 10.1016/j.jamcollsurg.2016.02.009] [Cited by in Crossref: 77] [Cited by in F6Publishing: 61] [Article Influence: 15.4] [Reference Citation Analysis]
141 Perkhofer L, Ettrich TJ, Seufferlein T. Pancreatic Cancer: Progress in Systemic Therapy. Gastrointest Tumors 2014;1:167-79. [PMID: 26672477 DOI: 10.1159/000380785] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
142 Kim SM, Eads JR. Adjuvant and Neoadjuvant Therapy for Resectable Pancreatic and Periampullary Cancer. Surg Clin North Am. 2016;96:1287-1300. [PMID: 27865278 DOI: 10.1016/j.suc.2016.07.004] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
143 Hartwig W, Gluth A, Hinz U, Bergmann F, Spronk PE, Hackert T, Werner J, Büchler MW. Total pancreatectomy for primary pancreatic neoplasms: renaissance of an unpopular operation. Ann Surg. 2015;261:537-546. [PMID: 24979606 DOI: 10.1097/sla.0000000000000791] [Cited by in Crossref: 77] [Cited by in F6Publishing: 25] [Article Influence: 12.8] [Reference Citation Analysis]
144 Gong J, Tuli R, Shinde A, Hendifar AE. Meta-analyses of treatment standards for pancreatic cancer. Mol Clin Oncol 2016;4:315-25. [PMID: 26998283 DOI: 10.3892/mco.2015.716] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 3.0] [Reference Citation Analysis]
145 Chapman CG, Long T, Waxman I. Liquid biopsies in pancreatic cancer: targeting the portal vein. Journal of Pancreatology 2019;2:76-81. [DOI: 10.1097/jp9.0000000000000027] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
146 Oettle H. Progress in the knowledge and treatment of advanced pancreatic cancer: from benchside to bedside. Cancer Treat Rev. 2014;40:1039-1047. [PMID: 25087471 DOI: 10.1016/j.ctrv.2014.07.003] [Cited by in Crossref: 69] [Cited by in F6Publishing: 52] [Article Influence: 9.9] [Reference Citation Analysis]
147 Olaoba OT, Ligali FC, Alabi ZO, Akinyemi AO, Ayinde KS. Of immune checkpoint maladies and remedies: The throwing of jabs in the oncogenic ring of PDAC. Biochim Biophys Acta Rev Cancer 2021;1875:188483. [PMID: 33232723 DOI: 10.1016/j.bbcan.2020.188483] [Reference Citation Analysis]
148 Zheng R, Nauheim D, Bassig J, Chadwick M, Schultz CW, Krampitz G, Lavu H, Winter JR, Yeo CJ, Berger AC. Margin-Positive Pancreatic Ductal Adenocarcinoma during Pancreaticoduodenectomy: Additional Resection Does Not Improve Survival. Ann Surg Oncol 2021;28:1552-62. [PMID: 32779052 DOI: 10.1245/s10434-020-09000-9] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
149 Donahue TR, Reber HA. Surgical management of pancreatic cancer--pancreaticoduodenectomy. Semin Oncol 2015;42:98-109. [PMID: 25726055 DOI: 10.1053/j.seminoncol.2014.12.009] [Cited by in Crossref: 25] [Cited by in F6Publishing: 20] [Article Influence: 3.6] [Reference Citation Analysis]
150 Lee AJ, Simoneau E, Chiang YJ, Lee JE, Kim MP, Aloia TA, Vauthey JN, Katz MH, Tzeng CD. Is early-stage pancreatic adenocarcinoma truly early: stage migration on final pathology with surgery-first vs neoadjuvant therapy sequencing. HPB (Oxford). 2019;21:1203-1210. [PMID: 30799277 DOI: 10.1016/j.hpb.2019.01.011] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 7.0] [Reference Citation Analysis]
151 Fujimoto T, Tsunedomi R, Matsukuma S, Yoshimura K, Oga A, Fujiwara N, Fujiwara Y, Matsui H, Shindo Y, Tokumitsu Y, Suzuki N, Kobayashi S, Hazama S, Eguchi H, Nagano H. Cathepsin B is highly expressed in pancreatic cancer stem-like cells and is associated with patients' surgical outcomes. Oncol Lett 2021;21:30. [PMID: 33240436 DOI: 10.3892/ol.2020.12291] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
152 Al Abbas AI, Zenati M, Reiser CJ, Hamad A, Jung JP, Zureikat AH, Zeh HJ 3rd, Hogg ME. Serum CA19-9 Response to Neoadjuvant Therapy Predicts Tumor Size Reduction and Survival in Pancreatic Adenocarcinoma. Ann Surg Oncol. 2020;27:2007-2014. [PMID: 31898105 DOI: 10.1245/s10434-019-08156-3] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 10.0] [Reference Citation Analysis]
153 Johnston A, Serhal A, Lopes Vendrami C, McCarthy RJ, Komanduri S, Horowitz JM, Nikolaidis P, Miller FH. The abrupt pancreatic duct cutoff sign on MDCT and MRI. Abdom Radiol (NY) 2020;45:2476-84. [PMID: 32444890 DOI: 10.1007/s00261-020-02582-8] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
154 Lewis HL, Chakedis JM, Talbert E, Haverick E, Rajasekera P, Hart P, Bloomston M, Dillhoff M, Pawlik TM, Guttridge D, Schmidt CR. Perioperative cytokine levels portend early death after pancreatectomy for ductal adenocarcinoma. J Surg Oncol 2018;117:1260-6. [DOI: 10.1002/jso.24940] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.8] [Reference Citation Analysis]
155 Kim BR, Kim JH, Ahn SJ, Joo I, Choi SY, Park SJ, Han JK. CT prediction of resectability and prognosis in patients with pancreatic ductal adenocarcinoma after neoadjuvant treatment using image findings and texture analysis. Eur Radiol. 2019;29:362-372. [PMID: 29931561 DOI: 10.1007/s00330-018-5574-0] [Cited by in Crossref: 26] [Cited by in F6Publishing: 20] [Article Influence: 8.7] [Reference Citation Analysis]
156 Sakaguchi T, Satoi S, Yamamoto T, Yamaki S, Sekimoto M. The past, present, and future status of multimodality treatment for resectable/borderline resectable pancreatic ductal adenocarcinoma. Surg Today 2020;50:335-43. [PMID: 31993761 DOI: 10.1007/s00595-020-01963-2] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
157 Ormanns S, Heinemann V, Raponi M, Isaacson J, Laubender RP, Haas M, Kruger S, Kleespies A, Mann E, Bartosiewicz M, Kirchner T, Boeck S. Human equilibrative nucleoside transporter 1 is not predictive for gemcitabine efficacy in advanced pancreatic cancer: Translational results from the AIO-PK0104 phase III study with the clone SP120 rabbit antibody. European Journal of Cancer 2014;50:1891-9. [DOI: 10.1016/j.ejca.2014.04.023] [Cited by in Crossref: 23] [Cited by in F6Publishing: 22] [Article Influence: 3.3] [Reference Citation Analysis]
158 Kosmidis C, Sapalidis K, Kotidis E, Mixalopoulos N, Zarogoulidis P, Tsavlis D, Baka S, Man YG, Kanellos J. Pancreatic cancer from bench to bedside: molecular pathways and treatment options. Ann Transl Med 2016;4:165. [PMID: 27275478 DOI: 10.21037/atm.2016.05.11] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
159 McGuigan A, Kelly P, Turkington RC, Jones C, Coleman HG, McCain RS. Pancreatic cancer: A review of clinical diagnosis, epidemiology, treatment and outcomes. World J Gastroenterol. 2018;24:4846-4861. [PMID: 30487695 DOI: 10.3748/wjg.v24.i43.4846] [Cited by in CrossRef: 335] [Cited by in F6Publishing: 261] [Article Influence: 167.5] [Reference Citation Analysis]
160 Watanabe Y, Nishihara K, Matsumoto S, Okayama T, Abe Y, Nakano T. Effect of postoperative major complications on prognosis after pancreatectomy for pancreatic cancer: a retrospective review. Surg Today 2017;47:555-67. [DOI: 10.1007/s00595-016-1426-1] [Cited by in Crossref: 21] [Cited by in F6Publishing: 17] [Article Influence: 4.2] [Reference Citation Analysis]
161 Yang SH, Kuo TC, Wu H, Guo JC, Hsu C, Hsu CH, Tien YW, Yeh KH, Cheng AL, Kuo SH. Perspectives on the combination of radiotherapy and targeted therapy with DNA repair inhibitors in the treatment of pancreatic cancer. World J Gastroenterol 2016;22:7275-88. [PMID: 27621574 DOI: 10.3748/wjg.v22.i32.7275] [Cited by in CrossRef: 18] [Cited by in F6Publishing: 15] [Article Influence: 4.5] [Reference Citation Analysis]
162 Miao JX, Wang JY, Li HZ, Guo HR, Dunmall LSC, Zhang ZX, Cheng ZG, Gao DL, Dong JZ, Wang ZD, Wang YH. Promising xenograft animal model recapitulating the features of human pancreatic cancer. World J Gastroenterol 2020;26:4802-16. [PMID: 32921958 DOI: 10.3748/wjg.v26.i32.4802] [Cited by in CrossRef: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
163 Burkhart RA, Javed AA, Ronnekleiv-kelly S, Wright MJ, Poruk KE, Eckhauser F, Makary MA, Cameron JL, Wolfgang CL, He J, Weiss MJ. The use of negative pressure wound therapy to prevent post-operative surgical site infections following pancreaticoduodenectomy. HPB 2017;19:825-31. [DOI: 10.1016/j.hpb.2017.05.004] [Cited by in Crossref: 17] [Cited by in F6Publishing: 12] [Article Influence: 4.3] [Reference Citation Analysis]
164 Meltzer RS, Kooby DA, Switchenko JM, Datta J, Carpizo DR, Maithel SK, Shah MM. Does Major Pancreatic Surgery Have Utility in Nonagenarians with Pancreas Cancer? Ann Surg Oncol 2021;28:2265-72. [PMID: 33141373 DOI: 10.1245/s10434-020-09279-8] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
165 Xie T, Wang X, Li M, Tong T, Yu X, Zhou Z. Pancreatic ductal adenocarcinoma: a radiomics nomogram outperforms clinical model and TNM staging for survival estimation after curative resection. Eur Radiol. 2020;30:2513-2524. [PMID: 32006171 DOI: 10.1007/s00330-019-06600-2] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 11.0] [Reference Citation Analysis]
166 Carpenter E, Nelson S, Bednar F, Cho C, Nathan H, Sahai V, di Magliano MP, Frankel TL. Immunotherapy for pancreatic ductal adenocarcinoma. J Surg Oncol 2021;123:751-9. [PMID: 33595893 DOI: 10.1002/jso.26312] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
167 Oneda E, Zaniboni A. Are We Sure that Adjuvant Chemotherapy is the Best Approach for Resectable Pancreatic Cancer? Are We in the Era of Neoadjuvant Treatment? A Review of Current Literature. J Clin Med 2019;8:E1922. [PMID: 31717439 DOI: 10.3390/jcm8111922] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
168 Khattab A, Patruni S, Abel S, Hasan S, Ludmir EB, Finley G, Monga D, Wegner RE, Verma V. Long-term outcomes by response to neoadjuvant chemotherapy or chemoradiation in patients with resected pancreatic adenocarcinoma. J Gastrointest Oncol 2019;10:918-27. [PMID: 31602330 DOI: 10.21037/jgo.2019.07.02] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
169 Al Haddad AH, Adrian TE. Challenges and future directions in therapeutics for pancreatic ductal adenocarcinoma. Expert Opin Investig Drugs. 2014;23:1499-1515. [PMID: 25078674 DOI: 10.1517/13543784.2014.933206] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 1.4] [Reference Citation Analysis]
170 van Roest MH, van der Aa MA, van der Geest LG, de Jong KP. The Impact of Socioeconomic Status, Surgical Resection and Type of Hospital on Survival in Patients with Pancreatic Cancer. A Population-Based Study in The Netherlands. PLoS One 2016;11:e0166449. [PMID: 27832174 DOI: 10.1371/journal.pone.0166449] [Cited by in Crossref: 25] [Cited by in F6Publishing: 16] [Article Influence: 5.0] [Reference Citation Analysis]
171 Kagedan DJ, Dixon ME, Raju RS, Li Q, Elmi M, Shin E, Liu N, El-Sedfy A, Paszat L, Kiss A, Earle CC, Mittmann N, Coburn NG. Predictors of adjuvant treatment for pancreatic adenocarcinoma at the population level. Curr Oncol 2016;23:334-42. [PMID: 27803598 DOI: 10.3747/co.23.3205] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
172 Ueno M, Morinaga S, Hashimoto Y, Umemoto K, Sasahira N, Saiura A, Seyama Y, Honda G, Ioka T, Takahashi H, Miyamoto A, Nakamori S, Unno M, Takadate T, Mizuno N, Shimizu Y, Ueno H, Sugiyama M, Fukutomi A, Shimizu S, Okusaka T, Furuse J. Tolerability of Nab-Paclitaxel Plus Gemcitabine as Adjuvant Setting in Japanese Patients With Resected Pancreatic Cancer: Phase I Study. Pancreas 2021;50:83-8. [PMID: 33370027 DOI: 10.1097/MPA.0000000000001702] [Reference Citation Analysis]
173 Chen Y, Su L, Huang C, Wu S, Qiu X, Zhao X, Meng Q, Meng YM, Kong X, Wang M, Liu C, Wong PP. Galactosyltransferase B4GALT1 confers chemoresistance in pancreatic ductal adenocarcinomas by upregulating N-linked glycosylation of CDK11p110. Cancer Lett 2021;500:228-43. [PMID: 33309857 DOI: 10.1016/j.canlet.2020.12.006] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
174 Essaji Y, Rocha FG. Seminars in surgical oncology-Pancreas cancer adjuvant therapy trials. J Surg Oncol 2021;123:1467-74. [PMID: 33831255 DOI: 10.1002/jso.26382] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
175 Yi X, Chen S, Wang W, Zou L, Diao D, Zheng Y, He Y, Li H, Luo L, Xiong W, Wan J. A Systematic Review and Meta-Analysis of Laparoscopic and Open Distal Pancreatectomy of Nonductal Adenocarcinomatous Pancreatic Tumor (NDACPT) in the Pancreatic Body and Tail. Surgical Laparoscopy, Endoscopy & Percutaneous Techniques 2017;27:206-19. [DOI: 10.1097/sle.0000000000000416] [Cited by in Crossref: 14] [Cited by in F6Publishing: 2] [Article Influence: 3.5] [Reference Citation Analysis]
176 Patel SH, Katz MHG, Ahmad SA. The Landmark Series: Preoperative Therapy for Pancreatic Cancer. Ann Surg Oncol 2021;28:4104-29. [PMID: 34047859 DOI: 10.1245/s10434-021-10075-1] [Reference Citation Analysis]
177 Elsayed M, Abdelrahim M. The Latest Advancement in Pancreatic Ductal Adenocarcinoma Therapy: A Review Article for the Latest Guidelines and Novel Therapies. Biomedicines 2021;9:389. [PMID: 33917380 DOI: 10.3390/biomedicines9040389] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
178 Ma SJ, Oladeru OT, Miccio JA, Iovoli AJ, Hermann GM, Singh AK. Association of Timing of Adjuvant Therapy With Survival in Patients With Resected Stage I to II Pancreatic Cancer. JAMA Netw Open 2019;2:e199126. [PMID: 31411712 DOI: 10.1001/jamanetworkopen.2019.9126] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 8.0] [Reference Citation Analysis]
179 Croome KP, Farnell MB, Que FG, Reid-lombardo K, Truty MJ, Nagorney DM, Kendrick ML. Total Laparoscopic Pancreaticoduodenectomy for Pancreatic Ductal Adenocarcinoma: Oncologic Advantages Over Open Approaches? Annals of Surgery 2014;260:633-40. [DOI: 10.1097/sla.0000000000000937] [Cited by in Crossref: 284] [Cited by in F6Publishing: 88] [Article Influence: 40.6] [Reference Citation Analysis]
180 Tomimaru Y, Eguchi H, Satoh T, Tomokuni A, Asaoka T, Wada H, Marubashi S, Ogawa K, Takehara T, Mori M, Doki Y, Nagano H. Feasibility of pre-operative chemoradiotherapy with gemcitabine to treat pancreatic cancer in patients with impaired renal function. Jpn J Clin Oncol 2015;45:343-8. [PMID: 25589454 DOI: 10.1093/jjco/hyu224] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
181 Rutenberg MS, Nichols RC. Proton beam radiotherapy for pancreas cancer. J Gastrointest Oncol 2020;11:166-75. [PMID: 32175120 DOI: 10.21037/jgo.2019.03.02] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 5.0] [Reference Citation Analysis]
182 Tol JA, Eshuis WJ, Besselink MG, van Gulik TM, Busch OR, Gouma DJ. Non-radical resection versus bypass procedure for pancreatic cancer - a consecutive series and systematic review. Eur J Surg Oncol 2015;41:220-7. [PMID: 25511567 DOI: 10.1016/j.ejso.2014.11.041] [Cited by in Crossref: 26] [Cited by in F6Publishing: 13] [Article Influence: 3.7] [Reference Citation Analysis]
183 Maftouh M, Belo AI, Avan A, Funel N, Peters GJ, Giovannetti E, Van Die I. Galectin-4 expression is associated with reduced lymph node metastasis and modulation of Wnt/β-catenin signalling in pancreatic adenocarcinoma. Oncotarget 2014;5:5335-49. [PMID: 24977327 DOI: 10.18632/oncotarget.2104] [Cited by in Crossref: 36] [Cited by in F6Publishing: 33] [Article Influence: 6.0] [Reference Citation Analysis]
184 Tzeng CD, Cao HST, Lee JE, Pisters PWT, Varadhachary GR, Wolff RA, Abbruzzese JL, Crane CH, Evans DB, Wang H, Abbott DE, Vauthey J, Aloia TA, Fleming JB, Katz MHG. Treatment Sequencing for Resectable Pancreatic Cancer: Influence of Early Metastases and Surgical Complications on Multimodality Therapy Completion and Survival. J Gastrointest Surg 2014;18:16-25. [DOI: 10.1007/s11605-013-2412-1] [Cited by in Crossref: 121] [Cited by in F6Publishing: 95] [Article Influence: 15.1] [Reference Citation Analysis]
185 Heinrich S, Besselink M, Moehler M, van Laethem JL, Ducreux M, Grimminger P, Mittler J, Lang H, Lutz MP, Lesurtel M;  Scientific and Research Committee of the E-AHPBA and the EORTC pancreas working group. Opinions and use of neoadjuvant therapy for resectable, borderline resectable, and locally advanced pancreatic cancer: international survey and case-vignette study. BMC Cancer. 2019;19:675. [PMID: 31288786 DOI: 10.1186/s12885-019-5889-5] [Cited by in Crossref: 13] [Cited by in F6Publishing: 8] [Article Influence: 6.5] [Reference Citation Analysis]
186 Bergquist JR, Thiels CA, Shubert CR, Ivanics T, Habermann EB, Vege SS, Grotz TE, Cleary SP, Smoot RL, Kendrick ML, Nagorney DM, Truty MJ. Perception versus reality: A National Cohort Analysis of the surgery-first approach for resectable pancreatic cancer. Cancer Med 2021. [PMID: 34289264 DOI: 10.1002/cam4.4144] [Reference Citation Analysis]
187 Oba A, Ho F, Bao QR, Al-Musawi MH, Schulick RD, Del Chiaro M. Neoadjuvant Treatment in Pancreatic Cancer. Front Oncol. 2020;10:245. [PMID: 32185128 DOI: 10.3389/fonc.2020.00245] [Cited by in Crossref: 29] [Cited by in F6Publishing: 24] [Article Influence: 29.0] [Reference Citation Analysis]
188 Golan T, Barenboim A, Lahat G, Nachmany I, Goykhman Y, Shacham-Shmueli E, Halpern N, Brazowski E, Geva R, Wolf I, Goldes Y, Ben-Haim M, Klausner JM, Lubezky N. Increased Rate of Complete Pathologic Response After Neoadjuvant FOLFIRINOX for BRCA Mutation Carriers with Borderline Resectable Pancreatic Cancer. Ann Surg Oncol 2020;27:3963-70. [PMID: 32314163 DOI: 10.1245/s10434-020-08469-8] [Cited by in Crossref: 15] [Cited by in F6Publishing: 10] [Article Influence: 15.0] [Reference Citation Analysis]
189 Li C, Wang J, Lu X, Ge H, Jin X, Guan Q, su Y, Pan R, Li P, Cai W, Zhu X. Hydrogen peroxide-response nanoprobe for CD44-targeted circulating tumor cell detection and H2O2 analysis. Biomaterials 2020;255:120071. [DOI: 10.1016/j.biomaterials.2020.120071] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 6.0] [Reference Citation Analysis]
190 Mirkin KA, Hollenbeak CS, Wong J. Prognostic impact of carbohydrate antigen 19-9 level at diagnosis in resected stage I-III pancreatic adenocarcinoma: a U.S. population study. J Gastrointest Oncol 2017;8:778-88. [PMID: 29184681 DOI: 10.21037/jgo.2017.07.04] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
191 Berger AW, Schwerdel D, Reinacher-Schick A, Uhl W, Algül H, Friess H, Janssen KP, König A, Ghadimi M, Gallmeier E, Bartsch DK, Geissler M, Staib L, Tannapfel A, Kleger A, Beutel A, Schulte LA, Kornmann M, Ettrich TJ, Seufferlein T. A Blood-Based Multi Marker Assay Supports the Differential Diagnosis of Early-Stage Pancreatic Cancer. Theranostics 2019;9:1280-7. [PMID: 30867830 DOI: 10.7150/thno.29247] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 9.0] [Reference Citation Analysis]
192 Zarei M, Lal S, Parker SJ, Nevler A, Vaziri-Gohar A, Dukleska K, Mambelli-Lisboa NC, Moffat C, Blanco FF, Chand SN, Jimbo M, Cozzitorto JA, Jiang W, Yeo CJ, Londin ER, Seifert EL, Metallo CM, Brody JR, Winter JM. Posttranscriptional Upregulation of IDH1 by HuR Establishes a Powerful Survival Phenotype in Pancreatic Cancer Cells. Cancer Res 2017;77:4460-71. [PMID: 28652247 DOI: 10.1158/0008-5472.CAN-17-0015] [Cited by in Crossref: 40] [Cited by in F6Publishing: 27] [Article Influence: 10.0] [Reference Citation Analysis]
193 Hackert T, Ulrich A, Büchler MW. Borderline resectable pancreatic cancer. Cancer Lett 2016;375:231-7. [PMID: 26970276 DOI: 10.1016/j.canlet.2016.02.039] [Cited by in Crossref: 31] [Cited by in F6Publishing: 19] [Article Influence: 6.2] [Reference Citation Analysis]
194 Kundranda MN, Niu J. Albumin-bound paclitaxel in solid tumors: clinical development and future directions. Drug Des Devel Ther 2015;9:3767-77. [PMID: 26244011 DOI: 10.2147/DDDT.S88023] [Cited by in Crossref: 93] [Cited by in F6Publishing: 37] [Article Influence: 15.5] [Reference Citation Analysis]
195 Chen D, Zhu X, Tao W, Kong Y, Huag Y, Zhang Y, Liu R, Jiang L, Tang Y, Yu H, Hao Q, Yang X, Zou H, Chen J, Lu Y, Zhang H, Li W. Regulation of pancreatic cancer microenvironment by an intelligent gemcitabine@nanogel system via in vitro 3D model for promoting therapeutic efficiency. Journal of Controlled Release 2020;324:545-59. [DOI: 10.1016/j.jconrel.2020.06.001] [Cited by in Crossref: 7] [Cited by in F6Publishing: 2] [Article Influence: 7.0] [Reference Citation Analysis]
196 Halfdanarson TR, Foster NR, Kim GP, Meyers JP, Smyrk TC, McCullough AE, Ames MM, Jaffe JP, Alberts SR. A Phase II Randomized Trial of Panitumumab, Erlotinib, and Gemcitabine Versus Erlotinib and Gemcitabine in Patients with Untreated, Metastatic Pancreatic Adenocarcinoma: North Central Cancer Treatment Group Trial N064B (Alliance). Oncologist 2019;24:589-e160. [PMID: 30679315 DOI: 10.1634/theoncologist.2018-0878] [Cited by in Crossref: 14] [Cited by in F6Publishing: 10] [Article Influence: 7.0] [Reference Citation Analysis]
197 Belfiori G, Crippa S, Francesca A, Pagnanelli M, Tamburrino D, Gasparini G, Partelli S, Andreasi V, Rubini C, Zamboni G, Falconi M. Long-Term Survivors after Upfront Resection for Pancreatic Ductal Adenocarcinoma: An Actual 5-Year Analysis of Disease-Specific and Post-Recurrence Survival. Ann Surg Oncol 2021. [PMID: 34258720 DOI: 10.1245/s10434-021-10401-7] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
198 Vidri RJ, Fitzgerald TL. GSK-3: An important kinase in colon and pancreatic cancers. Biochim Biophys Acta Mol Cell Res 2020;1867:118626. [PMID: 31987793 DOI: 10.1016/j.bbamcr.2019.118626] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
199 Chawla A, Molina G, Pak LM, Rosenthal M, Mancias JD, Clancy TE, Wolpin BM, Wang J. Neoadjuvant Therapy is Associated with Improved Survival in Borderline-Resectable Pancreatic Cancer. Ann Surg Oncol 2020;27:1191-200. [DOI: 10.1245/s10434-019-08087-z] [Cited by in Crossref: 15] [Cited by in F6Publishing: 10] [Article Influence: 7.5] [Reference Citation Analysis]
200 Shaib WL, Sayegh L, Zhang C, Belalcazar A, Ip A, Alese OB, Akce M, Wu C, Qu Y, Maithel SK, Kooby D, Cardona K, Sarmeinto JM, El-Rayes BF. Induction Therapy in Localized Pancreatic Cancer. Pancreas 2019;48:913-9. [PMID: 31268982 DOI: 10.1097/MPA.0000000000001353] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
201 Han D, Gao F, Liu JL, Wang H, Fu Q, Yang GW. Analysis of radiotherapy impact on survival in resected stage I/II pancreatic cancer patients: a population-based study. BMC Cancer 2021;21:560. [PMID: 34001035 DOI: 10.1186/s12885-021-08288-4] [Reference Citation Analysis]
202 Kurreck A, Weckwerth J, Modest DP, Striefler JK, Bahra M, Bischoff S, Pelzer U, Oettle H, Kruger S, Riess H, Sinn M. Impact of completeness of adjuvant gemcitabine, relapse pattern, and subsequent therapy on outcome of patients with resected pancreatic ductal adenocarcinoma - A pooled analysis of CONKO-001, CONKO-005, and CONKO-006 trials. Eur J Cancer 2021;150:250-9. [PMID: 33940349 DOI: 10.1016/j.ejca.2021.03.036] [Reference Citation Analysis]
203 Sato H, Liss AS, Mizukami Y. Large-duct pattern invasive adenocarcinoma of the pancreas-a variant mimicking pancreatic cystic neoplasms: A minireview. World J Gastroenterol 2021;27:3262-78. [PMID: 34163110 DOI: 10.3748/wjg.v27.i23.3262] [Reference Citation Analysis]
204 Conroy T, Ducreux M. Adjuvant treatment of pancreatic cancer. Curr Opin Oncol 2019;31:346-53. [PMID: 30994497 DOI: 10.1097/CCO.0000000000000546] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 9.0] [Reference Citation Analysis]
205 Neuzillet C, Gaujoux S, Williet N, Bachet JB, Bauguion L, Colson Durand L, Conroy T, Dahan L, Gilabert M, Huguet F, Marthey L, Meilleroux J, de Mestier L, Napoléon B, Portales F, Sa Cunha A, Schwarz L, Taieb J, Chibaudel B, Bouché O, Hammel P; Thésaurus National de Cancérologie Digestive (TNCD)., Société Nationale Française de Gastroentérologie (SNFGE)., Fédération Francophone de Cancérologie Digestive (FFCD)., Groupe Coopérateur multidisciplinaire en Oncologie (GERCOR)., Fédération Nationale des Centres de Lutte Contre le Cancer (UNICANCER)., Société Française de Chirurgie Digestive (SFCD)., Société Française d’Endoscopie Digestive (SFED)., Société Française de Radiothérapie Oncologique (SFRO)., Association de Chirurgie Hépato-Bilio-Pancréatique et Transplantation (ACHBT)., Association Française de Chirurgie (AFC). Pancreatic cancer: French clinical practice guidelines for diagnosis, treatment and follow-up (SNFGE, FFCD, GERCOR, UNICANCER, SFCD, SFED, SFRO, ACHBT, AFC). Dig Liver Dis 2018;50:1257-71. [PMID: 30219670 DOI: 10.1016/j.dld.2018.08.008] [Cited by in Crossref: 53] [Cited by in F6Publishing: 39] [Article Influence: 17.7] [Reference Citation Analysis]
206 Gabriel E, Thirunavukarasu P, Attwood K, Nurkin SJ. National disparities in minimally invasive surgery for pancreatic tumors. Surg Endosc 2017;31:398-409. [PMID: 27412124 DOI: 10.1007/s00464-016-4987-6] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.6] [Reference Citation Analysis]
207 Fujii Y, Kamachi H, Matsuzawa F, Mizukami T, Kobayashi N, Fukai M, Taketomi A. Early administration of amatuximab, a chimeric high-affinity anti-mesothelin monoclonal antibody, suppresses liver metastasis of mesothelin-expressing pancreatic cancer cells and enhances gemcitabine sensitivity in a xenograft mouse model. Invest New Drugs 2021. [PMID: 33905019 DOI: 10.1007/s10637-021-01118-1] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
208 Roth MT, Cardin DB, Berlin JD. Recent advances in the treatment of pancreatic cancer. F1000Res. 2020;9. [PMID: 32148767 DOI: 10.12688/f1000research.21981.1] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 9.0] [Reference Citation Analysis]
209 Roukos DH. Spatiotemporal diversification of intrapatient genomic clones and early drug development concepts realize the roadmap of precision cancer medicine. Drug Discov Today 2017;22:1148-64. [PMID: 28400153 DOI: 10.1016/j.drudis.2017.03.014] [Cited by in Crossref: 27] [Cited by in F6Publishing: 14] [Article Influence: 6.8] [Reference Citation Analysis]
210 Choi SB, Han HJ, Park P, Kim WB, Song TJ, Choi SY. Systematic review of the clinical significance of lymph node micrometastases of pancreatic adenocarcinoma following surgical resection. Pancreatology 2017;17:342-9. [PMID: 28336226 DOI: 10.1016/j.pan.2017.03.008] [Cited by in Crossref: 10] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
211 Li Y, Li X, Tip P, Zhang L. Use of a novel herbal medicine in a 75-year-old woman with multi-metastatic pancreatic cancer: A case report and review of the literature. Oncol Lett 2015;10:263-7. [PMID: 26171011 DOI: 10.3892/ol.2015.3237] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 1.2] [Reference Citation Analysis]
212 Herbst B, Zheng L. Precision medicine in pancreatic cancer: treating every patient as an exception. The Lancet Gastroenterology & Hepatology 2019;4:805-10. [DOI: 10.1016/s2468-1253(19)30175-x] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 4.5] [Reference Citation Analysis]
213 Girgis MD, Zenati MS, King JC, Hamad A, Zureikat AH, Zeh HJ, Hogg ME. Oncologic Outcomes After Robotic Pancreatic Resections Are Not Inferior to Open Surgery. Ann Surg. 2019;. [PMID: 31663967 DOI: 10.1097/sla.0000000000003615] [Cited by in Crossref: 21] [Cited by in F6Publishing: 11] [Article Influence: 10.5] [Reference Citation Analysis]
214 Eubanks A, Pepe J, Veldhuis P, de la Fuente SG. Age as a prognostic indicator for adjuvant therapy in patients who underwent pancreatic resections for cancer. J Geriatr Oncol 2018;9:362-6. [PMID: 29330039 DOI: 10.1016/j.jgo.2017.12.004] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.7] [Reference Citation Analysis]
215 Terasaki F, Sugiura T, Okamura Y, Ito T, Yamamoto Y, Ashida R, Ohgi K, Uesaka K. The preoperative controlling nutritional status (CONUT) score is an independent prognostic marker for pancreatic ductal adenocarcinoma. Updates Surg 2021;73:251-9. [PMID: 32410163 DOI: 10.1007/s13304-020-00792-9] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
216 Principe DR, Underwood PW, Korc M, Trevino JG, Munshi HG, Rana A. The Current Treatment Paradigm for Pancreatic Ductal Adenocarcinoma and Barriers to Therapeutic Efficacy. Front Oncol 2021;11:688377. [PMID: 34336673 DOI: 10.3389/fonc.2021.688377] [Reference Citation Analysis]
217 Xie C, Duffy AG, Brar G, Fioravanti S, Mabry-Hrones D, Walker M, Bonilla CM, Wood BJ, Citrin DE, Gil Ramirez EM, Escorcia FE, Redd B, Hernandez JM, Davis JL, Gasmi B, Kleiner D, Steinberg SM, Jones JC, Greten TF. Immune Checkpoint Blockade in Combination with Stereotactic Body Radiotherapy in Patients with Metastatic Pancreatic Ductal Adenocarcinoma. Clin Cancer Res 2020;26:2318-26. [PMID: 31996388 DOI: 10.1158/1078-0432.CCR-19-3624] [Cited by in Crossref: 15] [Cited by in F6Publishing: 7] [Article Influence: 15.0] [Reference Citation Analysis]
218 Sinn M, Riess H, Sinn BV, Stieler JM, Pelzer U, Striefler JK, Oettle H, Bahra M, Denkert C, Bläker H. Human equilibrative nucleoside transporter 1 expression analysed by the clone SP 120 rabbit antibody is not predictive in patients with pancreatic cancer treated with adjuvant gemcitabine - Results from the CONKO-001 trial. Eur J Cancer. 2015;51:1546-1554. [PMID: 26049689 DOI: 10.1016/j.ejca.2015.05.005] [Cited by in Crossref: 33] [Cited by in F6Publishing: 24] [Article Influence: 5.5] [Reference Citation Analysis]
219 Kimura K, Amano R, Nakata B, Yamazoe S, Hirata K, Murata A, Miura K, Nishio K, Hirakawa T, Ohira M, Hirakawa K. Clinical and pathological features of five-year survivors after pancreatectomy for pancreatic adenocarcinoma. World J Surg Oncol 2014;12:360. [PMID: 25429841 DOI: 10.1186/1477-7819-12-360] [Cited by in Crossref: 22] [Cited by in F6Publishing: 18] [Article Influence: 3.1] [Reference Citation Analysis]
220 Qiu J, Yang G, Feng M, Zheng S, Cao Z, You L, Zheng L, Zhang T, Zhao Y. Extracellular vesicles as mediators of the progression and chemoresistance of pancreatic cancer and their potential clinical applications. Mol Cancer. 2018;17:2. [PMID: 29304816 DOI: 10.1186/s12943-017-0755-z] [Cited by in Crossref: 37] [Cited by in F6Publishing: 34] [Article Influence: 12.3] [Reference Citation Analysis]
221 Shaib WL, Hawk N, Cassidy RJ, Chen Z, Zhang C, Brutcher E, Kooby D, Maithel SK, Sarmiento JM, Landry J, El-Rayes BF. A Phase 1 Study of Stereotactic Body Radiation Therapy Dose Escalation for Borderline Resectable Pancreatic Cancer After Modified FOLFIRINOX (NCT01446458). Int J Radiat Oncol Biol Phys 2016;96:296-303. [PMID: 27475674 DOI: 10.1016/j.ijrobp.2016.05.010] [Cited by in Crossref: 40] [Cited by in F6Publishing: 28] [Article Influence: 8.0] [Reference Citation Analysis]
222 Boyle J, Czito B, Willett C, Palta M. Adjuvant radiation therapy for pancreatic cancer: a review of the old and the new. J Gastrointest Oncol 2015;6:436-44. [PMID: 26261730 DOI: 10.3978/j.issn.2078-6891.2015.014] [Cited by in F6Publishing: 7] [Reference Citation Analysis]
223 Rahal A, Musher B. Oncolytic viral therapy for pancreatic cancer. J Surg Oncol 2017;116:94-103. [PMID: 28407327 DOI: 10.1002/jso.24626] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 5.3] [Reference Citation Analysis]
224 Hidalgo M, Cascinu S, Kleeff J, Labianca R, Löhr JM, Neoptolemos J, Real FX, Van Laethem JL, Heinemann V. Addressing the challenges of pancreatic cancer: future directions for improving outcomes. Pancreatology. 2013;15:8-18. [PMID: 25547205 DOI: 10.1016/j.pan.2014.10.001] [Cited by in Crossref: 222] [Cited by in F6Publishing: 185] [Article Influence: 31.7] [Reference Citation Analysis]
225 Tomihara H, Eguchi H, Yamada D, Gotoh K, Kawamoto K, Wada H, Asaoka T, Noda T, Takeda Y, Tanemura M, Mori M, Doki Y. Preoperative chemoradiotherapy does not compromise the feasibility of adjuvant chemotherapy for patients with pancreatic ductal adenocarcinoma. Surg Today 2017;47:218-26. [PMID: 27586014 DOI: 10.1007/s00595-016-1405-6] [Cited by in Crossref: 22] [Cited by in F6Publishing: 18] [Article Influence: 4.4] [Reference Citation Analysis]
226 Vitolo V, Cobianchi L, Brugnatelli S, Barcellini A, Peloso A, Facoetti A, Vanoli A, Delfanti S, Preda L, Molinelli S, Klersy C, Fossati P, Orecchia R, Valvo F. Preoperative chemotherapy and carbon ions therapy for treatment of resectable and borderline resectable pancreatic adenocarcinoma: a prospective, phase II, multicentre, single-arm study. BMC Cancer 2019;19:922. [PMID: 31521134 DOI: 10.1186/s12885-019-6108-0] [Cited by in Crossref: 11] [Cited by in F6Publishing: 6] [Article Influence: 5.5] [Reference Citation Analysis]
227 Fujii T, Satoi S, Yamada S, Murotani K, Yanagimoto H, Takami H, Yamamoto T, Kanda M, Yamaki S, Hirooka S, Kon M, Kodera Y. Clinical benefits of neoadjuvant chemoradiotherapy for adenocarcinoma of the pancreatic head: an observational study using inverse probability of treatment weighting. J Gastroenterol 2017;52:81-93. [PMID: 27169844 DOI: 10.1007/s00535-016-1217-x] [Cited by in Crossref: 26] [Cited by in F6Publishing: 21] [Article Influence: 5.2] [Reference Citation Analysis]
228 Moaven O, Clark CJ, Russell GB, Votanopoulos KI, Howerton R, Levine EA, Shen P. Optimal Adjuvant Treatment Approach After Upfront Resection of Pancreatic Cancer: Revisiting the Role of Radiation Based on Pathologic Features. Ann Surg 2020. [PMID: 31913868 DOI: 10.1097/SLA.0000000000003770] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
229 Tanaka H, Imai H, Higashi T, Murase K, Matsuhashi N, Yoshida K. Splenic artery transposition for hepatic arterial reconstruction in conversion surgery of an initially unresectable, locally advanced pancreatic cancer after gemcitabine/nab-paclitaxel: A case report. Int J Surg Case Rep 2021;78:192-6. [PMID: 33360334 DOI: 10.1016/j.ijscr.2020.12.041] [Reference Citation Analysis]
230 Erdmann JI, Eskens FA, Vollmer CM, Kok NF, Groot Koerkamp B, Biermann K, van Eijck CH. Histological and Molecular Subclassification of Pancreatic and Nonpancreatic Periampullary Cancers: Implications for (Neo) Adjuvant Systemic Treatment. Ann Surg Oncol. 2015;22:2401-2407. [PMID: 25503345 DOI: 10.1245/s10434-014-4267-4] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
231 Erdmann JI, Morak MJ, Duivenvoorden HJ, van Dekken H, Kazemier G, Kok NF, van Eijck CH. Long-term survival after resection for non-pancreatic periampullary cancer followed by adjuvant intra-arterial chemotherapy and concomitant radiotherapy. HPB (Oxford) 2015;17:573-9. [PMID: 25800041 DOI: 10.1111/hpb.12401] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
232 Sohal DP, Walsh RM, Ramanathan RK, Khorana AA. Pancreatic adenocarcinoma: treating a systemic disease with systemic therapy. J Natl Cancer Inst. 2014;106:dju011. [PMID: 24563516 DOI: 10.1093/jnci/dju011] [Cited by in Crossref: 84] [Cited by in F6Publishing: 67] [Article Influence: 12.0] [Reference Citation Analysis]
233 Ohmine K, Kawaguchi K, Ohtsuki S, Motoi F, Ohtsuka H, Kamiie J, Abe T, Unno M, Terasaki T. Quantitative Targeted Proteomics of Pancreatic Cancer: Deoxycytidine Kinase Protein Level Correlates to Progression-Free Survival of Patients Receiving Gemcitabine Treatment. Mol Pharm 2015;12:3282-91. [PMID: 26280109 DOI: 10.1021/acs.molpharmaceut.5b00282] [Cited by in Crossref: 28] [Cited by in F6Publishing: 16] [Article Influence: 4.7] [Reference Citation Analysis]
234 Katz MH, Kim MP, Tzeng CW, Lee JE. Preoperative Chemoradiation for Borderline Resectable Pancreatic Cancer: The New Standard? Ann Surg 2018;268:223-4. [PMID: 29672417 DOI: 10.1097/SLA.0000000000002783] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
235 Lutz MP, Zalcberg JR, Ducreux M, Aust D, Bruno MJ, Büchler MW, Delpero JR, Gloor B, Glynne-Jones R, Hartwig W, Huguet F, Laurent-Puig P, Lordick F, Maisonneuve P, Mayerle J, Martignoni M, Neoptolemos J, Rhim AD, Schmied BM, Seufferlein T, Werner J, van Laethem JL, Otto F. 3rd St. Gallen EORTC Gastrointestinal Cancer Conference: Consensus recommendations on controversial issues in the primary treatment of pancreatic cancer. Eur J Cancer 2017;79:41-9. [PMID: 28460245 DOI: 10.1016/j.ejca.2017.03.022] [Cited by in Crossref: 31] [Cited by in F6Publishing: 22] [Article Influence: 7.8] [Reference Citation Analysis]
236 Strijker M, Gerritsen A, van Hilst J, Bijlsma MF, Bonsing BA, Brosens LA, Bruno MJ, van Dam RM, Dijk F, van Eijck CH, Farina Sarasqueta A, Fockens P, Gerhards MF, Groot Koerkamp B, van der Harst E, de Hingh IH, van Hooft JE, Huysentruyt CJ, Kazemier G, Klaase JM, van Laarhoven CJ, van Laarhoven HW, Liem MS, de Meijer VE, van Rijssen LB, van Santvoort HC, Suker M, Verhagen JH, Verheij J, Verspaget HW, Wennink RA, Wilmink JW, Molenaar IQ, Boermeester MA, Busch OR, Besselink MG; Dutch Pancreatitis Study Group and Dutch Pancreatic Cancer Group. The Dutch Pancreas Biobank Within the Parelsnoer Institute: A Nationwide Biobank of Pancreatic and Periampullary Diseases. Pancreas 2018;47:495-501. [PMID: 29521943 DOI: 10.1097/MPA.0000000000001018] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
237 Mas L, Schwarz L, Bachet JB. Adjuvant chemotherapy in pancreatic cancer: state of the art and future perspectives. Curr Opin Oncol 2020;32:356-63. [PMID: 32541325 DOI: 10.1097/CCO.0000000000000639] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
238 Blanco VM, Latif T, Chu Z, Qi X. Imaging and Therapy of Pancreatic Cancer with Phosphatidylserine-Targeted Nanovesicles. Transl Oncol 2015;8:196-203. [PMID: 26055177 DOI: 10.1016/j.tranon.2015.03.011] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 2.5] [Reference Citation Analysis]
239 Engebretson A, Matrisian L, Thompson C. Pancreatic cancer: Patient and caregiver perceptions on diagnosis, psychological impact, and importance of support. Pancreatology 2015;15:701-7. [PMID: 26092655 DOI: 10.1016/j.pan.2015.05.471] [Cited by in Crossref: 14] [Cited by in F6Publishing: 10] [Article Influence: 2.3] [Reference Citation Analysis]
240 Zheng ZJ, Wang MJ, Tan CL, Chen YH, Ping J, Liu XB. Prognostic impact of lymph node status in patients after total pancreatectomy for pancreatic ductal adenocarcinoma: A strobe-compliant study. Medicine (Baltimore) 2020;99:e19327. [PMID: 32080152 DOI: 10.1097/MD.0000000000019327] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
241 Blaszak M, El-Masri M, Hirmiz K, Mathews J, Omar A, Elfiki T, Gupta R, Hamm C, Kanjeekal S, Kay A, Kulkarni S, Ghafoor A. Survival of patients with pancreatic cancer treated with varied modalities: A single-centre study. Mol Clin Oncol 2017;6:583-8. [PMID: 28413673 DOI: 10.3892/mco.2017.1179] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
242 Li M, Wang MM, Guo XW, Wu CY, Li DR, Zhang X, Zhang PT. Different Survival Benefits of Chinese Medicine for Pancreatic Cancer: How to Choose? Chin J Integr Med 2018;24:178-84. [PMID: 29063468 DOI: 10.1007/s11655-017-2971-1] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
243 Tomimaru Y, Eguchi H, Iwagami Y, Akita H, Noda T, Gotoh K, Kobayashi S, Nagano H, Mori M, Doki Y. Preoperative chemoradiotherapy using gemcitabine for pancreatic ductal adenocarcinoma in patients with impaired renal function. Cancer Chemother Pharmacol 2020;85:537-45. [PMID: 31834436 DOI: 10.1007/s00280-019-04005-y] [Reference Citation Analysis]
244 Aoki S, Motoi F, Murakami Y, Sho M, Satoi S, Honda G, Uemura K, Okada KI, Matsumoto I, Nagai M, Yanagimoto H, Kurata M, Fukumoto T, Mizuma M, Yamaue H, Unno M; Multicenter Study Group of Pancreatobiliary Surgery (MSG-PBS). Decreased serum carbohydrate antigen 19-9 levels after neoadjuvant therapy predict a better prognosis for patients with pancreatic adenocarcinoma: a multicenter case-control study of 240 patients. BMC Cancer 2019;19:252. [PMID: 30898101 DOI: 10.1186/s12885-019-5460-4] [Cited by in Crossref: 27] [Cited by in F6Publishing: 15] [Article Influence: 13.5] [Reference Citation Analysis]
245 Bradley A, Van Der Meer R. Upfront Surgery versus Neoadjuvant Therapy for Resectable Pancreatic Cancer: Systematic Review and Bayesian Network Meta-analysis. Sci Rep 2019;9:4354. [PMID: 30867522 DOI: 10.1038/s41598-019-40951-6] [Cited by in Crossref: 21] [Cited by in F6Publishing: 12] [Article Influence: 10.5] [Reference Citation Analysis]
246 Okamura Y, Yasukawa S, Narimatsu H, Boku N, Fukutomi A, Konishi M, Morinaga S, Toyama H, Kaneoka Y, Shimizu Y, Nakamori S, Sata N, Yamakita K, Takahashi A, Kainuma O, Hishinuma S, Yamaguchi R, Nagino M, Hirano S, Yanagisawa A, Mori K, Uesaka K. Human equilibrative nucleoside transporter-1 expression is a predictor in patients with resected pancreatic cancer treated with adjuvant S-1 chemotherapy. Cancer Sci 2020;111:548-60. [PMID: 31778273 DOI: 10.1111/cas.14258] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
247 Heestand GM, Murphy JD, Lowy AM. Approach to Patients With Pancreatic Cancer Without Detectable Metastases. JCO 2015;33:1770-8. [DOI: 10.1200/jco.2014.59.7930] [Cited by in Crossref: 81] [Cited by in F6Publishing: 40] [Article Influence: 13.5] [Reference Citation Analysis]
248 Blaauboer A, Booy S, van Koetsveld PM, Karels B, Dogan F, van Zwienen S, van Eijck CHJ, Hofland LJ. Interferon-beta enhances sensitivity to gemcitabine in pancreatic cancer. BMC Cancer 2020;20:913. [PMID: 32967656 DOI: 10.1186/s12885-020-07420-0] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
249 Liu H, Naxerova K, Pinter M, Incio J, Lee H, Shigeta K, Ho WW, Crain JA, Jacobson A, Michelakos T, Dias-Santos D, Zanconato A, Hong TS, Clark JW, Murphy JE, Ryan DP, Deshpande V, Lillemoe KD, Fernandez-Del Castillo C, Downes M, Evans RM, Michaelson J, Ferrone CR, Boucher Y, Jain RK. Use of Angiotensin System Inhibitors Is Associated with Immune Activation and Longer Survival in Nonmetastatic Pancreatic Ductal Adenocarcinoma. Clin Cancer Res. 2017;23:5959-5969. [PMID: 28600474 DOI: 10.1158/1078-0432.ccr-17-0256] [Cited by in Crossref: 34] [Cited by in F6Publishing: 25] [Article Influence: 8.5] [Reference Citation Analysis]
250 Myrehaug S, Sahgal A, Russo SM, Lo SS, Rosati LM, Mayr NA, Lock M, Small W Jr, Dorth JA, Ellis RJ, Teh BS, Herman JM. Stereotactic body radiotherapy for pancreatic cancer: recent progress and future directions. Expert Rev Anticancer Ther 2016;16:523-30. [PMID: 26999329 DOI: 10.1586/14737140.2016.1168698] [Cited by in Crossref: 18] [Cited by in F6Publishing: 12] [Article Influence: 3.6] [Reference Citation Analysis]
251 Tsai S, Christians KK, Ritch PS, George B, Khan AH, Erickson B, Evans DB. Multimodality Therapy in Patients With Borderline Resectable or Locally Advanced Pancreatic Cancer: Importance of Locoregional Therapies for a Systemic Disease. J Oncol Pract 2016;12:915-23. [PMID: 27858562 DOI: 10.1200/JOP.2016.016162] [Cited by in Crossref: 14] [Cited by in F6Publishing: 4] [Article Influence: 3.5] [Reference Citation Analysis]
252 Postlewait LM, Kooby DA. Laparoscopic distal pancreatectomy for adenocarcinoma: safe and reasonable? J Gastrointest Oncol 2015;6:406-17. [PMID: 26261727 DOI: 10.3978/j.issn.2078-6891.2015.034] [Cited by in F6Publishing: 6] [Reference Citation Analysis]
253 Draper A. Updates in pancreatic cancer: Modest gains and hopeful targets. J Oncol Pharm Pract 2019;25:101-9. [PMID: 29580162 DOI: 10.1177/1078155218763035] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
254 Yoo J, Kistler CA, Yan L, Dargan A, Siddiqui AA. Endoscopic ultrasound in pancreatic cancer: innovative applications beyond the basics. J Gastrointest Oncol 2016;7:1019-29. [PMID: 28078128 DOI: 10.21037/jgo.2016.08.07] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 1.4] [Reference Citation Analysis]
255 Rangelova E, Wefer A, Persson S, Valente R, Tanaka K, Orsini N, Segersvärd R, Arnelo U, Del Chiaro M. Surgery Improves Survival After Neoadjuvant Therapy for Borderline and Locally Advanced Pancreatic Cancer: A Single Institution Experience. Annals of Surgery 2021;273:579-86. [DOI: 10.1097/sla.0000000000003301] [Cited by in Crossref: 36] [Cited by in F6Publishing: 16] [Article Influence: 18.0] [Reference Citation Analysis]
256 Mayer RJ, Venook AP, Schilsky RL. Progress against GI cancer during the American Society of Clinical Oncology’s first 50 years. J Clin Oncol. 2014;32:1521-1530. [PMID: 24752046 DOI: 10.1200/jco.2014.55.4121] [Cited by in Crossref: 24] [Cited by in F6Publishing: 14] [Article Influence: 3.4] [Reference Citation Analysis]
257 Goel N, Nadler A, Reddy S, Hoffman JP, Pitt HA. Biliary microbiome in pancreatic cancer: alterations with neoadjuvant therapy. HPB 2019;21:1753-60. [DOI: 10.1016/j.hpb.2019.04.005] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 5.0] [Reference Citation Analysis]
258 Sweigert PJ, Eguia E, Baker MS, Paredes AZ, Tsilimigras DI, Dillhoff M, Ejaz A, Cloyd J, Tsung A, Pawlik TM. Assessment of textbook oncologic outcomes following pancreaticoduodenectomy for pancreatic adenocarcinoma. J Surg Oncol 2020;121:936-44. [DOI: 10.1002/jso.25861] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 13.0] [Reference Citation Analysis]
259 Barrett MT, Deiotte R, Lenkiewicz E, Malasi S, Holley T, Evers L, Posner RG, Jones T, Han H, Sausen M, Velculescu VE, Drebin J, O'Dwyer P, Jameson G, Ramanathan RK, Von Hoff DD. Clinical study of genomic drivers in pancreatic ductal adenocarcinoma. Br J Cancer 2017;117:572-82. [PMID: 28720843 DOI: 10.1038/bjc.2017.209] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 3.5] [Reference Citation Analysis]
260 Wolff RA. Adjuvant or Neoadjuvant Therapy in the Treatment in Pancreatic Malignancies: Where Are We? Surg Clin North Am 2018;98:95-111. [PMID: 29191281 DOI: 10.1016/j.suc.2017.09.009] [Cited by in Crossref: 16] [Cited by in F6Publishing: 10] [Article Influence: 4.0] [Reference Citation Analysis]
261 Nishio K, Kimura K, Amano R, Yamazoe S, Ohrira G, Nakata B, Hirakawa K, Ohira M. Preoperative predictors for early recurrence of resectable pancreatic cancer. World J Surg Oncol 2017;15:16. [PMID: 28069033 DOI: 10.1186/s12957-016-1078-z] [Cited by in Crossref: 34] [Cited by in F6Publishing: 28] [Article Influence: 8.5] [Reference Citation Analysis]
262 Barzi A, Miksad R, Surinach A, Corvino FA, Wang S, Torres AZ, Mamlouk K, Pulgar S, Valderrama A, Bekaii-Saab T, Ahn D. Real-World Dosing Patterns and Outcomes of Patients With Metastatic Pancreatic Cancer Treated With a Liposomal Irinotecan Regimen in the United States. Pancreas 2020;49:193-200. [PMID: 32011529 DOI: 10.1097/MPA.0000000000001479] [Cited by in Crossref: 7] [Cited by in F6Publishing: 2] [Article Influence: 7.0] [Reference Citation Analysis]
263 Palmquist C, Dehlendorff C, Calatayud D, Hansen CP, Hasselby JP, Johansen JS. Prediction of Unresectability and Prognosis in Patients Undergoing Surgery on Suspicion of Pancreatic Cancer Using Carbohydrate Antigen 19-9, Interleukin 6, and YKL-40. Pancreas 2020;49:53-61. [PMID: 31856080 DOI: 10.1097/MPA.0000000000001466] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
264 Chien MH, Lee TH, Lee WJ, Yeh YH, Li TK, Wang PC, Chen JJ, Chow JM, Lin YW, Hsiao M, Wang SW, Hua KT. Trichodermin induces c-Jun N-terminal kinase-dependent apoptosis caused by mitotic arrest and DNA damage in human p53-mutated pancreatic cancer cells and xenografts. Cancer Lett 2017;388:249-61. [PMID: 27965041 DOI: 10.1016/j.canlet.2016.12.002] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
265 Sinn M, Liersch T, Riess H, Gellert K, Stübs P, Waldschmidt D, Lammert F, Maschmeyer G, Bechstein W, Bitzer M, Denzlinger C, Hofheinz R, Lindig U, Ghadimi M, Hinke A, Striefler JK, Pelzer U, Bischoff S, Bahra M, Oettle H. CONKO-006: A randomised double-blinded phase IIb-study of additive therapy with gemcitabine + sorafenib/placebo in patients with R1 resection of pancreatic cancer - Final results. Eur J Cancer 2020;138:172-81. [PMID: 32890813 DOI: 10.1016/j.ejca.2020.06.032] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
266 Aston WJ, Hope DE, Nowak AK, Robinson BW, Lake RA, Lesterhuis WJ. A systematic investigation of the maximum tolerated dose of cytotoxic chemotherapy with and without supportive care in mice. BMC Cancer 2017;17:684. [PMID: 29037232 DOI: 10.1186/s12885-017-3677-7] [Cited by in Crossref: 60] [Cited by in F6Publishing: 45] [Article Influence: 15.0] [Reference Citation Analysis]
267 Shi S, Yu X. Selecting chemotherapy for pancreatic cancer: Far away or so close? Semin Oncol 2019;46:39-47. [PMID: 30611527 DOI: 10.1053/j.seminoncol.2018.12.004] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
268 Lu S, Zhang Y, Zhou X, Zhou D, Yang Q, Ju B, Zhao X, Hu Z, Xie H, Zhou L, Zheng S, Wang W. Therapeutic efficacy and safety of S-1-based combination therapy compare with S-1 monotherapy following gemcitabine failure in pancreatic cancer: a meta-analysis. Sci Rep 2016;6:36944. [PMID: 27833144 DOI: 10.1038/srep36944] [Reference Citation Analysis]
269 Franklin O, Billing O, Öhlund D, Berglund A, Herdenberg C, Wang W, Hellman U, Sund M. Novel prognostic markers within the CD44-stromal ligand network in pancreatic cancer. J Pathol Clin Res 2019;5:130-41. [PMID: 30456933 DOI: 10.1002/cjp2.122] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
270 Gupta R, Amanam I, Chung V. Current and future therapies for advanced pancreatic cancer. J Surg Oncol 2017;116:25-34. [PMID: 28591939 DOI: 10.1002/jso.24623] [Cited by in Crossref: 41] [Cited by in F6Publishing: 44] [Article Influence: 10.3] [Reference Citation Analysis]
271 Rieser CJ, Zenati M, Narayanan S, Bahary N, Lee KK, Paniccia A, Bartlett DL, Zureikat AH. Optimal Management of Resectable Pancreatic Head Cancer in the Elderly Patient: Does Neoadjuvant Therapy Offer a Survival Benefit? Ann Surg Oncol 2021. [PMID: 33748894 DOI: 10.1245/s10434-021-09822-1] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
272 Ostapoff KT, Gabriel E, Attwood K, Kuvshinoff BW, Nurkin SJ, Hochwald SN. Does adjuvant therapy improve overall survival for stage IA/B pancreatic adenocarcinoma? HPB (Oxford) 2017;19:587-94. [PMID: 28433254 DOI: 10.1016/j.hpb.2017.03.002] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
273 Patel H, Okamura R, Fanta P, Patel C, Lanman RB, Raymond VM, Kato S, Kurzrock R. Clinical correlates of blood-derived circulating tumor DNA in pancreatic cancer. J Hematol Oncol. 2019;12:130. [PMID: 31801585 DOI: 10.1186/s13045-019-0824-4] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 10.0] [Reference Citation Analysis]
274 Deng Y, Ming B, Zhou T, Wu JL, Chen Y, Liu P, Zhang J, Zhang SY, Chen TW, Zhang XM. Radiomics Model Based on MR Images to Discriminate Pancreatic Ductal Adenocarcinoma and Mass-Forming Chronic Pancreatitis Lesions. Front Oncol 2021;11:620981. [PMID: 33842325 DOI: 10.3389/fonc.2021.620981] [Reference Citation Analysis]
275 Blakaj A, Stein SM, Khan SA, Johung KL. Review and current state of radiation therapy for locally advanced pancreatic adenocarcinoma. J Gastrointest Oncol 2018;9:1027-36. [PMID: 30603121 DOI: 10.21037/jgo.2018.03.07] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
276 Warschkow R, Tsai C, Köhn N, Erdem S, Schmied B, Nussbaum DP, Gloor B, Müller SA, Blazer D 3rd, Worni M. Role of lymphadenectomy, adjuvant chemotherapy, and treatment at high-volume centers in patients with resected pancreatic cancer-a distinct view on lymph node yield. Langenbecks Arch Surg 2020;405:43-54. [PMID: 32040705 DOI: 10.1007/s00423-020-01859-2] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
277 Xu JZ, Wang WQ, Zhang SR, Xu HX, Wu CT, Qi ZH, Gao HL, Li S, Ni QX, Yu XJ, Liu L. Neoadjuvant Therapy is Essential for Resectable Pancreatic Cancer. Curr Med Chem. 2019;26:7196-7211. [PMID: 29651946 DOI: 10.2174/0929867325666180413101722] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 5.0] [Reference Citation Analysis]
278 Lucas AL, Malvezzi M, Carioli G, Negri E, La Vecchia C, Boffetta P, Bosetti C. Global Trends in Pancreatic Cancer Mortality From 1980 Through 2013 and Predictions for 2017. Clin Gastroenterol Hepatol. 2016;14:1452-1462.e4. [PMID: 27266982 DOI: 10.1016/j.cgh.2016.05.034] [Cited by in Crossref: 58] [Cited by in F6Publishing: 50] [Article Influence: 11.6] [Reference Citation Analysis]
279 Wu L, Zhang F, Chen X, Wan J, Wang Y, Li T, Wang H. Self-Assembled Gemcitabine Prodrug Nanoparticles Show Enhanced Efficacy against Patient-Derived Pancreatic Ductal Adenocarcinoma. ACS Appl Mater Interfaces 2020;12:3327-40. [DOI: 10.1021/acsami.9b16209] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 8.5] [Reference Citation Analysis]
280 McDowell BD, Chapman CG, Smith BJ, Button AM, Chrischilles EA, Mezhir JJ. Pancreatectomy predicts improved survival for pancreatic adenocarcinoma: results of an instrumental variable analysis. Ann Surg. 2015;261:740-745. [PMID: 24979599 DOI: 10.1097/sla.0000000000000796] [Cited by in Crossref: 32] [Cited by in F6Publishing: 16] [Article Influence: 5.3] [Reference Citation Analysis]
281 Shinoto M, Ebner DK, Yamada S. Particle Radiation Therapy for Gastrointestinal Cancers. Curr Oncol Rep 2016;18:17. [PMID: 26849660 DOI: 10.1007/s11912-016-0499-8] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
282 Furukawa D, Chijiwa T, Matsuyama M, Mukai M, Matsuo EI, Nishimura O, Kawai K, Suemizu H, Nakagohri T, Ozawa S, Shimada K, Hiraoka N, Nakamura M. Plasma membrane expression of ZNF185 is a prognostic factor in pancreatic ductal carcinoma. Oncol Lett 2017;14:3633-40. [PMID: 28927124 DOI: 10.3892/ol.2017.6633] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
283 Sugimoto M, Takahashi N, Farnell MB, Smyrk TC, Truty MJ, Nagorney DM, Smoot RL, Chari ST, Carter RE, Kendrick ML. Survival benefit of neoadjuvant therapy in patients with non-metastatic pancreatic ductal adenocarcinoma: A propensity matching and intention-to-treat analysis. J Surg Oncol. 2019;120:976-984. [PMID: 31452208 DOI: 10.1002/jso.25681] [Cited by in Crossref: 20] [Cited by in F6Publishing: 17] [Article Influence: 10.0] [Reference Citation Analysis]
284 Suzuki S, Okada M, Sanomachi T, Togashi K, Seino S, Sato A, Yamamoto M, Kitanaka C. Therapeutic targeting of pancreatic cancer stem cells by dexamethasone modulation of the MKP-1-JNK axis. J Biol Chem 2020;295:18328-42. [PMID: 33115754 DOI: 10.1074/jbc.RA120.015223] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 5.0] [Reference Citation Analysis]
285 Tu MJ, Pan YZ, Qiu JX, Kim EJ, Yu AM. MicroRNA-1291 targets the FOXA2-AGR2 pathway to suppress pancreatic cancer cell proliferation and tumorigenesis. Oncotarget 2016;7:45547-61. [PMID: 27322206 DOI: 10.18632/oncotarget.9999] [Cited by in Crossref: 20] [Cited by in F6Publishing: 17] [Article Influence: 6.7] [Reference Citation Analysis]
286 Wu X, Liu Z, Guo K, Ma G, Song S. Inactivation of ATF-2 enhances epithelial-mesenchymal transition and gemcitabine sensitivity in human pancreatic cancer cells. J Cell Biochem 2019;120:4463-71. [PMID: 30367508 DOI: 10.1002/jcb.27734] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
287 Abe T, Amano H, Kobayashi T, Hattori M, Hanada K, Nakahara M, Ohdan H, Noriyuki T. Efficacy of the physiobiological parameter-based grading system for predicting the long-term prognosis after curative surgery for resectable pancreatic cancer. Eur J Surg Oncol 2021;47:613-9. [PMID: 32978015 DOI: 10.1016/j.ejso.2020.09.008] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
288 Gbolahan OB, Tong Y, Sehdev A, O'Neil B, Shahda S. Overall survival of patients with recurrent pancreatic cancer treated with systemic therapy: a retrospective study. BMC Cancer 2019;19:468. [PMID: 31101022 DOI: 10.1186/s12885-019-5630-4] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 5.0] [Reference Citation Analysis]
289 Sclafani F, Iyer R, Cunningham D, Starling N. Management of metastatic pancreatic cancer: Current treatment options and potential new therapeutic targets. Crit Rev Oncol Hematol 2015;95:318-36. [PMID: 25921418 DOI: 10.1016/j.critrevonc.2015.03.008] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 2.5] [Reference Citation Analysis]
290 Winer LK, Dhar VK, Wima K, Morris MC, Lee TC, Shah SA, Ahmad SA, Patel SH. The Impact of Tumor Location on Resection and Survival for Pancreatic Ductal Adenocarcinoma. Journal of Surgical Research 2019;239:60-6. [DOI: 10.1016/j.jss.2019.01.061] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 8.5] [Reference Citation Analysis]
291 Chu QD, Zhou M, Peddi P, Medeiros KL, Zibari GB, Shokouh-amiri H, Wu X. Influence of facility type on survival outcomes after pancreatectomy for pancreatic adenocarcinoma. HPB 2017;19:1046-57. [DOI: 10.1016/j.hpb.2017.04.017] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 2.8] [Reference Citation Analysis]
292 Zdenkowski N, Radvan G, Pugliese L, Charlton J, Oldmeadow C, Fraser A, Bonaventura A. Treatment of pancreatic insufficiency using pancreatic extract in patients with advanced pancreatic cancer: a pilot study (PICNIC). Support Care Cancer 2017;25:1963-71. [DOI: 10.1007/s00520-017-3602-2] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
293 Valero V 3rd, Saunders TJ, He J, Weiss MJ, Cameron JL, Dholakia A, Wild AT, Shin EJ, Khashab MA, O'Broin-Lennon AM, Ali SZ, Laheru D, Hruban RH, Iacobuzio-Donahue CA, Herman JM, Wolfgang CL. Reliable Detection of Somatic Mutations in Fine Needle Aspirates of Pancreatic Cancer With Next-generation Sequencing: Implications for Surgical Management. Ann Surg 2016;263:153-61. [PMID: 26020105 DOI: 10.1097/SLA.0000000000001156] [Cited by in Crossref: 32] [Cited by in F6Publishing: 16] [Article Influence: 6.4] [Reference Citation Analysis]
294 Wang W, He Y, Wu L, Ye L, Yao L, Tang Z. Efficacy of extended versus standard lymphadenectomy in pancreatoduodenectomy for pancreatic head adenocarcinoma. An update meta-analysis. Pancreatology 2019;19:1074-80. [PMID: 31668841 DOI: 10.1016/j.pan.2019.10.003] [Cited by in Crossref: 11] [Cited by in F6Publishing: 4] [Article Influence: 5.5] [Reference Citation Analysis]
295 Young K, Hughes DJ, Cunningham D, Starling N. Immunotherapy and pancreatic cancer: unique challenges and potential opportunities. Ther Adv Med Oncol. 2018;10:1758835918816281. [PMID: 30574212 DOI: 10.1177/1758835918816281] [Cited by in Crossref: 26] [Cited by in F6Publishing: 19] [Article Influence: 8.7] [Reference Citation Analysis]
296 Sonohara F, Yamada S, Takami H, Hayashi M, Kanda M, Tanaka C, Kobayashi D, Nakayama G, Koike M, Fujiwara M, Fujii T, Kodera Y. Novel implications of combined arterial resection for locally advanced pancreatic cancer in the era of newer chemo-regimens. Eur J Surg Oncol 2019;45:1895-900. [PMID: 31147087 DOI: 10.1016/j.ejso.2019.05.019] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
297 Riechelmann RP, Peixoto RD, Fernandes GDS, Weschenfelder RF, Prolla G, Filho DR, Andrade AC, Crosara M, Rego JFM, Gansl RC, Coimbra F, Aguiar S Jr, Carvalho E, Hoff PM, Coutinho AK. Evidence-based recommendations for gastrointestinal cancers during the COVID-19 pandemic by the Brazilian Gastrointestinal Tumours Group. Ecancermedicalscience 2020;14:1048. [PMID: 32565901 DOI: 10.3332/ecancer.2020.1048] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
298 Sonohara F, Yamada S, Kurimoto K, Inokawa Y, Takami H, Hayashi M, Shimizu D, Hattori N, Kanda M, Tanaka C, Nakayama G, Koike M, Fujii T, Kodera Y. Age-Related Differences in the Prognosis of Pancreatic Cancer According to Perioperative Systemic Therapy. Pancreas 2021;50:37-46. [PMID: 33370021 DOI: 10.1097/MPA.0000000000001712] [Reference Citation Analysis]
299 Blair AB, Groot VP, Gemenetzis G, Wei J, Cameron JL, Weiss MJ, Goggins M, Wolfgang CL, Yu J, He J. BRCA1/BRCA2 Germline Mutation Carriers and Sporadic Pancreatic Ductal Adenocarcinoma. J Am Coll Surg 2018;226:630-637.e1. [PMID: 29309945 DOI: 10.1016/j.jamcollsurg.2017.12.021] [Cited by in Crossref: 32] [Cited by in F6Publishing: 23] [Article Influence: 10.7] [Reference Citation Analysis]
300 Sperlongano P, Esposito E, Esposito A, Clarizia G, Moccia G, Malinconico FA, Foroni F, Manfredi C, Sperlongano S, Gubitosi A. Laparoscopic pancreatectomy: Did the indications change? A review from literature. Int J Surg 2015;21 Suppl 1:S22-5. [PMID: 26123387 DOI: 10.1016/j.ijsu.2015.04.094] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
301 Chopra A, Hodges JC, Olson A, Burton S, Ellsworth SG, Bahary N, Singhi AD, Boone BA, Beane JD, Bartlett D, Lee KK, Hogg ME, Lotze MT, Paniccia A, Zeh H, Zureikat AH. Outcomes of Neoadjuvant Chemotherapy Versus Chemoradiation in Localized Pancreatic Cancer: A Case-Control Matched Analysis. Ann Surg Oncol 2021;28:3779-88. [PMID: 33231769 DOI: 10.1245/s10434-020-09391-9] [Reference Citation Analysis]
302 Li F, Liang J, Bai L. MicroRNA-449a functions as a tumor suppressor in pancreatic cancer by the epigenetic regulation of ATDC expression. Biomedicine & Pharmacotherapy 2018;103:782-9. [DOI: 10.1016/j.biopha.2018.04.101] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 5.3] [Reference Citation Analysis]
303 Marsman EM, de Rooij T, van Eijck CH, Boerma D, Bonsing BA, van Dam RM, van Dieren S, Erdmann JI, Gerhards MF, de Hingh IH, Kazemier G, Klaase J, Molenaar IQ, Patijn GA, Scheepers JJ, Tanis PJ, Busch OR, Besselink MG. Pancreatoduodenectomy with colon resection for cancer: A nationwide retrospective analysis. Surgery 2016;160:145-52. [DOI: 10.1016/j.surg.2016.02.022] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 1.8] [Reference Citation Analysis]
304 Chen K, Qian W, Jiang Z, Cheng L, Li J, Sun L, Zhou C, Gao L, Lei M, Yan B, Cao J, Duan W, Ma Q. Metformin suppresses cancer initiation and progression in genetic mouse models of pancreatic cancer. Mol Cancer 2017;16:131. [PMID: 28738823 DOI: 10.1186/s12943-017-0701-0] [Cited by in Crossref: 46] [Cited by in F6Publishing: 39] [Article Influence: 11.5] [Reference Citation Analysis]
305 Jin L, Zou Y, Ruan S, Han H, Zhang Y, Chen Z, Jin H, Shi N. Score for predicting overall survival in pancreatic adenocarcinoma patients with positive lymph nodes after surgery: a novel nomogram-based risk assessment. Gland Surg 2021;10:529-40. [PMID: 33708536 DOI: 10.21037/gs-20-597] [Reference Citation Analysis]
306 Deng A, Wang C, Cohen SJ, Winter JM, Posey J, Yeo C, Basu Mallick A. Multi-agent neoadjuvant chemotherapy improves survival in early-stage pancreatic cancer: A National Cancer Database analysis. Eur J Cancer 2021;147:17-28. [PMID: 33607382 DOI: 10.1016/j.ejca.2021.01.004] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
307 Sugano H, Shirai Y, Sato S, Hamatani S, Hamura R, Taniai T, Horiuchi T, Gocho T, Eto K, Ikegami T. Thrombomodulin expression impacts the recurrence and long-term survival in pancreatic cancer. Ann Gastroenterol Surg 2021;5:567-74. [PMID: 34337305 DOI: 10.1002/ags3.12447] [Reference Citation Analysis]
308 Sugarbaker PH, Stuart OA. Intraperitoneal gemcitabine chemotherapy is safe for patients with resected pancreatic cancer: final clinical and pharmacologic data from a phase II protocol and recommended future directions. J Gastrointest Oncol 2021;12:S99-S109. [PMID: 33968430 DOI: 10.21037/jgo-2020-02] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
309 Sala Elarre P, Oyaga-Iriarte E, Yu KH, Baudin V, Arbea Moreno L, Carranza O, Chopitea Ortega A, Ponz-Sarvise M, Mejías Sosa LD, Rotellar Sastre F, Larrea Leoz B, Iragorri Barberena Y, Subtil Iñigo JC, Benito Boíllos A, Pardo F, Rodríguez Rodríguez J. Use of Machine-Learning Algorithms in Intensified Preoperative Therapy of Pancreatic Cancer to Predict Individual Risk of Relapse. Cancers (Basel) 2019;11:E606. [PMID: 31052270 DOI: 10.3390/cancers11050606] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 3.5] [Reference Citation Analysis]
310 Sinn M, Bahra M, Liersch T, Gellert K, Messmann H, Bechstein W, Waldschmidt D, Jacobasch L, Wilhelm M, Rau BM, Grützmann R, Weinmann A, Maschmeyer G, Pelzer U, Stieler JM, Striefler JK, Ghadimi M, Bischoff S, Dörken B, Oettle H, Riess H. CONKO-005: Adjuvant Chemotherapy With Gemcitabine Plus Erlotinib Versus Gemcitabine Alone in Patients After R0 Resection of Pancreatic Cancer: A Multicenter Randomized Phase III Trial. J Clin Oncol 2017;35:3330-7. [PMID: 28817370 DOI: 10.1200/JCO.2017.72.6463] [Cited by in Crossref: 124] [Cited by in F6Publishing: 51] [Article Influence: 31.0] [Reference Citation Analysis]
311 Yoo C, Hwang I, Song TJ, Lee SS, Jeong JH, Park DH, Seo DW, Lee SK, Kim MH, Byun JH, Park JH, Hwang DW, Song KB, Lee JH, Lee W, Chang HM, Kim KP, Kim SC, Ryoo BY. FOLFIRINOX in borderline resectable and locally advanced unresectable pancreatic adenocarcinoma.Ther Adv Med Oncol. 2020;12:1758835920953294. [PMID: 32983266 DOI: 10.1177/1758835920953294] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
312 Yamada S, Takami H, Sonohara F, Hayashi M, Fujii T, Kodera Y. Effects of duration of initial treatment on postoperative complications in pancreatic cancer. J Hepatobiliary Pancreat Sci 2019;26:235-41. [PMID: 30919565 DOI: 10.1002/jhbp.622] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
313 Singh RR, Goldberg J, Varghese AM, Yu KH, Park W, O'Reilly EM. Genomic profiling in pancreatic ductal adenocarcinoma and a pathway towards therapy individualization: A scoping review. Cancer Treat Rev 2019;75:27-38. [PMID: 30927677 DOI: 10.1016/j.ctrv.2019.03.003] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 10.0] [Reference Citation Analysis]
314 Xia BT, Habib DA, Dhar VK, Levinsky NC, Kim Y, Hanseman DJ, Sutton JM, Wilson GC, Smith M, Choe KA, Sussman JJ, Ahmad SA, Abbott DE. Early Recurrence and Omission of Adjuvant Therapy after Pancreaticoduodenectomy Argue against a Surgery-First Approach. Ann Surg Oncol 2016;23:4156-64. [PMID: 27459987 DOI: 10.1245/s10434-016-5457-z] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 2.4] [Reference Citation Analysis]
315 Asano T, Yamada S, Fujii T, Yabusaki N, Nakayama G, Sugimoto H, Koike M, Fujiwara M, Kodera Y. The Charlson age comorbidity index predicts prognosis in patients with resected pancreatic cancer. Int J Surg 2017;39:169-75. [PMID: 28161529 DOI: 10.1016/j.ijsu.2017.01.115] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 4.0] [Reference Citation Analysis]
316 Iwasaki T, Hiraoka N, Ino Y, Nakajima K, Kishi Y, Nara S, Esaki M, Shimada K, Katai H. Reduction of intrapancreatic neural density in cancer tissue predicts poorer outcome in pancreatic ductal carcinoma. Cancer Sci. 2019;110:1491-1502. [PMID: 30776178 DOI: 10.1111/cas.13975] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 4.0] [Reference Citation Analysis]
317 Chen H, He R, Shi X, Zhou M, Zhao C, Zhang H, Qin R. Meta-analysis on resected pancreatic cancer: a comparison between adjuvant treatments and gemcitabine alone. BMC Cancer 2018;18:1034. [PMID: 30352573 DOI: 10.1186/s12885-018-4948-7] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
318 Vogel A, Römmler-Zehrer J, Li JS, McGovern D, Romano A, Stahl M. Efficacy and safety profile of nab-paclitaxel plus gemcitabine in patients with metastatic pancreatic cancer treated to disease progression: a subanalysis from a phase 3 trial (MPACT). BMC Cancer 2016;16:817. [PMID: 27769210 DOI: 10.1186/s12885-016-2798-8] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 1.8] [Reference Citation Analysis]
319 Gallmeier E, Gress TM. [Pancreatic ductal adenocarcinoma]. Internist (Berl). 2018;59:805-822. [PMID: 29980819 DOI: 10.1007/s00108-018-0460-z] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
320 Shin DW, Lee JC, Kim J, Yoon YS, Han HS, Kim H, Hwang JH. Tailored adjuvant gemcitabine versus 5-fluorouracil/folinic acid based on hENT1 immunohistochemical staining in resected pancreatic ductal adenocarcinoma: A biomarker stratified prospective trial. Pancreatology 2021;21:796-804. [PMID: 33795193 DOI: 10.1016/j.pan.2021.02.022] [Reference Citation Analysis]
321 Xu X, Yang Y, Mo X, Wei J, Zhang X, You Q. Design, synthesis, and evaluation of benzofuran derivatives as novel anti-pancreatic carcinoma agents via interfering the hypoxia environment by targeting HIF-1α pathway. European Journal of Medicinal Chemistry 2017;137:45-62. [DOI: 10.1016/j.ejmech.2017.05.042] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 3.8] [Reference Citation Analysis]
322 Tai C, Wang H, Wang C, Tai C, Huang M, Wu C, Chen R, Kuo L, Wei P, Chang Y, Chang C, Chiou H, Wu C. Bevacizumab and cetuximab with conventional chemotherapy reduced pancreatic tumor weight in mouse pancreatic cancer xenografts. Clin Exp Med 2017;17:141-50. [DOI: 10.1007/s10238-016-0409-2] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
323 Imaoka H, Shimizu Y, Senda Y, Natsume S, Mizuno N, Hara K, Hijioka S, Hieda N, Tajika M, Tanaka T, Ishihara M, Niwa Y, Yamao K. Post-adjuvant chemotherapy CA19-9 levels predict prognosis in patients with pancreatic ductal adenocarcinoma: A retrospective cohort study. Pancreatology 2016;16:658-64. [PMID: 27178104 DOI: 10.1016/j.pan.2016.04.007] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 3.0] [Reference Citation Analysis]
324 Du C, da Silva A, Morales-Oyarvide V, Dias Costa A, Kozak MM, Dunne RF, Rubinson DA, Perez K, Masugi Y, Hamada T, Brais LK, Yuan C, Babic A, Ducar MD, Thorner AR, Aguirre A, Kulke MH, Ng K, Clancy TE, Findeis-Hosey JJ, Chang DT, Hornick JL, Fuchs CS, Ogino S, Koong AC, Hezel AF, Wolpin BM, Nowak JA. Insulin-Like Growth Factor-1 Receptor Expression and Disease Recurrence and Survival in Patients with Resected Pancreatic Ductal Adenocarcinoma. Cancer Epidemiol Biomarkers Prev 2020;29:1586-95. [PMID: 32467349 DOI: 10.1158/1055-9965.EPI-19-1315] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
325 Ansari D, Gustafsson A, Andersson R. Update on the management of pancreatic cancer: surgery is not enough. World J Gastroenterol. 2015;21:3157-3165. [PMID: 25805920 DOI: 10.3748/wjg.v21.i11.3157] [Cited by in CrossRef: 84] [Cited by in F6Publishing: 66] [Article Influence: 14.0] [Reference Citation Analysis]
326 Morales-Oyarvide V, Rubinson DA, Dunne RF, Kozak MM, Bui JL, Yuan C, Qian ZR, Babic A, Da Silva A, Nowak JA, Khalaf N, Brais LK, Welch MW, Zellers CL, Ng K, Chang DT, Miksad RA, Bullock AJ, Tseng JF, Swanson RS, Clancy TE, Linehan DC, Findeis-Hosey JJ, Doyle LA, Hornick JL, Ogino S, Fuchs CS, Hezel AF, Koong AC, Wolpin BM. Lymph node metastases in resected pancreatic ductal adenocarcinoma: predictors of disease recurrence and survival. Br J Cancer. 2017;117:1874-1882. [PMID: 28982112 DOI: 10.1038/bjc.2017.349] [Cited by in Crossref: 35] [Cited by in F6Publishing: 29] [Article Influence: 8.8] [Reference Citation Analysis]
327 Wu H, Guo JC, Yang SH, Tien YW, Kuo SH. Postoperative Imaging and Tumor Marker Surveillance in Resected Pancreatic Cancer. J Clin Med 2019;8:E1115. [PMID: 31357636 DOI: 10.3390/jcm8081115] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
328 Ghidini M, Lampis A, Mirchev MB, Okuducu AF, Ratti M, Valeri N, Hahne JC. Immune-Based Therapies and the Role of Microsatellite Instability in Pancreatic Cancer. Genes (Basel) 2020;12:33. [PMID: 33383713 DOI: 10.3390/genes12010033] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
329 Roth MT, Berlin JD. Current Concepts in the Treatment of Resectable Pancreatic Cancer. Curr Oncol Rep 2018;20. [DOI: 10.1007/s11912-018-0685-y] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 3.7] [Reference Citation Analysis]
330 Szmola R, Farkas G, Hegyi P, Czakó L, Dubravcsik Z, Hritz I, Kelemen D, Lásztity N, Morvay Z, Oláh A, Párniczky A, Rubovszky G, Sahin-Tóth M, Szentkereszti Z, Szücs Á, Takács T, Tiszlavicz L, Pap Á; Magyar Hasnyálmirigy Munkacsoport, Hungarian Pancreatic Study Group. [Pancreatic cancer. Evidence based management guidelines of the Hungarian Pancreatic Study Group]. Orv Hetil 2015;156:326-39. [PMID: 25662149 DOI: 10.1556/OH.2015.30063] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 1.2] [Reference Citation Analysis]
331 Sharma GG, Okada Y, Von Hoff D, Goel A. Non-coding RNA biomarkers in pancreatic ductal adenocarcinoma. Semin Cancer Biol 2020:S1044-579X(20)30204-2. [PMID: 33049362 DOI: 10.1016/j.semcancer.2020.10.001] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
332 Mariette C, Brouquet A, Tzanis D, Laurenzi A, de la Rochefordière A, Mariani P, Piessen G, Sa Cunha A, Penna C. What is the impact of neoadjuvant chemoradiation on outcomes in gastro-intestinal cancer? Journal of Visceral Surgery 2017;154:185-95. [DOI: 10.1016/j.jviscsurg.2017.05.004] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
333 Sohal DP, Shrotriya S, Glass KT, Pelley RJ, McNamara MJ, Estfan B, Shapiro M, Wey J, Chalikonda S, Morris-Stiff G, Walsh RM, Khorana AA. Predicting early mortality in resectable pancreatic adenocarcinoma: A cohort study. Cancer 2015;121:1779-84. [PMID: 25676016 DOI: 10.1002/cncr.29298] [Cited by in Crossref: 19] [Cited by in F6Publishing: 15] [Article Influence: 3.2] [Reference Citation Analysis]
334 Skau Rasmussen L, Vittrup B, Ladekarl M, Pfeiffer P, Karen Yilmaz M, Østergaard Poulsen L, Østerlind K, Palnæs Hansen C, Bau Mortensen M, Viborg Mortensen F, Sall M, Detlefsen S, Bøgsted M, Wilki Fristrup C. The effect of postoperative gemcitabine on overall survival in patients with resected pancreatic cancer: A nationwide population-based Danish register study. Acta Oncol 2019;58:864-71. [PMID: 30905248 DOI: 10.1080/0284186X.2019.1581374] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
335 Newhook TE, Lindberg JM, Adair SJ, Kim AJ, Stelow EB, Rahma OE, Parsons JT, Bauer TW. Adjuvant Trametinib Delays the Outgrowth of Occult Pancreatic Cancer in a Mouse Model of Patient-Derived Liver Metastasis. Ann Surg Oncol 2016;23:1993-2000. [PMID: 26847682 DOI: 10.1245/s10434-016-5116-4] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
336 Simionato F, Zecchetto C, Merz V, Cavaliere A, Casalino S, Gaule M, D'Onofrio M, Malleo G, Landoni L, Esposito A, Marchegiani G, Casetti L, Tuveri M, Paiella S, Scopelliti F, Giardino A, Frigerio I, Regi P, Capelli P, Gobbo S, Gabbrielli A, Bernardoni L, Fedele V, Rossi I, Piazzola C, Giacomazzi S, Pasquato M, Gianfortone M, Milleri S, Milella M, Butturini G, Salvia R, Bassi C, Melisi D. A phase II study of liposomal irinotecan with 5-fluorouracil, leucovorin and oxaliplatin in patients with resectable pancreatic cancer: the nITRO trial. Ther Adv Med Oncol. 2020;12:1758835920947969. [PMID: 33403007 DOI: 10.1177/1758835920947969] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
337 Lee JC, Ahn S, Cho IK, Lee J, Kim J, Hwang JH. Management of recurrent pancreatic cancer after surgical resection: a protocol for systematic review, evidence mapping and meta-analysis. BMJ Open 2018;8:e017249. [PMID: 29632079 DOI: 10.1136/bmjopen-2017-017249] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
338 Nevler A, Muller AJ, Sutanto-Ward E, DuHadaway JB, Nagatomo K, Londin E, O'Hayer K, Cozzitorto JA, Lavu H, Yeo TP, Curtis M, Villatoro T, Leiby BE, Mandik-Nayak L, Winter JM, Yeo CJ, Prendergast GC, Brody JR. Host IDO2 Gene Status Influences Tumor Progression and Radiotherapy Response in KRAS-Driven Sporadic Pancreatic Cancers. Clin Cancer Res 2019;25:724-34. [PMID: 30266763 DOI: 10.1158/1078-0432.CCR-18-0814] [Cited by in Crossref: 20] [Cited by in F6Publishing: 11] [Article Influence: 6.7] [Reference Citation Analysis]
339 Lee JM, Kim H, Kang JS, Byun Y, Choi YJ, Sohn HJ, Han Y, Kwon W, Jang JY. Comparison of perioperative short-term outcomes and oncologic long-term outcomes between open and laparoscopic distal pancreatectomy in patients with pancreatic ductal adenocarcinoma. Ann Surg Treat Res 2021;100:320-8. [PMID: 34136428 DOI: 10.4174/astr.2021.100.6.320] [Reference Citation Analysis]
340 Barreto SG. Pancreatic Cancer. In: Barreto SG, Windsor JA, editors. Surgical Diseases of the Pancreas and Biliary Tree. Singapore: Springer; 2018. pp. 427-69. [DOI: 10.1007/978-981-10-8755-4_16] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
341 Gamboa AC, Rupji M, Switchenko JM, Lee RM, Turgeon MK, Meyer BI, Russell MC, Cardona K, Kooby DA, Maithel SK, Shah MM. Optimal timing and treatment strategy for pancreatic cancer. J Surg Oncol 2020;122:457-68. [PMID: 32470166 DOI: 10.1002/jso.25976] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 4.0] [Reference Citation Analysis]
342 Pietrasz D, Marthey L, Wagner M, Blanc JF, Laurent C, Turrini O, Raoul JL, Terrebonne E, Hentic O, Trouilloud I, Coriat R, Regenet N, Innominato P, Taieb J, Cunha AS, Bachet JB. Pathologic Major Response After FOLFIRINOX is Prognostic for Patients Secondary Resected for Borderline or Locally Advanced Pancreatic Adenocarcinoma: An AGEO-FRENCH, Prospective, Multicentric Cohort. Ann Surg Oncol. 2015;22 Suppl 3:S1196-S1205. [PMID: 26271395 DOI: 10.1245/s10434-015-4783-x] [Cited by in Crossref: 50] [Cited by in F6Publishing: 43] [Article Influence: 8.3] [Reference Citation Analysis]
343 Petrelli F, Coinu A, Borgonovo K, Cabiddu M, Ghilardi M, Lonati V, Aitini E, Barni S. FOLFIRINOX-Based Neoadjuvant Therapy in Borderline Resectable or Unresectable Pancreatic Cancer: A Meta-Analytical Review of Published Studies. Pancreas 2015;44:515-21. [DOI: 10.1097/mpa.0000000000000314] [Cited by in Crossref: 126] [Cited by in F6Publishing: 38] [Article Influence: 21.0] [Reference Citation Analysis]
344 Partelli S, Sclafani F, Barbu ST, Beishon M, Bonomo P, Braz G, de Braud F, Brunner T, Cavestro GM, Crul M, Trill MD, Ferollà P, Herrmann K, Karamitopoulou E, Neuzillet C, Orsi F, Seppänen H, Torchio M, Valenti D, Zamboni G, Zins M, Costa A, Poortmans P. European Cancer Organisation Essential Requirements for Quality Cancer Care (ERQCC): Pancreatic Cancer. Cancer Treat Rev 2021;99:102208. [PMID: 34238640 DOI: 10.1016/j.ctrv.2021.102208] [Reference Citation Analysis]
345 Golcher H, Brunner TB, Witzigmann H, Marti L, Bechstein WO, Bruns C, Jungnickel H, Schreiber S, Grabenbauer GG, Meyer T, Merkel S, Fietkau R, Hohenberger W. Neoadjuvant chemoradiation therapy with gemcitabine/cisplatin and surgery versus immediate surgery in resectable pancreatic cancer: results of the first prospective randomized phase II trial. Strahlenther Onkol. 2015;191:7-16. [PMID: 25252602 DOI: 10.1007/s00066-014-0737-7] [Cited by in Crossref: 167] [Cited by in F6Publishing: 117] [Article Influence: 23.9] [Reference Citation Analysis]
346 Rocha FG, Hashimoto Y, Traverso LW, Dorer R, Kozarek R, Helton WS, Picozzi VJ. Interferon-based Adjuvant Chemoradiation for Resected Pancreatic Head Cancer: Long-term Follow-up of the Virginia Mason Protocol. Annals of Surgery 2016;263:376-84. [DOI: 10.1097/sla.0000000000001190] [Cited by in Crossref: 16] [Cited by in F6Publishing: 6] [Article Influence: 3.2] [Reference Citation Analysis]
347 Baek B, Lee H. Prediction of survival and recurrence in patients with pancreatic cancer by integrating multi-omics data. Sci Rep 2020;10:18951. [PMID: 33144687 DOI: 10.1038/s41598-020-76025-1] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
348 Hoshimoto S, Hishinuma S, Shirakawa H, Tomikawa M, Ozawa I, Hoshi N, Hoshi S, Hirabayashi K, Ogata Y. Prognostic significance of intraoperative peritoneal washing cytology for patients with potentially resectable pancreatic ductal adenocarcinoma. Pancreatology 2017;17:109-14. [DOI: 10.1016/j.pan.2016.11.001] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 2.8] [Reference Citation Analysis]
349 Li T, Zheng Y, Sun H, Zhuang R, Liu J, Liu T, Cai W. K-Ras mutation detection in liquid biopsy and tumor tissue as prognostic biomarker in patients with pancreatic cancer: a systematic review with meta-analysis. Med Oncol 2016;33:61. [PMID: 27225938 DOI: 10.1007/s12032-016-0777-1] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 2.4] [Reference Citation Analysis]
350 Ishida J, Toyama H, Matsumoto I, Asari S, Goto T, Terai S, Nanno Y, Yamashita A, Mizumoto T, Ueda Y, Kido M, Ajiki T, Fukumoto T, Ku Y. Second primary pancreatic ductal carcinoma in the remnant pancreas after pancreatectomy for pancreatic ductal carcinoma: High cumulative incidence rates at 5 years after pancreatectomy. Pancreatology 2016;16:615-20. [DOI: 10.1016/j.pan.2016.05.003] [Cited by in Crossref: 15] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
351 Moslim MA, Hall MJ, Meyer JE, Reddy SS. Pancreatic cancer in the era of COVID-19 pandemic: Which one is the lesser of two evils? World J Clin Oncol 2021;12:54-60. [PMID: 33680873 DOI: 10.5306/wjco.v12.i2.54] [Reference Citation Analysis]
352 Waterhouse MA, Burmeister EA, O'Connell DL, Ballard EL, Jordan SJ, Merrett ND, Goldstein D, Wyld D, Janda M, Beesley VL, Payne ME, Gooden HM, Neale RE. Determinants of Outcomes Following Resection for Pancreatic Cancer-a Population-Based Study. J Gastrointest Surg 2016;20:1471-81. [PMID: 27184672 DOI: 10.1007/s11605-016-3157-4] [Cited by in Crossref: 15] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
353 Neoptolemos JP, Palmer DH, Ghaneh P, Psarelli EE, Valle JW, Halloran CM, Faluyi O, O'reilly DA, Cunningham D, Wadsley J, Darby S, Meyer T, Gillmore R, Anthoney A, Lind P, Glimelius B, Falk S, Izbicki JR, Middleton GW, Cummins S, Ross PJ, Wasan H, Mcdonald A, Crosby T, Ma YT, Patel K, Sherriff D, Soomal R, Borg D, Sothi S, Hammel P, Hackert T, Jackson R, Büchler MW. Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-label, randomised, phase 3 trial. The Lancet 2017;389:1011-24. [DOI: 10.1016/s0140-6736(16)32409-6] [Cited by in Crossref: 832] [Cited by in F6Publishing: 316] [Article Influence: 208.0] [Reference Citation Analysis]
354 Badiyan SN, Molitoris JK, Chuong MD, Regine WF, Kaiser A. The Role of Radiation Therapy for Pancreatic Cancer in the Adjuvant and Neoadjuvant Settings. Surg Oncol Clin N Am 2017;26:431-53. [PMID: 28576181 DOI: 10.1016/j.soc.2017.01.012] [Cited by in Crossref: 20] [Cited by in F6Publishing: 12] [Article Influence: 5.0] [Reference Citation Analysis]
355 van Roessel S, Strijker M, Steyerberg EW, Groen JV, Mieog JS, Groot VP, He J, De Pastena M, Marchegiani G, Bassi C, Suhool A, Jang JY, Busch OR, Halimi A, Zarantonello L, Groot Koerkamp B, Samra JS, Mittal A, Gill AJ, Bolm L, van Eijck CH, Abu Hilal M, Del Chiaro M, Keck T, Alseidi A, Wolfgang CL, Malleo G, Besselink MG. International validation and update of the Amsterdam model for prediction of survival after pancreatoduodenectomy for pancreatic cancer. Eur J Surg Oncol 2020;46:796-803. [PMID: 31924432 DOI: 10.1016/j.ejso.2019.12.023] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
356 Yamada D, Takahashi H, Asukai K, Hasegawa S, Tomokuni A, Wada H, Akita H, Yasui M, Miyata H, Ishikawa O. Pathological complete response (pCR) with or without the residual intraductal carcinoma component following preoperative treatment for pancreatic cancer: Revisiting the definition of "pCR" from the prognostic standpoint. Ann Gastroenterol Surg 2019;3:676-85. [PMID: 31788656 DOI: 10.1002/ags3.12288] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
357 Brown ZJ, Cloyd JM. Trends in the utilization of neoadjuvant therapy for pancreatic ductal adenocarcinoma. J Surg Oncol. 2021;123:1432-1440. [PMID: 33831253 DOI: 10.1002/jso.26384] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
358 Klein F, Bahra M, Schirmeier A, Al-Abadi H, Pratschke J, Pelzer U, Oettle H, Striefler J, Riess H, Sinn M. Prognostic significance of DNA cytometry for adjuvant therapy response in pancreatic cancer. J Surg Oncol 2015;112:66-71. [PMID: 26193339 DOI: 10.1002/jso.23951] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
359 Anderson KL Jr, Adam MA, Thomas S, Roman SA, Sosa JA. Impact of minimally invasive vs. open distal pancreatectomy on use of adjuvant chemoradiation for pancreatic adenocarcinoma. Am J Surg 2017;213:601-5. [PMID: 28093119 DOI: 10.1016/j.amjsurg.2017.01.005] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 4.3] [Reference Citation Analysis]
360 Mcdonald AM, Dulaney CR, López-araujo J, Posey JA, Keene KS, Christein JD, Heslin MJ, Wood TE, Jacob R. Patterns of Failure for Lymph Node-Positive Resected Pancreatic Adenocarcinoma After Adjuvant Radiotherapy or Gemcitabine-based Chemotherapy Alone. J Gastrointest Canc 2015;46:149-55. [DOI: 10.1007/s12029-015-9702-7] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.2] [Reference Citation Analysis]
361 Nishiwada S, Sho M, Cui Y, Yamamura K, Akahori T, Nakagawa K, Nagai M, Nakamura K, Takagi T, Ikeda N, Li W, Baba H, Goel A. A gene expression signature for predicting response to neoadjuvant chemoradiotherapy in pancreatic ductal adenocarcinoma. Int J Cancer 2021;148:769-79. [PMID: 32895958 DOI: 10.1002/ijc.33284] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
362 Sinn M, Bahra M, Denecke T, Travis S, Pelzer U, Riess H. Perioperative treatment options in resectable pancreatic cancer - how to improve long-term survival. World J Gastrointest Oncol 2016;8:248-57. [PMID: 26989460 DOI: 10.4251/wjgo.v8.i3.248] [Cited by in CrossRef: 16] [Cited by in F6Publishing: 11] [Article Influence: 3.2] [Reference Citation Analysis]
363 Swords DS, Mulvihill SJ, Brooke BS, Skarda DE, Firpo MA, Scaife CL. Disparities in utilization of treatment for clinical stage I-II pancreatic adenocarcinoma by area socioeconomic status and race/ethnicity. Surgery 2019;165:751-9. [PMID: 30551868 DOI: 10.1016/j.surg.2018.10.035] [Cited by in Crossref: 15] [Cited by in F6Publishing: 10] [Article Influence: 5.0] [Reference Citation Analysis]
364 Åkerberg D, Björnsson B, Ansari D. Factors influencing receipt of adjuvant chemotherapy after surgery for pancreatic cancer: a two-center retrospective cohort study. Scand J Gastroenterol 2017;52:56-60. [PMID: 27598522 DOI: 10.1080/00365521.2016.1228118] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
365 Yamada S, Fujii T, Hirakawa A, Takami H, Suenaga M, Hayashi M, Niwa Y, Hattori N, Iwata N, Kanda M, Tanaka C, Kobayashi D, Nakayama G, Koike M, Fujiwara M, Kodera Y. Comparison of the Survival Outcomes of Pancreatic Cancer and Intraductal Papillary Mucinous Neoplasms. Pancreas. 2018;47:974-979. [PMID: 30028445 DOI: 10.1097/mpa.0000000000001110] [Cited by in Crossref: 13] [Cited by in F6Publishing: 3] [Article Influence: 6.5] [Reference Citation Analysis]
366 Lin H, Xue X, Wang X, Dang S, Gu M. Application of artificial intelligence for the diagnosis, treatment, and prognosis of pancreatic cancer. AIG 2020;1:19-29. [DOI: 10.35712/aig.v1.i1.19] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
367 Miyazawa M, Katsuda M, Maguchi H, Katanuma A, Ishii H, Ozaka M, Yamao K, Imaoka H, Kawai M, Hirono S, Okada KI, Yamaue H. Phase II clinical trial using novel peptide cocktail vaccine as a postoperative adjuvant treatment for surgically resected pancreatic cancer patients.Int J Cancer. 2017;140:973-982. [PMID: 27861852 DOI: 10.1002/ijc.30510] [Cited by in Crossref: 31] [Cited by in F6Publishing: 26] [Article Influence: 6.2] [Reference Citation Analysis]
368 Zhu X, Cao Y, Liu W, Ju X, Zhao X, Jiang L, Ye Y, Jin G, Zhang H. Stereotactic body radiotherapy plus pembrolizumab and trametinib versus stereotactic body radiotherapy plus gemcitabine for locally recurrent pancreatic cancer after surgical resection: an open-label, randomised, controlled, phase 2 trial. Lancet Oncol 2021;22:1093-102. [PMID: 34237249 DOI: 10.1016/S1470-2045(21)00286-2] [Reference Citation Analysis]
369 Sugawara T, Ban D, Nishino J, Watanabe S, Maekawa A, Ishikawa Y, Akahoshi K, Ogawa K, Ono H, Kudo A, Tanaka S, Tanabe M. Prediction of early recurrence of pancreatic ductal adenocarcinoma after resection. PLoS One 2021;16:e0249885. [PMID: 33844700 DOI: 10.1371/journal.pone.0249885] [Reference Citation Analysis]
370 Kim HS, Nakagawa K, Akahori T, Nakamura K, Takagi T, Sho M, Park JS, Yoon DS. Is Neoadjuvant Treatment Justified in Clinical T1 Pancreatic Ductal Adenocarcinoma? J Clin Med 2021;10:873. [PMID: 33672686 DOI: 10.3390/jcm10040873] [Reference Citation Analysis]
371 Wang S, Feng W, Wang W, Ye X, Chen H, Yu C. Girdin Knockdown Increases Gemcitabine Chemosensitivity to Pancreatic Cancer by Modulating Autophagy. Front Oncol 2021;11:618764. [PMID: 33854963 DOI: 10.3389/fonc.2021.618764] [Reference Citation Analysis]
372 Mavros MN, Moris D, Karanicolas PJ, Katz MHG, O'Reilly EM, Pawlik TM. Clinical Trials of Systemic Chemotherapy for Resectable Pancreatic Cancer: A Review. JAMA Surg 2021;156:663-72. [PMID: 33787841 DOI: 10.1001/jamasurg.2021.0149] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
373 Nan JN, Kim OR, Lee MA. β-Catenin expression is associated with cell invasiveness in pancreatic cancer. Korean J Intern Med 2019;34:618-25. [PMID: 30360026 DOI: 10.3904/kjim.2017.155] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
374 Wustefeld-Janssens B, Smith L, Wilson-Robles H. Neoadjuvant chemotherapy and radiation therapy in veterinary cancer treatment: a review. J Small Anim Pract 2021;62:237-43. [PMID: 33305431 DOI: 10.1111/jsap.13245] [Reference Citation Analysis]
375 Anger F, Döring A, van Dam J, Lock JF, Klein I, Bittrich M, Germer CT, Wiegering A, Kunzmann V, van Eijck C, Löb S. Impact of Borderline Resectability in Pancreatic Head Cancer on Patient Survival: Biology Matters According to the New International Consensus Criteria. Ann Surg Oncol 2021;28:2325-36. [PMID: 32920720 DOI: 10.1245/s10434-020-09100-6] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
376 da Costa WL Jr, Tran Cao HS, Sheetz KH, Gu X, Norton EC, Massarweh NN. Comparative Effectiveness of Neoadjuvant Therapy and Upfront Resection for Patients with Resectable Pancreatic Adenocarcinoma: An Instrumental Variable Analysis. Ann Surg Oncol 2021;28:3186-95. [PMID: 33174146 DOI: 10.1245/s10434-020-09327-3] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
377 Shi X, Peng J, Jiang H, Gao Y, Wang W, Zhou F. Impact of Adjuvant Chemoradiotherapy on Survival of Resected Pancreatic Adenocarcinoma Cancer: A Surveillance, Epidemiology and End Results (SEER) Analysis. Front Oncol 2021;11:651671. [PMID: 34277405 DOI: 10.3389/fonc.2021.651671] [Reference Citation Analysis]
378 DePeralta DK, Ogami T, Zhou JM, Schell MJ, Powers BD, Hodul PJ, Malafa MP, Fleming JB. Completion of adjuvant therapy in patients with resected pancreatic cancer. HPB (Oxford) 2020;22:241-8. [PMID: 31563326 DOI: 10.1016/j.hpb.2019.07.008] [Cited by in Crossref: 9] [Cited by in F6Publishing: 4] [Article Influence: 4.5] [Reference Citation Analysis]
379 Powell-Brett S, Pande R, Roberts KJ. Achieving 'Marginal Gains' to Optimise Outcomes in Resectable Pancreatic Cancer. Cancers (Basel) 2021;13:1669. [PMID: 33916294 DOI: 10.3390/cancers13071669] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
380 Hasegawa S, Eguchi H, Tomokuni A, Tomimaru Y, Asaoka T, Wada H, Hama N, Kawamoto K, Kobayashi S, Marubashi S, Konnno M, Ishii H, Mori M, Doki Y, Nagano H. Pre-treatment neutrophil to lymphocyte ratio as a predictive marker for pathological response to preoperative chemoradiotherapy in pancreatic cancer. Oncol Lett 2016;11:1560-6. [PMID: 26893780 DOI: 10.3892/ol.2015.4057] [Cited by in Crossref: 32] [Cited by in F6Publishing: 27] [Article Influence: 5.3] [Reference Citation Analysis]
381 Rieser CJ, Narayanan S, Bahary N, Bartlett DL, Lee KK, Paniccia A, Smith K, Zureikat AH. Optimal management of patients with operable pancreatic head cancer: A Markov decision analysis. J Surg Oncol 2021. [PMID: 34231222 DOI: 10.1002/jso.26589] [Reference Citation Analysis]
382 Perri G, Prakash L, Katz MHG. Defining and Treating Borderline Resectable Pancreatic Cancer. Curr Treat Options Oncol 2020;21:71. [PMID: 32725270 DOI: 10.1007/s11864-020-00769-1] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
383 Tsai HJ, Chang JS. Environmental Risk Factors of Pancreatic Cancer. J Clin Med. 2019;8. [PMID: 31510046 DOI: 10.3390/jcm8091427] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 8.5] [Reference Citation Analysis]
384 Wald P, Liu XS, Pettit C, Dillhoff M, Manilchuk A, Schmidt C, Wuthrick E, Chen W, Williams TM. Prognostic value of microRNA expression levels in pancreatic adenocarcinoma: a review of the literature. Oncotarget 2017;8:73345-61. [PMID: 29069873 DOI: 10.18632/oncotarget.20277] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 4.0] [Reference Citation Analysis]
385 Burotto M, Wilkerson J, Stein WD, Bates SE, Fojo T. Adjuvant and neoadjuvant cancer therapies: A historical review and a rational approach to understand outcomes. Seminars in Oncology 2019;46:83-99. [DOI: 10.1053/j.seminoncol.2019.01.002] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
386 Babiker HM, Riaz IB, Shah SR, Von Hoff DD, Borad MJ. Hypoxia-activated prodrugs in the treatment of advanced pancreatic adenocarcinoma. Anticancer Drugs 2017;28:127-32. [PMID: 27685167 DOI: 10.1097/CAD.0000000000000437] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
387 Jang JY, Kang JS, Han Y, Heo JS, Choi SH, Choi DW, Park SJ, Han SS, Yoon DS, Park JS, Yu HC, Kang KJ, Kim SG, Lee H, Kwon W, Yoon YS, Han HS, Kim SW. Long-term outcomes and recurrence patterns of standard versus extended pancreatectomy for pancreatic head cancer: a multicenter prospective randomized controlled study. J Hepatobiliary Pancreat Sci 2017;24:426-33. [PMID: 28514000 DOI: 10.1002/jhbp.465] [Cited by in Crossref: 16] [Cited by in F6Publishing: 9] [Article Influence: 5.3] [Reference Citation Analysis]
388 Meltzer RS, Maithel SK, Shah MM. ASO Author Reflections: Chemoradiation as the Mainstay of Therapy for Nonagenarians with Pancreatic Cancer. Ann Surg Oncol 2021;28:2273-4. [PMID: 33386545 DOI: 10.1245/s10434-020-09319-3] [Reference Citation Analysis]
389 Benzing C, Lam H, Tsang CM, Rimmer A, Arroyo-Berdugo Y, Calle Y, Wells CM. TIMP-2 secreted by monocyte-like cells is a potent suppressor of invadopodia formation in pancreatic cancer cells. BMC Cancer 2019;19:1214. [PMID: 31836008 DOI: 10.1186/s12885-019-6429-z] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
390 Lewis S, Sastri SC, Arya S, Mehta S, Patil P, Shrivastava S, Phurailatpam R, Shrikhande SV, Engineer R. Dose escalated concurrent chemo-radiation in borderline resectable and locally advanced pancreatic cancers with tomotherapy based intensity modulated radiotherapy: a phase II study. J Gastrointest Oncol 2019;10:474-82. [PMID: 31183197 DOI: 10.21037/jgo.2019.01.25] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
391 Ajina R, Weiner LM. T-Cell Immunity in Pancreatic Cancer. Pancreas 2020;49:1014-23. [PMID: 32833941 DOI: 10.1097/MPA.0000000000001621] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
392 Cerullo M, Gani F, Chen SY, Canner JK, Herman JM, Laheru D, Pawlik TM. Assessing the Financial Burden Associated With Treatment Options for Resectable Pancreatic Cancer. Ann Surg 2018;267:544-51. [PMID: 27787294 DOI: 10.1097/SLA.0000000000002069] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 3.5] [Reference Citation Analysis]
393 Rovers KP, Bakkers C, van Erning FN, Burger JWA, Nienhuijs SW, Simkens GAAM, Creemers GM, Hemmer PHJ, Punt CJA, Lemmens VEPP, Tanis PJ, de Hingh IHJT. Adjuvant Systemic Chemotherapy vs Active Surveillance Following Up-front Resection of Isolated Synchronous Colorectal Peritoneal Metastases. JAMA Oncol 2020;6:e202701. [PMID: 32672798 DOI: 10.1001/jamaoncol.2020.2701] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 6.0] [Reference Citation Analysis]
394 Grossberg AJ, Chu LC, Deig CR, Fishman EK, Hwang WL, Maitra A, Marks DL, Mehta A, Nabavizadeh N, Simeone DM, Weekes CD, Thomas CR Jr. Multidisciplinary standards of care and recent progress in pancreatic ductal adenocarcinoma. CA Cancer J Clin 2020;70:375-403. [PMID: 32683683 DOI: 10.3322/caac.21626] [Cited by in Crossref: 25] [Cited by in F6Publishing: 21] [Article Influence: 25.0] [Reference Citation Analysis]
395 Jeune F, Coriat R, Prat F, Dousset B, Vaillant JC, Gaujoux S. Pancreatic cancer surgical management. Presse Med 2019;48:e147-58. [PMID: 30905395 DOI: 10.1016/j.lpm.2019.02.027] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 4.0] [Reference Citation Analysis]
396 Raufi AG, Manji GA, Chabot JA, Bates SE. Neoadjuvant Treatment for Pancreatic Cancer. Seminars in Oncology 2019;46:19-27. [DOI: 10.1053/j.seminoncol.2018.12.002] [Cited by in Crossref: 43] [Cited by in F6Publishing: 30] [Article Influence: 21.5] [Reference Citation Analysis]
397 Naqvi I, Gunaratne R, McDade JE, Moreno A, Rempel RE, Rouse DC, Herrera SG, Pisetsky DS, Lee J, White RR, Sullenger BA. Polymer-Mediated Inhibition of Pro-invasive Nucleic Acid DAMPs and Microvesicles Limits Pancreatic Cancer Metastasis. Mol Ther 2018;26:1020-31. [PMID: 29550075 DOI: 10.1016/j.ymthe.2018.02.018] [Cited by in Crossref: 19] [Cited by in F6Publishing: 13] [Article Influence: 6.3] [Reference Citation Analysis]
398 Huang L, Jansen L, Balavarca Y, Molina-Montes E, Babaei M, van der Geest L, Lemmens V, Van Eycken L, De Schutter H, Johannesen TB, Fristrup CW, Mortensen MB, Primic-Žakelj M, Zadnik V, Becker N, Hackert T, Mägi M, Cassetti T, Sassatelli R, Grützmann R, Merkel S, Gonçalves AF, Bento MJ, Hegyi P, Lakatos G, Szentesi A, Moreau M, van de Velde T, Broeks A, Sant M, Minicozzi P, Mazzaferro V, Real FX, Carrato A, Molero X, Besselink MG, Malats N, Büchler MW, Schrotz-King P, Brenner H. Resection of pancreatic cancer in Europe and USA: an international large-scale study highlighting large variations. Gut 2019;68:130-9. [PMID: 29158237 DOI: 10.1136/gutjnl-2017-314828] [Cited by in Crossref: 58] [Cited by in F6Publishing: 43] [Article Influence: 14.5] [Reference Citation Analysis]
399 Kong B, Wu W, Valkovska N, Jäger C, Hong X, Nitsche U, Friess H, Esposito I, Erkan M, Kleeff J, Michalski CW. A common genetic variation of melanoma inhibitory activity-2 labels a subtype of pancreatic adenocarcinoma with high endoplasmic reticulum stress levels. Sci Rep 2015;5:8109. [PMID: 25657029 DOI: 10.1038/srep08109] [Cited by in Crossref: 17] [Cited by in F6Publishing: 13] [Article Influence: 2.8] [Reference Citation Analysis]
400 Acharya A, Markar SR, Sodergren MH, Malietzis G, Darzi A, Athanasiou T, Khan AZ. Meta-analysis of adjuvant therapy following curative surgery for periampullary adenocarcinoma. Br J Surg. 2017;104:814-822. [PMID: 28518410 DOI: 10.1002/bjs.10563] [Cited by in Crossref: 24] [Cited by in F6Publishing: 11] [Article Influence: 6.0] [Reference Citation Analysis]
401 Greco SH, August DA, Shah MM, Chen C, Moore DF, Masanam M, Turner AL, Jabbour SK, Javidian P, Grandhi MS, Kennedy TJ, Alexander HR, Carpizo DR, Langan RC. Neoadjuvant therapy is associated with lower margin positivity rates after Pancreaticoduodenectomy in T1 and T2 pancreatic head cancers: An analysis of the National Cancer Database. Surg Open Sci 2021;3:22-8. [PMID: 33490937 DOI: 10.1016/j.sopen.2020.12.001] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
402 Nakamura K, Sho M, Akahori T, Nishiwada S, Kunishige T, Nakagawa K, Nagai M, Takagi T, Terai T, Ikeda N. Clinical relevance of CD70 expression in resected pancreatic cancer: Prognostic value and therapeutic potential. Pancreatology 2021;21:573-80. [PMID: 33541781 DOI: 10.1016/j.pan.2021.01.013] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
403 Andreou A, Knitter S, Klein F, Malinka T, Schmelzle M, Struecker B, Schmuck RB, Noltsch AR, Lee D, Pelzer U, Denecke T, Pratschke J, Bahra M. The role of hepatectomy for synchronous liver metastases from pancreatic adenocarcinoma. Surg Oncol. 2018;27:688-694. [PMID: 30449494 DOI: 10.1016/j.suronc.2018.09.004] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 3.7] [Reference Citation Analysis]
404 Nelson SR, Roche S, Cotter M, Garcia PA, Reitmeier D, Zollbrecht E, O'Neill F, Clynes M, Doolan P, Medha JP, Swan N, Larkin A, Walsh N. Genomic Profiling and Functional Analysis of let-7c miRNA-mRNA Interactions Identify SOX13 to Be Involved in Invasion and Progression of Pancreatic Cancer. J Oncol 2020;2020:2951921. [PMID: 33424970 DOI: 10.1155/2020/2951921] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
405 Eguchi H, Takeda Y, Takahashi H, Nakahira S, Kashiwazaki M, Shimizu J, Sakai D, Isohashi F, Nagano H, Mori M, Doki Y. A Prospective, Open-Label, Multicenter Phase 2 Trial of Neoadjuvant Therapy Using Full-Dose Gemcitabine and S-1 Concurrent with Radiation for Resectable Pancreatic Ductal Adenocarcinoma. Ann Surg Oncol. 2019;26:4498-4505. [PMID: 31440928 DOI: 10.1245/s10434-019-07735-8] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 5.5] [Reference Citation Analysis]
406 Ogden JR, Xie H, Ma WW, Hubbard JM. The Management of Older Adults with Pancreatic Adenocarcinoma. Geriatrics (Basel) 2018;3:E85. [PMID: 31011120 DOI: 10.3390/geriatrics3040085] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
407 Fujii T, Yamada S, Murotani K, Kanda M, Sugimoto H, Nakao A, Kodera Y. Inverse Probability of Treatment Weighting Analysis of Upfront Surgery Versus Neoadjuvant Chemoradiotherapy Followed by Surgery for Pancreatic Adenocarcinoma with Arterial Abutment. Medicine (Baltimore) 2015;94:e1647. [PMID: 26426657 DOI: 10.1097/MD.0000000000001647] [Cited by in Crossref: 35] [Cited by in F6Publishing: 15] [Article Influence: 7.0] [Reference Citation Analysis]
408 Riazy M, Kalloger SE, Sheffield BS, Peixoto RD, Li-Chang HH, Scudamore CH, Renouf DJ, Schaeffer DF. Mismatch repair status may predict response to adjuvant chemotherapy in resectable pancreatic ductal adenocarcinoma. Mod Pathol 2015;28:1383-9. [PMID: 26226846 DOI: 10.1038/modpathol.2015.89] [Cited by in Crossref: 29] [Cited by in F6Publishing: 24] [Article Influence: 4.8] [Reference Citation Analysis]
409 Hüttner FJ, Fitzmaurice C, Schwarzer G, Seiler CM, Antes G, Büchler MW, Diener MK. Pylorus-preserving pancreaticoduodenectomy (pp Whipple) versus pancreaticoduodenectomy (classic Whipple) for surgical treatment of periampullary and pancreatic carcinoma. Cochrane Database Syst Rev 2016;2:CD006053. [PMID: 26905229 DOI: 10.1002/14651858.CD006053.pub6] [Cited by in Crossref: 26] [Cited by in F6Publishing: 23] [Article Influence: 5.2] [Reference Citation Analysis]
410 Karakas Y, Lacin S, Yalcin S. Recent advances in the management of pancreatic adenocarcinoma. Expert Review of Anticancer Therapy 2018;18:51-62. [DOI: 10.1080/14737140.2018.1403319] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 2.5] [Reference Citation Analysis]
411 Elamir AM, Hutchinson S, Albaba H, Keshavarzi S, Xu W, Moulton CA, McGilvary I, Cleary S, Wei A, Dodd A, Knox J, O'Kane G, Prince RM, Kalimuthu S, Kim J, Ringash J, Dawson LA, Wong R, Barry A, Brierley J, Gallinger S, Hosni A. A Risk Score Model for Locoregional Recurrence Following Upfront Surgery for Pancreatic Adenocarcinoma: Implications for Adjuvant Therapy. Clin Oncol (R Coll Radiol) 2021;33:527-35. [PMID: 33875360 DOI: 10.1016/j.clon.2021.03.007] [Reference Citation Analysis]
412 Winter JM, Jiang W, Basturk O, Mino-Kenudson M, Fong ZV, Tan WP, Lavu H, Vollmer CM, Furth EE, Haviland D, Klimstra DS, Jarnagin WR, Lillemoe KD, Yeo CJ, Fernandez-Del Castillo C, Allen PJ. Recurrence and Survival After Resection of Small Intraductal Papillary Mucinous Neoplasm-associated Carcinomas (≤20-mm Invasive Component): A Multi-institutional Analysis. Ann Surg 2016;263:793-801. [PMID: 26135696 DOI: 10.1097/SLA.0000000000001319] [Cited by in Crossref: 40] [Cited by in F6Publishing: 11] [Article Influence: 8.0] [Reference Citation Analysis]
413 Motoyama H, Kobayashi A, Yokoyama T, Shimizu A, Kitagawa N, Notake T, Fukushima K, Masuo H, Yoshizawa T, Miyagawa S. Survival Benefits of Surgical Resection in Patients with Recurrent Biliary Tract Carcinoma. World J Surg 2017;41:2817-29. [DOI: 10.1007/s00268-017-4107-3] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
414 Vreeland TJ, Katz MHG. Timing of Pancreatic Resection and Patient Outcomes: Is There a Difference? Surg Clin North Am 2018;98:57-71. [PMID: 29191278 DOI: 10.1016/j.suc.2017.09.006] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
415 Saharia A, Potter LM, Baio F, Elaileh A, Mobley C, Ghobrial RM, Abdelrahim M, Heyne K. Is Surgery-first Still a Reasonable Option in the Era of Neoadjuvant Chemotherapy for Resectable Pancreatic Cancer? Am J Clin Oncol 2020;43:298-304. [PMID: 31895096 DOI: 10.1097/COC.0000000000000661] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
416 Joubert F, Martin L, Perrier S, Pasparakis G. Development of a Gemcitabine-Polymer Conjugate with Prolonged Cytotoxicity against a Pancreatic Cancer Cell Line. ACS Macro Lett 2017;6:535-40. [DOI: 10.1021/acsmacrolett.7b00160] [Cited by in Crossref: 15] [Cited by in F6Publishing: 4] [Article Influence: 3.8] [Reference Citation Analysis]
417 Corrigan LR, Bracken-Clarke DM, Horgan AM. The challenge of treating older patients with pancreaticobiliary malignancies. Curr Probl Cancer 2018;42:59-72. [PMID: 29459178 DOI: 10.1016/j.currproblcancer.2018.01.015] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
418 Ikuta S, Aihara T, Yamanaka N. Preoperative C-reactive protein to albumin ratio is a predictor of survival after pancreatic resection for pancreatic ductal adenocarcinoma. Asia Pac J Clin Oncol 2019;15:e109-14. [PMID: 30632282 DOI: 10.1111/ajco.13123] [Cited by in Crossref: 12] [Cited by in F6Publishing: 5] [Article Influence: 6.0] [Reference Citation Analysis]
419 Cid-Arregui A, Juarez V. Perspectives in the treatment of pancreatic adenocarcinoma. World J Gastroenterol 2015;21:9297-316. [PMID: 26309356 DOI: 10.3748/wjg.v21.i31.9297] [Cited by in CrossRef: 82] [Cited by in F6Publishing: 64] [Article Influence: 16.4] [Reference Citation Analysis]
420 Holyoake DLP, Robinson M, Silva M, Grose D, McIntosh D, Sebag-Montefiore D, Radhakrishna G, Mukherjee S, Hawkins MA. SPARC, a phase-I trial of pre-operative, margin intensified, stereotactic body radiation therapy for pancreatic cancer. Radiother Oncol 2021;155:278-84. [PMID: 33217498 DOI: 10.1016/j.radonc.2020.11.007] [Reference Citation Analysis]
421 Yoshitomi H, Takano S, Furukawa K, Takayashiki T, Kuboki S, Ohtsuka M. Conversion surgery for initially unresectable pancreatic cancer: current status and unresolved issues. Surg Today 2019;49:894-906. [PMID: 30949842 DOI: 10.1007/s00595-019-01804-x] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 6.0] [Reference Citation Analysis]
422 Mori S, Aoki T, Sakuraoka Y, Shimizu T, Yamaguchi T, Park KH, Matsumoto T, Shiraki T, Iso Y, Kubota K. Impact of adverse events of adjuvant and neoadjuvant chemotherapies on outcomes of patients with pancreatic ductal adenocarcinoma. Cancer Chemother Pharmacol 2021;88:109-20. [PMID: 33825991 DOI: 10.1007/s00280-021-04267-5] [Reference Citation Analysis]
423 Sugimoto M, Kobayashi T, Kobayashi S, Takahashi S, Konishi M, Mitsunaga S, Ikeda M, Gotohda N. Extrapancreatic Nerve Plexus Invasion on Imaging Predicts Poor Survival After Upfront Surgery for Anatomically Resectable Pancreatic Cancer. Pancreas 2020;49:675-82. [PMID: 32433406 DOI: 10.1097/MPA.0000000000001547] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
424 Kizy S, Altman AM, Wirth KM, Marmor S, Hui JYC, Tuttle TM, Lou E, Amin K, Denbo JW, Jensen EH. Systemic therapy without radiation may be appropriate as neoadjuvant therapy for localized pancreas cancer. Hepatobiliary Surg Nutr 2020;9:296-303. [PMID: 32509815 DOI: 10.21037/hbsn.2019.04.17] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
425 Sato H, Sasajima J, Okada T, Hayashi A, Kawabata H, Goto T, Koizumi K, Tamamura N, Tanabe H, Fujiya M, Chiba SI, Tanino M, Ono Y, Mizukami Y, Okumura T. Resection for pancreatic cancer metastases contributes to survival: A case report with sequential tumor genotype profiling during the long-term postoperative course. Medicine (Baltimore) 2020;99:e20564. [PMID: 32569179 DOI: 10.1097/MD.0000000000020564] [Reference Citation Analysis]
426 Nishizawa N, Harada H, Kumamoto Y, Kaizu T, Katoh H, Tajima H, Ushiku H, Yokoi K, Igarashi K, Fujiyama Y, Okuwaki K, Iwai T, Watanabe M, Yamashita K. Diagnostic potential of hypermethylation of the cysteine dioxygenase 1 gene (CDO1) promoter DNA in pancreatic cancer.Cancer Sci. 2019;110:2846-2855. [PMID: 31325200 DOI: 10.1111/cas.14134] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 5.5] [Reference Citation Analysis]
427 Le A, Huang B, Hnoosh D, Saeed H, Dineen SP, Hosein PJ, Durbin EB, Kudrimoti M, Mcgrath PC, Tzeng CD. Effect of complications on oncologic outcomes after pancreaticoduodenectomy for pancreatic cancer. Journal of Surgical Research 2017;214:1-8. [DOI: 10.1016/j.jss.2017.02.036] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 2.8] [Reference Citation Analysis]
428 Tonini V, Zanni M. Pancreatic cancer in 2021: What you need to know to win. WJG 2021;27:5851-89. [DOI: 10.3748/wjg.v27.i35.5851] [Reference Citation Analysis]
429 Beleù A, Calabrese A, Rizzo G, Capelli P, Bellini N, Caloggero S, Calbi R, Tinazzi Martini P, De Robertis R, Carbognin G, Marchegiani G, Scarpa A, Salvia R, Bassi C, D'Onofrio M. Preoperative Imaging Evaluation after Downstaging of Pancreatic Ductal Adenocarcinoma: A Multi-Center Study. Cancers (Basel) 2019;11:E267. [PMID: 30823544 DOI: 10.3390/cancers11020267] [Cited by in Crossref: 11] [Cited by in F6Publishing: 4] [Article Influence: 5.5] [Reference Citation Analysis]
430 Liu ZQ, Han YC, Zhang X, Chu L, Fang JM, Zhao HX, Chen YJ, Xu Q. Prognostic value of human equilibrative nucleoside transporter1 in pancreatic cancer receiving gemcitabin-based chemotherapy: a meta-analysis. PLoS One. 2014;9:e87103. [PMID: 24475233 DOI: 10.1371/journal.pone.0087103] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 1.4] [Reference Citation Analysis]
431 Mirkin KA, Hollenbeak CS, Wong J. Survival impact of neoadjuvant therapy in resected pancreatic cancer: A Prospective Cohort Study involving 18,332 patients from the National Cancer Data Base. International Journal of Surgery 2016;34:96-102. [DOI: 10.1016/j.ijsu.2016.08.523] [Cited by in Crossref: 31] [Cited by in F6Publishing: 24] [Article Influence: 6.2] [Reference Citation Analysis]
432 Nagakawa Y, Nakagawa N, Takishita C, Uyama I, Kozono S, Osakabe H, Suzuki K, Nakagawa N, Hosokawa Y, Shirota T, Honda M, Yamada T, Katsumata K, Tsuchida A. Reconsideration of the Appropriate Dissection Range Based on Japanese Anatomical Classification for Resectable Pancreatic Head Cancer in the Era of Multimodal Treatment. Cancers (Basel) 2021;13:3605. [PMID: 34298818 DOI: 10.3390/cancers13143605] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
433 Yabar CS, Winter JM. Pancreatic Cancer: A Review. Gastroenterol Clin North Am. 2016;45:429-445. [PMID: 27546841 DOI: 10.1016/j.gtc.2016.04.003] [Cited by in Crossref: 51] [Cited by in F6Publishing: 36] [Article Influence: 12.8] [Reference Citation Analysis]
434 Kirby MK, Ramaker RC, Gertz J, Davis NS, Johnston BE, Oliver PG, Sexton KC, Greeno EW, Christein JD, Heslin MJ, Posey JA, Grizzle WE, Vickers SM, Buchsbaum DJ, Cooper SJ, Myers RM. RNA sequencing of pancreatic adenocarcinoma tumors yields novel expression patterns associated with long-term survival and reveals a role for ANGPTL4. Mol Oncol. 2016;10:1169-1182. [PMID: 27282075 DOI: 10.1016/j.molonc.2016.05.004] [Cited by in Crossref: 32] [Cited by in F6Publishing: 29] [Article Influence: 6.4] [Reference Citation Analysis]
435 Liu Q, Zhang R, Zhang X, Liu J, Wu H, Li Y, Cui M, Li T, Song H, Gao J, Zhang Y, Yang S, Liao Q. Dopamine improves chemotherapeutic efficacy for pancreatic cancer by regulating macrophage-derived inflammations. Cancer Immunol Immunother 2021;70:2165-77. [PMID: 33454798 DOI: 10.1007/s00262-020-02816-0] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
436 Sutton JM, Abbott DE. Neoadjuvant therapy for pancreas cancer: past lessons and future therapies. World J Gastroenterol. 2014;20:15564-15579. [PMID: 25400440 DOI: 10.3748/wjg.v20.i42.15564] [Cited by in CrossRef: 30] [Cited by in F6Publishing: 27] [Article Influence: 5.0] [Reference Citation Analysis]
437 Schmuck RB, de Carvalho-Fischer CV, Neumann C, Pratschke J, Bahra M. Distal bile duct carcinomas and pancreatic ductal adenocarcinomas: postulating a common tumor entity. Cancer Med. 2016;5:88-99. [PMID: 26645826 DOI: 10.1002/cam4.566] [Cited by in Crossref: 27] [Cited by in F6Publishing: 21] [Article Influence: 4.5] [Reference Citation Analysis]
438 Gaskill CE, Maxwell J, Ikoma N, Kim MP, Tzeng CW, Lee JE, Katz MHG. History of preoperative therapy for pancreatic cancer and the MD Anderson experience. J Surg Oncol 2021;123:1414-22. [PMID: 33831256 DOI: 10.1002/jso.26394] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
439 Buchsbaum DJ, Croce CM. Will detection of microRNA biomarkers in blood improve the diagnosis and survival of patients with pancreatic cancer? JAMA 2014;311:363-5. [PMID: 24449314 DOI: 10.1001/jama.2013.284665] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
440 Abe T, Ohuchida K, Endo S, Ookubo F, Mori Y, Nakata K, Miyasaka Y, Manabe T, Ohtsuka T, Nagai E, Oda Y, Nakamura M. Clinical importance of intraoperative peritoneal cytology in patients with pancreatic cancer. Surgery 2017;161:951-8. [DOI: 10.1016/j.surg.2016.10.035] [Cited by in Crossref: 13] [Cited by in F6Publishing: 8] [Article Influence: 3.3] [Reference Citation Analysis]
441 Janssen QP, van Dam JL, Bonsing BA, Bos H, Bosscha KP, Coene PPLO, van Eijck CHJ, de Hingh IHJT, Karsten TM, van der Kolk MB, Patijn GA, Liem MSL, van Santvoort HC, Loosveld OJL, de Vos-Geelen J, Zonderhuis BM, Homs MYV, van Tienhoven G, Besselink MG, Wilmink JW, Groot Koerkamp B; Dutch Pancreatic Cancer Group. Total neoadjuvant FOLFIRINOX versus neoadjuvant gemcitabine-based chemoradiotherapy and adjuvant gemcitabine for resectable and borderline resectable pancreatic cancer (PREOPANC-2 trial): study protocol for a nationwide multicenter randomized controlled trial. BMC Cancer 2021;21:300. [PMID: 33757440 DOI: 10.1186/s12885-021-08031-z] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
442 Barenboim A, Lahat G, Geva R, Nachmany I, Nakache R, Goykhman Y, Brazowski E, Rosen G, Isakov O, Wolf I, Klausner JM, Lubezky N. Neoadjuvant FOLFIRINOX for locally advanced and borderline resectable pancreatic cancer: An intention to treat analysis. European Journal of Surgical Oncology 2018;44:1619-23. [DOI: 10.1016/j.ejso.2018.07.057] [Cited by in Crossref: 51] [Cited by in F6Publishing: 41] [Article Influence: 17.0] [Reference Citation Analysis]
443 Nishiwada S, Sho M, Banwait JK, Yamamura K, Akahori T, Nakamura K, Baba H, Goel A. A MicroRNA Signature Identifies Pancreatic Ductal Adenocarcinoma Patients at Risk for Lymph Node Metastases. Gastroenterology 2020;159:562-74. [PMID: 32376411 DOI: 10.1053/j.gastro.2020.04.057] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 5.0] [Reference Citation Analysis]
444 Roland CL, Yang AD, Katz MH, Chatterjee D, Wang H, Lin H, Vauthey JN, Pisters PW, Varadhachary GR, Wolff RA, Crane CH, Lee JE, Fleming JB. Neoadjuvant therapy is associated with a reduced lymph node ratio in patients with potentially resectable pancreatic cancer. Ann Surg Oncol. 2015;22:1168-1175. [PMID: 25352267 DOI: 10.1245/s10434-014-4192-6] [Cited by in Crossref: 68] [Cited by in F6Publishing: 57] [Article Influence: 9.7] [Reference Citation Analysis]
445 Liedtke KR, Bekeschus S, Kaeding A, Hackbarth C, Kuehn JP, Heidecke CD, von Bernstorff W, von Woedtke T, Partecke LI. Non-thermal plasma-treated solution demonstrates antitumor activity against pancreatic cancer cells in vitro and in vivo. Sci Rep 2017;7:8319. [PMID: 28814809 DOI: 10.1038/s41598-017-08560-3] [Cited by in Crossref: 68] [Cited by in F6Publishing: 44] [Article Influence: 17.0] [Reference Citation Analysis]
446 Ocuin LM, Miller-Ocuin JL, Zenati MS, Vargo JA, Singhi AD, Burton SA, Bahary N, Hogg ME, Zeh HJ, Zureikat AH. A margin distance analysis of the impact of adjuvant chemoradiation on survival after pancreatoduodenectomy for pancreatic adenocarcinoma. J Gastrointest Oncol. 2017;8:696-704. [PMID: 28890820 DOI: 10.21037/jgo.2017.04.02] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
447 Van Cutsem E, Tempero MA, Sigal D, Oh DY, Fazio N, Macarulla T, Hitre E, Hammel P, Hendifar AE, Bates SE, Li CP, Hingorani SR, de la Fouchardiere C, Kasi A, Heinemann V, Maraveyas A, Bahary N, Layos L, Sahai V, Zheng L, Lacy J, Park JO, Portales F, Oberstein P, Wu W, Chondros D, Bullock AJ; HALO 109-301 Investigators. Randomized Phase III Trial of Pegvorhyaluronidase Alfa With Nab-Paclitaxel Plus Gemcitabine for Patients With Hyaluronan-High Metastatic Pancreatic Adenocarcinoma. J Clin Oncol 2020;38:3185-94. [PMID: 32706635 DOI: 10.1200/JCO.20.00590] [Cited by in Crossref: 50] [Cited by in F6Publishing: 21] [Article Influence: 50.0] [Reference Citation Analysis]
448 Ansari D, Tingstedt B, Andersson B, Holmquist F, Sturesson C, Williamsson C, Sasor A, Borg D, Bauden M, Andersson R. Pancreatic cancer: yesterday, today and tomorrow. Future Oncol. 2016;12:1929-1946. [PMID: 27246628 DOI: 10.2217/fon-2016-0010] [Cited by in Crossref: 106] [Cited by in F6Publishing: 87] [Article Influence: 21.2] [Reference Citation Analysis]
449 Seppänen H, Juuti A, Mustonen H, Haapamäki C, Nordling S, Carpelan-Holmström M, Sirén J, Luettges J, Haglund C, Kiviluoto T. The Results of Pancreatic Resections and Long-Term Survival for Pancreatic Ductal Adenocarcinoma: A Single-Institution Experience. Scand J Surg 2017;106:54-61. [PMID: 27130378 DOI: 10.1177/1457496916645963] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 3.8] [Reference Citation Analysis]
450 Karandish F, Mallik S. Biomarkers and Targeted Therapy in Pancreatic Cancer. Biomark Cancer 2016;8:27-35. [PMID: 27147897 DOI: 10.4137/BiC.s34414] [Cited by in Crossref: 11] [Cited by in F6Publishing: 17] [Article Influence: 2.2] [Reference Citation Analysis]
451 Galvano A, Castiglia M, Rizzo S, Silvestris N, Brunetti O, Vaccaro G, Gristina V, Barraco N, Bono M, Guercio G, Graceffa G, Fulfaro F, Gori S, Bazan V, Russo A. Moving the Target on the Optimal Adjuvant Strategy for Resected Pancreatic Cancers: A Systematic Review with Meta-Analysis.Cancers (Basel). 2020;12. [PMID: 32110977 DOI: 10.3390/cancers12030534] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
452 Nishizawa N, Kumamoto Y, Katoh H, Ushiku H, Yokoi K, Tanaka T, Ishii S, Igarashi K, Tajima H, Kaizu T, Yoshida T, Saegusa M, Watanabe M, Yamashita K. Dissected peripancreatic tissue margin is a critical prognostic factor and is associated with a K-ras gene mutation in pancreatic ductal adenocarcinoma. Oncol Lett 2019;17:2141-50. [PMID: 30675280 DOI: 10.3892/ol.2018.9839] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
453 Lohneis P, Sinn M, Klein F, Bischoff S, Striefler JK, Wislocka L, Sinn BV, Pelzer U, Oettle H, Riess H, Denkert C, Bläker H, Jühling A. Tumour buds determine prognosis in resected pancreatic ductal adenocarcinoma. Br J Cancer 2018;118:1485-91. [PMID: 29755112 DOI: 10.1038/s41416-018-0093-y] [Cited by in Crossref: 20] [Cited by in F6Publishing: 17] [Article Influence: 6.7] [Reference Citation Analysis]
454 Jones WE 3rd, Suh WW, Abdel-Wahab M, Abrams RA, Azad N, Das P, Dragovic J, Goodman KA, Jabbour SK, Konski AA, Koong AC, Kumar R, Lee P, Pawlik TM, Small W Jr, Herman JM; Expert Panel on Radiation OncologyGastrointestinal. ACR Appropriateness Criteria® Resectable Pancreatic Cancer. Am J Clin Oncol 2017;40:109-17. [PMID: 28230650 DOI: 10.1097/COC.0000000000000370] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
455 Lau SC, Cheung WY. Evolving treatment landscape for early and advanced pancreatic cancer. World J Gastrointest Oncol 2017;9:281-92. [PMID: 28808501 DOI: 10.4251/wjgo.v9.i7.281] [Cited by in CrossRef: 16] [Cited by in F6Publishing: 14] [Article Influence: 4.0] [Reference Citation Analysis]
456 Sudo K, Nakamura K, Yamaguchi T. S-1 in the treatment of pancreatic cancer. World J Gastroenterol. 2014;20:15110-15118. [PMID: 25386059 DOI: 10.3748/wjg.v20.i41.15110] [Cited by in CrossRef: 34] [Cited by in F6Publishing: 24] [Article Influence: 5.7] [Reference Citation Analysis]
457 Lee SY, Sissoko M, Hartshorn KL. Update on the Management of Pancreatic Cancer in Older Adults. Curr Oncol Rep 2016;18:60. [PMID: 27492426 DOI: 10.1007/s11912-016-0547-4] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
458 Oikonomou D, Karamouzis MV, Moris D, Dimitrokallis N, Papamichael D, Kountourakis P, Astras G, Davakis S, Papalampros A, Schizas D, Petrou AS, Felekouras E. Irreversible Electroporation (IRE) Combined With Chemotherapy Increases Survival in Locally Advanced Pancreatic Cancer (LAPC). Am J Clin Oncol 2021;44:325-30. [PMID: 33979098 DOI: 10.1097/COC.0000000000000826] [Reference Citation Analysis]
459 Awasthi N, Kronenberger D, Stefaniak A, Hassan MS, von Holzen U, Schwarz MA, Schwarz RE. Dual inhibition of the PI3K and MAPK pathways enhances nab-paclitaxel/gemcitabine chemotherapy response in preclinical models of pancreatic cancer. Cancer Letters 2019;459:41-9. [DOI: 10.1016/j.canlet.2019.05.037] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 7.5] [Reference Citation Analysis]
460 Janssen QP, O'Reilly EM, van Eijck CHJ, Groot Koerkamp B. Neoadjuvant Treatment in Patients With Resectable and Borderline Resectable Pancreatic Cancer.Front Oncol. 2020;10:41. [PMID: 32083002 DOI: 10.3389/fonc.2020.00041] [Cited by in Crossref: 14] [Cited by in F6Publishing: 8] [Article Influence: 14.0] [Reference Citation Analysis]
461 Pointer DT Jr, Roife D, Powers BD, Murimwa G, Elessawy S, Thompson ZJ, Schell MJ, Hodul PJ, Pimiento JM, Fleming JB, Malafa MP. Neutrophil to lymphocyte ratio, not platelet to lymphocyte or lymphocyte to monocyte ratio, is predictive of patient survival after resection of early-stage pancreatic ductal adenocarcinoma. BMC Cancer 2020;20:750. [PMID: 32782024 DOI: 10.1186/s12885-020-07182-9] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
462 Chan E, Arlinghaus LR, Cardin DB, Goff L, Berlin JD, Parikh A, Abramson RG, Yankeelov TE, Hiebert S, Merchant N. Phase I trial of vorinostat added to chemoradiation with capecitabine in pancreatic cancer. Radiother Oncol. 2016;119:312-318. [PMID: 27106554 DOI: 10.1016/j.radonc.2016.04.013] [Cited by in Crossref: 30] [Cited by in F6Publishing: 25] [Article Influence: 6.0] [Reference Citation Analysis]
463 Cho M, Wang-Gillam A, Myerson R, Gao F, Strasberg S, Picus J, Sorscher S, Fournier C, Nagaraj G, Parikh P, Suresh R, Linehan D, Tan BR. A phase II study of adjuvant gemcitabine plus docetaxel followed by concurrent chemoradation in resected pancreaticobiliary carcinoma. HPB (Oxford) 2015;17:587-93. [PMID: 25800066 DOI: 10.1111/hpb.12413] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 1.5] [Reference Citation Analysis]
464 Benavides M, Abad A, Ales I, Carrato A, Díaz Rubio E, Gallego J, García-foncillas J, Grávalos C, Laquente B, Pericay C, Rivera F, Tabernero J, Aranda E. TTD consensus document on the diagnosis and management of exocrine pancreatic cancer. Clin Transl Oncol 2014;16:865-78. [DOI: 10.1007/s12094-014-1177-7] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
465 Yoon SJ, Shin SH, Yoon SK, Jung JH, You Y, Han IW, Choi DW, Heo JS. Appraisal of 5-year recurrence-free survival after surgery in pancreatic ductal adenocarcinoma. J Hepatobiliary Pancreat Sci 2021;28:287-96. [PMID: 32790012 DOI: 10.1002/jhbp.815] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
466 Li F, Dai L, Niu J. GPX2 silencing relieves epithelial-mesenchymal transition, invasion, and metastasis in pancreatic cancer by downregulating Wnt pathway. J Cell Physiol 2020;235:7780-90. [PMID: 31774184 DOI: 10.1002/jcp.29391] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
467 Torphy RJ, Fujiwara Y, Schulick RD. Pancreatic cancer treatment: better, but a long way to go. Surg Today 2020;50:1117-25. [PMID: 32474642 DOI: 10.1007/s00595-020-02028-0] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 7.0] [Reference Citation Analysis]
468 Holyoake DL, Ward E, Grose D, McIntosh D, Sebag-Montefiore D, Radhakrishna G, Patel N, Silva M, Mukherjee S, Strauss VY, Odondi L, Fokas E, Melcher A, Hawkins MA. A phase-I trial of pre-operative, margin intensive, stereotactic body radiation therapy for pancreatic cancer: the 'SPARC' trial protocol. BMC Cancer 2016;16:728. [PMID: 27619800 DOI: 10.1186/s12885-016-2765-4] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 1.6] [Reference Citation Analysis]
469 Roeder F. Neoadjuvant radiotherapeutic strategies in pancreatic cancer. World J Gastrointest Oncol 2016;8:186-97. [PMID: 26909133 DOI: 10.4251/wjgo.v8.i2.186] [Cited by in CrossRef: 10] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
470 Nakashima Y, Kawae T, Iwaki D, Fudeyasu K, Kimura H, Uemura K, Okamura H. Changes in motor function and quality of life after surgery in patients with pancreatic cancer. Eur J Cancer Care (Engl) 2021;30:e13368. [PMID: 33244846 DOI: 10.1111/ecc.13368] [Reference Citation Analysis]
471 Yoo C, Lee SS, Song KB, Jeong JH, Hyung J, Park DH, Song TJ, Seo DW, Lee SK, Kim MH, Lee SS, Kim JH, Jin HS, Park JH, Hwang DW, Lee JH, Lee W, Chang HM, Kim KP, Ryoo BY, Kim SC. Neoadjuvant modified FOLFIRINOX followed by postoperative gemcitabine in borderline resectable pancreatic adenocarcinoma: a Phase 2 study for clinical and biomarker analysis. Br J Cancer 2020;123:362-8. [PMID: 32433600 DOI: 10.1038/s41416-020-0867-x] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 8.0] [Reference Citation Analysis]
472 Piątek M, Kuśnierz K, Bieńkowski M, Pęksa R, Kowalczyk M, Nawrocki S. Primarily resectable pancreatic adenocarcinoma - to operate or to refer the patient to an oncologist? Crit Rev Oncol Hematol 2019;135:95-102. [PMID: 30819452 DOI: 10.1016/j.critrevonc.2019.01.010] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
473 Li D, O'Reilly EM. Adjuvant and neoadjuvant systemic therapy for pancreas adenocarcinoma. Semin Oncol 2015;42:134-43. [PMID: 25726058 DOI: 10.1053/j.seminoncol.2014.12.012] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 1.9] [Reference Citation Analysis]
474 Mondal G, Almawash S, Chaudhary AK, Mahato RI. EGFR-Targeted Cationic Polymeric Mixed Micelles for Codelivery of Gemcitabine and miR-205 for Treating Advanced Pancreatic Cancer. Mol Pharm 2017;14:3121-33. [PMID: 28719220 DOI: 10.1021/acs.molpharmaceut.7b00355] [Cited by in Crossref: 23] [Cited by in F6Publishing: 21] [Article Influence: 5.8] [Reference Citation Analysis]
475 Shen Q, Wang J, Liu C, Cui W, Zhang L, Zhang Y, Wang Y, Wu J, Li J. Synthesis and evaluation of tetrahydroquinolin-2(1H)-one derivatives as novel anti-pancreatic cancer agents via targeting autophagy. European Journal of Medicinal Chemistry 2019;170:28-44. [DOI: 10.1016/j.ejmech.2019.03.013] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
476 Einama T, Kamachi H, Tsuruga Y, Sakata T, Shibuya K, Sakamoto Y, Shimada S, Wakayama K, Orimo T, Yokoo H, Kamiyama T, Katoh N, Uchinami Y, Mitsuhashi T, Taketomi A. Optimal resection area for superior mesenteric artery nerve plexuses after neoadjuvant chemoradiotherapy for locally advanced pancreatic carcinoma. Medicine (Baltimore) 2018;97:e11309. [PMID: 30075497 DOI: 10.1097/MD.0000000000011309] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
477 Wang Y, Lakoma A, Zogopoulos G. Building towards Precision Oncology for Pancreatic Cancer: Real-World Challenges and Opportunities. Genes (Basel) 2020;11:E1098. [PMID: 32967105 DOI: 10.3390/genes11091098] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
478 Hilmi M, Cros J, Puleo F, Augustin J, Emile JF, Svrcek M, Hammel P, Arsenijevic T, Van Laethem JL, Bachet JB, Nicolle R. Tumour and stroma RNA signatures predict more accurately distant recurrence than clinicopathological factors in resected pancreatic adenocarcinoma. Eur J Cancer. 2021;148:171-180. [PMID: 33743485 DOI: 10.1016/j.ejca.2021.01.042] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
479 Byun Y, Choi YJ, Han Y, Kang JS, Kim H, Kwon W, Jang JY. Outcomes of 5000 pancreatectomies in Korean single referral center and literature reviews. J Hepatobiliary Pancreat Sci 2021. [PMID: 33636051 DOI: 10.1002/jhbp.933] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
480 Maeda S, Moore AM, Yohanathan L, Hata T, Truty MJ, Smoot RL, Cleary SP, Nagorney DM, Grotz TE, Park EJ, Girgis MD, Reber HA, Motoi F, Masuda T, Unno M, Kendrick ML, Donahue TR. Impact of resection margin status on survival in pancreatic cancer patients after neoadjuvant treatment and pancreatoduodenectomy. Surgery 2020;167:803-11. [PMID: 31992444 DOI: 10.1016/j.surg.2019.12.008] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 8.0] [Reference Citation Analysis]
481 He D, Miao H, Xu Y, Xiong L, Wang Y, Xiang H, Zhang H, Zhang Z. MiR-371-5p facilitates pancreatic cancer cell proliferation and decreases patient survival. PLoS One 2014;9:e112930. [PMID: 25411783 DOI: 10.1371/journal.pone.0112930] [Cited by in Crossref: 32] [Cited by in F6Publishing: 23] [Article Influence: 4.6] [Reference Citation Analysis]
482 Fan X, Zhang X, Shen J, Zhao H, Yu X, Chen Y, Zhuang Z, Deng X, Feng H, Wang Y, Peng L. Decreased TUSC3 Promotes Pancreatic Cancer Proliferation, Invasion and Metastasis. PLoS One 2016;11:e0149028. [PMID: 26871953 DOI: 10.1371/journal.pone.0149028] [Cited by in Crossref: 14] [Cited by in F6Publishing: 18] [Article Influence: 2.8] [Reference Citation Analysis]
483 Delpero JR, Boher JM, Sauvanet A, Le Treut YP, Sa-Cunha A, Mabrut JY, Chiche L, Turrini O, Bachellier P, Paye F. Pancreatic adenocarcinoma with venous involvement: is up-front synchronous portal-superior mesenteric vein resection still justified? Ann Surg Oncol. 2015;22:1874-1883. [PMID: 25665947 DOI: 10.1245/s10434-014-4304-3] [Cited by in Crossref: 64] [Cited by in F6Publishing: 53] [Article Influence: 10.7] [Reference Citation Analysis]
484 Burmeister EA, OʼConnell DL, Beesley VL, Goldstein D, Gooden HM, Janda M, Jordan SJ, Merrett ND, Payne ME, Wyld D, Neale RE; Pancreatic Cancer Patterns of Care Study Group. Describing Patterns of Care in Pancreatic Cancer: A Population-Based Study. Pancreas 2015;44:1259-65. [PMID: 26262591 DOI: 10.1097/MPA.0000000000000384] [Cited by in Crossref: 26] [Cited by in F6Publishing: 4] [Article Influence: 5.2] [Reference Citation Analysis]
485 Boeck S, Heinemann V. Improving post-surgical management of resected pancreatic cancer. Lancet 2017;390:847-8. [PMID: 28850041 DOI: 10.1016/S0140-6736(17)31806-8] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
486 Jiang Y, Su Y, Chen Y, Li Z. Refining the American Joint Committee on Cancer Staging Scheme For Resectable Pancreatic Ductal Adenocarcinoma Using Recursive Partitioning Analysis. J Cancer 2017;8:2765-73. [PMID: 28928865 DOI: 10.7150/jca.19515] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
487 Silvestris N, Brunetti O, Vasile E, Cellini F, Cataldo I, Pusceddu V, Cattaneo M, Partelli S, Scartozzi M, Aprile G, Casadei Gardini A, Morganti AG, Valentini V, Scarpa A, Falconi M, Calabrese A, Lorusso V, Reni M, Cascinu S. Multimodal treatment of resectable pancreatic ductal adenocarcinoma. Crit Rev Oncol Hematol. 2017;111:152-165. [PMID: 28259290 DOI: 10.1016/j.critrevonc.2017.01.015] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 5.0] [Reference Citation Analysis]
488 Takaori K, Bassi C, Biankin A, Brunner TB, Cataldo I, Campbell F, Cunningham D, Falconi M, Frampton AE, Furuse J, Giovannini M, Jackson R, Nakamura A, Nealon W, Neoptolemos JP, Real FX, Scarpa A, Sclafani F, Windsor JA, Yamaguchi K, Wolfgang C, Johnson CD;  IAP/EPC study group on the clinical managements of pancreatic cancer. International Association of Pancreatology (IAP)/European Pancreatic Club (EPC) consensus review of guidelines for the treatment of pancreatic cancer. Pancreatology. 2016;16:14-27. [PMID: 26699808 DOI: 10.1016/j.pan.2015.10.013] [Cited by in Crossref: 46] [Cited by in F6Publishing: 32] [Article Influence: 7.7] [Reference Citation Analysis]
489 Kawai M, Murakami Y, Motoi F, Sho M, Satoi S, Matsumoto I, Honda G, Hirono S, Okada K, Unno M, Nakajima Y, Uemura K, Kwon A, Fukumoto T, Kurata M, Yamaue H. Grade B pancreatic fistulas do not affect survival after pancreatectomy for pancreatic cancer: A multicenter observational study. Surgery 2016;160:293-305. [DOI: 10.1016/j.surg.2016.02.032] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 3.2] [Reference Citation Analysis]
490 Johnson B, Vanderwalde A, Javadi N, Feldman R, Reddy SB. Molecular profiling of a case of advanced pancreatic cancer identifies an active and tolerable combination of targeted therapy with backbone chemotherapy. J Gastrointest Oncol 2016;7:E6-E12. [PMID: 27034805 DOI: 10.3978/j.issn.2078-6891.2015.091] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
491 Barhli A, Cros J, Bartholin L, Neuzillet C. Prognostic stratification of resected pancreatic ductal adenocarcinoma: Past, present, and future. Dig Liver Dis 2018;50:979-90. [PMID: 30205952 DOI: 10.1016/j.dld.2018.08.009] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 5.0] [Reference Citation Analysis]
492 Hashemi-Sadraei N, Gbolahan OB, Salfity H, O'Neil B, House MG, Shahda S. Clinical Characteristics of Patients Experiencing Pathologic Complete Response Following Neoadjuvant Therapy for Borderline Resectable/Locally Advanced Pancreatic Adenocarcinoma. Am J Clin Oncol 2018;41:982-5. [PMID: 28968257 DOI: 10.1097/COC.0000000000000409] [Cited by in Crossref: 9] [Cited by in F6Publishing: 4] [Article Influence: 4.5] [Reference Citation Analysis]
493 Sirohi B, Singh A, Dawood S, Shrikhande SV. Advances in chemotherapy for pancreatic cancer. Indian J Surg Oncol 2015;6:47-56. [PMID: 25937764 DOI: 10.1007/s13193-014-0371-y] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
494 Akasaka H, Mizushina Y, Yoshida K, Ejima Y, Mukumoto N, Wang T, Inubushi S, Nakayama M, Wakahara Y, Sasaki R. MGDG extracted from spinach enhances the cytotoxicity of radiation in pancreatic cancer cells. Radiat Oncol 2016;11:153. [PMID: 27876069 DOI: 10.1186/s13014-016-0729-0] [Cited by in Crossref: 15] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
495 Bonaroti JW, Zenati MS, Al-Abbas AI, Rieser CJ, Zureikat AH, Hogg ME, Zeh HJ, Boone BA. Impact of postoperative pancreatic fistula on long-term oncologic outcomes after pancreatic resection. HPB (Oxford) 2021;23:1269-76. [PMID: 33526357 DOI: 10.1016/j.hpb.2020.12.010] [Reference Citation Analysis]
496 Li J, Wu H, Li W, Yin L, Guo S, Xu X, Ouyang Y, Zhao Z, Liu S, Tian Y, Tian Z, Ju J, Ni B, Wang H. Downregulated miR-506 expression facilitates pancreatic cancer progression and chemoresistance via SPHK1/Akt/NF-κB signaling. Oncogene 2016;35:5501-14. [PMID: 27065335 DOI: 10.1038/onc.2016.90] [Cited by in Crossref: 92] [Cited by in F6Publishing: 88] [Article Influence: 18.4] [Reference Citation Analysis]
497 Karamitopoulou E, Esposito I, Zlobec I, Insilla AC, Wartenberg M, Schaeffer DF, Kalloger S, La Rosa S, Sempoux C, Ramos Centeno I, Lohneis P. Reproducibility of tumor budding assessment in pancreatic cancer based on a multicenter interobserver study. Virchows Arch 2021;478:719-26. [PMID: 33330964 DOI: 10.1007/s00428-020-02987-2] [Reference Citation Analysis]
498 Sinn M, Denkert C, Striefler JK, Pelzer U, Stieler JM, Bahra M, Lohneis P, Dörken B, Oettle H, Riess H. α-Smooth muscle actin expression and desmoplastic stromal reaction in pancreatic cancer: results from the CONKO-001 study. Br J Cancer. 2014;111:1917-1923. [PMID: 25314063 DOI: 10.1038/bjc.2014.495] [Cited by in Crossref: 74] [Cited by in F6Publishing: 66] [Article Influence: 10.6] [Reference Citation Analysis]
499 Wei AC, Ou FS, Shi Q, Carrero X, O'Reilly EM, Meyerhardt J, Wolff RA, Kindler HL, Evans DB, Deshpande V, Misdraji J, Tamm E, Sahani D, Moore M, Newman E, Merchant N, Berlin J, Goff LW, Pisters P, Posner MC. Perioperative Gemcitabine + Erlotinib Plus Pancreaticoduodenectomy for Resectable Pancreatic Adenocarcinoma: ACOSOG Z5041 (Alliance) Phase II Trial. Ann Surg Oncol 2019;26:4489-97. [PMID: 31418130 DOI: 10.1245/s10434-019-07685-1] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 5.5] [Reference Citation Analysis]
500 Swords DS, Francis SR, Lloyd S, Garrido-laguna I, Mulvihill SJ, Gruhl JD, Christensen MC, Stoddard GJ, Firpo MA, Scaife CL. Lymph Node Ratio in Pancreatic Adenocarcinoma After Preoperative Chemotherapy vs. Preoperative Chemoradiation and Its Utility in Decisions About Postoperative Chemotherapy. J Gastrointest Surg 2019;23:1401-13. [DOI: 10.1007/s11605-018-3953-0] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
501 Takahashi H, Akita H, Wada H, Tomokuni A, Asukai K, Takahashi Y, Yanagimoto Y, Matsunaga T, Sugimura K, Yamamoto K, Nishimura J, Yasui M, Omori T, Miyata H, Yamamoto T, Nakanishi M, Shirayanagi M, Yamasaki T, Ohue M, Yano M, Sakon M, Ishikawa O. Subclinical cancer cell dissemination in peritoneal lavage fluid detected by reverse-transcription polymerase chain reaction identifies patients at high risk for peritoneal recurrence and consequent impaired survival in the setting of preoperative chemoradiation therapy for pancreatic cancer. Surgery 2018;164:1168-77. [PMID: 30146098 DOI: 10.1016/j.surg.2018.06.047] [Cited by in Crossref: 7] [Cited by in F6Publishing: 2] [Article Influence: 2.3] [Reference Citation Analysis]
502 Johnson B, Khalil M, Blansfield J, Lin F, Zhu S, Kirchner HL, Weir AB 3rd. Investigating the prognostic value of KOC (K homology domain containing protein overexpressed in cancer) overexpression after curative intent resection of pancreatic ductal adenocarcinoma. J Gastrointest Oncol 2016;7:E113-7. [PMID: 28078135 DOI: 10.21037/jgo.2016.11.05] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
503 Lai IL, Chou CC, Lai PT, Fang CS, Shirley LA, Yan R, Mo X, Bloomston M, Kulp SK, Bekaii-Saab T. Targeting the Warburg effect with a novel glucose transporter inhibitor to overcome gemcitabine resistance in pancreatic cancer cells. Carcinogenesis. 2014;35:2203-2213. [PMID: 24879635 DOI: 10.1093/carcin/bgu124] [Cited by in Crossref: 27] [Cited by in F6Publishing: 25] [Article Influence: 3.9] [Reference Citation Analysis]
504 Verdaguer H, Arroyo A, Macarulla T. New Horizons in the Treatment of Metastatic Pancreatic Cancer: A Review of the Key Biology Features and the Most Recent Advances to Treat Metastatic Pancreatic Cancer. Targ Oncol 2018;13:691-704. [DOI: 10.1007/s11523-018-0609-7] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
505 Mehtsun WT, Hashimoto DA, Ferrone CR. Status of 5-Year Survivors of the Whipple Procedure for Pancreatic Adenocarcinoma. Advances in Surgery 2019;53:253-69. [DOI: 10.1016/j.yasu.2019.04.012] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
506 Liao W, Huang J, Zhu G, Zhou J, Wen F, Zhang P, Zhou K, Wu Q, Wang X, Gou H, Li Q. S-1 or gemcitabine adjuvant therapy in resected pancreatic cancer: a cost-effectiveness analysis based on the JASPAC-01 trial. Expert Review of Pharmacoeconomics & Outcomes Research 2020;20:133-8. [DOI: 10.1080/14737167.2020.1677155] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
507 Parikh AA, Maiga A, Bentrem D, Squires MH, Kooby DA, Maithel SK, Weber SM, Cho CS, Katz M, Martin RC, Scoggins CR, Sutton J, Ahmad SA, Abbott DE, Carr J, Kim HJ, Yakoub D, Idrees K, Merchant N. Adjuvant Therapy in Pancreas Cancer: Does It Influence Patterns of Recurrence? Journal of the American College of Surgeons 2016;222:448-56. [DOI: 10.1016/j.jamcollsurg.2015.12.031] [Cited by in Crossref: 27] [Cited by in F6Publishing: 18] [Article Influence: 5.4] [Reference Citation Analysis]
508 Luu AM, Belyaev O, Höhn P, Praktiknjo M, Janot M, Uhl W, Braumann C. Late recurrences of pancreatic cancer in patients with long-term survival after pancreaticoduodenectomy. J Gastrointest Oncol 2021;12:474-83. [PMID: 34012641 DOI: 10.21037/jgo-20-433] [Reference Citation Analysis]
509 Ohgi K, Yamamoto Y, Sugiura T, Okamura Y, Ito T, Ashida R, Aramaki T, Uesaka K. Is Pancreatic Head Cancer with Portal Venous Involvement Really Borderline Resectable? Appraisal of an Upfront Surgery Series. Ann Surg Oncol 2017;24:2752-61. [PMID: 28685356 DOI: 10.1245/s10434-017-5972-6] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 2.8] [Reference Citation Analysis]
510 Conway JR, Herrmann D, Evans TJ, Morton JP, Timpson P. Combating pancreatic cancer with PI3K pathway inhibitors in the era of personalised medicine. Gut 2019;68:742-58. [PMID: 30396902 DOI: 10.1136/gutjnl-2018-316822] [Cited by in Crossref: 21] [Cited by in F6Publishing: 15] [Article Influence: 7.0] [Reference Citation Analysis]
511 Sun Y, Cao S, Li Z, Liu X, Xu J, Tian Y, Shen S, Zhou Y. A novel prognostic factor TIPE2 inhibits cell proliferation and promotes apoptosis in pancreatic ductal adenocarcinoma (PDAC). Int J Med Sci 2021;18:2051-62. [PMID: 33850476 DOI: 10.7150/ijms.51497] [Reference Citation Analysis]
512 Hashimoto A, Tanaka T, Sho M, Nishiofuku H, Masada T, Sato T, Marugami N, Anai H, Sakaguchi H, Kanno M, Tamamoto T, Hasegawa M, Nakajima Y, Kichikawa K. Adjuvant Hepatic Arterial Infusion Chemotherapy After Resection for Pancreatic Cancer Using Coaxial Catheter-Port System Compared with Conventional System. Cardiovasc Intervent Radiol 2016;39:831-9. [PMID: 26762632 DOI: 10.1007/s00270-016-1292-7] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 1.2] [Reference Citation Analysis]
513 Labori KJ, Katz MH, Tzeng CW, Bjørnbeth BA, Cvancarova M, Edwin B, Kure EH, Eide TJ, Dueland S, Buanes T, Gladhaug IP. Impact of early disease progression and surgical complications on adjuvant chemotherapy completion rates and survival in patients undergoing the surgery first approach for resectable pancreatic ductal adenocarcinoma – A population-based cohort study. Acta Oncologica 2016;55:265-77. [DOI: 10.3109/0284186x.2015.1068445] [Cited by in Crossref: 67] [Cited by in F6Publishing: 26] [Article Influence: 11.2] [Reference Citation Analysis]
514 Kleeff J, Korc M, Apte M, La Vecchia C, Johnson CD, Biankin AV, Neale RE, Tempero M, Tuveson DA, Hruban RH, Neoptolemos JP. Pancreatic cancer. Nat Rev Dis Primers. 2016;2:16022. [PMID: 27158978 DOI: 10.1038/nrdp.2016.22] [Cited by in Crossref: 657] [Cited by in F6Publishing: 527] [Article Influence: 131.4] [Reference Citation Analysis]
515 Armacki M, Polaschek S, Waldenmaier M, Morawe M, Ruhland C, Schmid R, Lechel A, Tharehalli U, Steup C, Bektas Y, Li H, Kraus JM, Kestler HA, Kruger S, Ormanns S, Walther P, Eiseler T, Seufferlein T. Protein Kinase D1, Reduced in Human Pancreatic Tumors, Increases Secretion of Small Extracellular Vesicles From Cancer Cells That Promote Metastasis to Lung in Mice. Gastroenterology 2020;159:1019-1035.e22. [PMID: 32446697 DOI: 10.1053/j.gastro.2020.05.052] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 9.0] [Reference Citation Analysis]
516 Tatarian T, Jiang W, Leiby BE, Grigoli A, Jimbo M, Dabbish N, Neoptolemos JP, Greenhalf W, Costello E, Ghaneh P, Halloran C, Palmer D, Buchler M, Yeo CJ, Winter JM, Brody JR. Cytoplasmic HuR Status Predicts Disease-free Survival in Resected Pancreatic Cancer: A Post-hoc Analysis From the International Phase III ESPAC-3 Clinical Trial. Ann Surg. 2018;267:364-369. [PMID: 27893535 DOI: 10.1097/sla.0000000000002088] [Cited by in Crossref: 17] [Cited by in F6Publishing: 10] [Article Influence: 8.5] [Reference Citation Analysis]
517 Dawson DW, Fernandez-Zapico ME. Gemcitabine Activates Natural Killer Cells to Attenuate Pancreatic Cancer Recurrence. Gastroenterology 2016;151:234-7. [PMID: 27374366 DOI: 10.1053/j.gastro.2016.06.032] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
518 Bradley A, Van Der Meer R. Neoadjuvant therapy versus upfront surgery for potentially resectable pancreatic cancer: A Markov decision analysis. PLoS One 2019;14:e0212805. [PMID: 30817807 DOI: 10.1371/journal.pone.0212805] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 3.5] [Reference Citation Analysis]
519 Totti S, Vernardis SI, Meira L, Pérez-mancera PA, Costello E, Greenhalf W, Palmer D, Neoptolemos J, Mantalaris A, Velliou EG. Designing a bio-inspired biomimetic in vitro system for the optimization of ex vivo studies of pancreatic cancer. Drug Discovery Today 2017;22:690-701. [DOI: 10.1016/j.drudis.2017.01.012] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
520 Oziel-Taieb S, Faure M, Gilabert M, Autret A, Turrini O, Moureau-Zabotto L, Giovannini M, Rousseau F, Raoul JL. Treatment of Pancreatic Adenocarcinoma in Elderly Patients over 75 Years of Age: A Retrospective Series of 129 Patients. J Gastrointest Cancer 2016;47:15-9. [PMID: 26545612 DOI: 10.1007/s12029-015-9774-4] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.2] [Reference Citation Analysis]
521 Conroy T, Bachet JB, Ayav A, Huguet F, Lambert A, Caramella C, Maréchal R, Van Laethem JL, Ducreux M. Current standards and new innovative approaches for treatment of pancreatic cancer. Eur J Cancer. 2016;57:10-22. [PMID: 26851397 DOI: 10.1016/j.ejca.2015.12.026] [Cited by in Crossref: 85] [Cited by in F6Publishing: 79] [Article Influence: 17.0] [Reference Citation Analysis]
522 Nadeem SO, Jajja MR, Maxwell DW, Pouch SM, Sarmiento JM. Neoadjuvant chemotherapy for pancreatic cancer and changes in the biliary microbiome. The American Journal of Surgery 2021;222:3-7. [DOI: 10.1016/j.amjsurg.2020.09.042] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
523 Landau E, Kalnicki S. The Evolving Role of Radiation in Pancreatic Cancer. Surg Clin North Am 2018;98:113-25. [PMID: 29191268 DOI: 10.1016/j.suc.2017.09.008] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 3.5] [Reference Citation Analysis]
524 Brown JA, Zenati MS, Simmons RL, Al Abbas AI, Chopra A, Smith K, Lee KKW, Hogg ME, Zeh HJ, Paniccia A, Zureikat AH. Long-Term Surgical Complications After Pancreatoduodenectomy: Incidence, Outcomes, and Risk Factors.J Gastrointest Surg. 2020;24:1581-1589. [PMID: 32410174 DOI: 10.1007/s11605-020-04641-3] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
525 Prabhu RS, Hwang J. Adjuvant therapy in biliary tract and gall bladder carcinomas: a review. J Gastrointest Oncol 2017;8:302-13. [PMID: 28480069 DOI: 10.21037/jgo.2017.01.17] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
526 Kamarajah SK, Sonnenday CJ, Cho CS, Frankel TL, Bednar F, Lawrence TS, Nathan H. Association of Adjuvant Radiotherapy With Survival After Margin-negative Resection of Pancreatic Ductal Adenocarcinoma: A Propensity-matched National Cancer Database (NCDB) Analysis. Annals of Surgery 2021;273:587-94. [DOI: 10.1097/sla.0000000000003242] [Cited by in Crossref: 22] [Cited by in F6Publishing: 10] [Article Influence: 11.0] [Reference Citation Analysis]
527 Nehlsen AD, Goodman KA. Controversies in radiotherapy for pancreas cancer. J Surg Oncol 2021;123:1460-6. [PMID: 33831248 DOI: 10.1002/jso.26313] [Reference Citation Analysis]
528 Petrelli F, Tomasello G, Ghidini M, Lonati V, Passalacqua R, Barni S. Disease-free survival is not a surrogate endpoint for overall survival in adjuvant trials of pancreatic cancer: a systematic review of randomized trials. HPB 2017;19:944-50. [DOI: 10.1016/j.hpb.2017.07.005] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
529 Yamada M, Sugiura T, Okamura Y, Ito T, Yamamoto Y, Ashida R, Sasaki K, Nagino M, Uesaka K. Microscopic Venous Invasion in Pancreatic Cancer. Ann Surg Oncol. 2018;25:1043-1051. [PMID: 29302820 DOI: 10.1245/s10434-017-6324-2] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 3.3] [Reference Citation Analysis]
530 Kamarajah SK, Bundred JR, Alrawashdeh W, Manas D, White SA. A systematic review and network meta-analysis of phase III randomised controlled trials for adjuvant therapy following resection of pancreatic ductal adenocarcinoma (PDAC).HPB (Oxford). 2020;22:649-659. [PMID: 31894014 DOI: 10.1016/j.hpb.2019.12.001] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
531 Uwagawa T, Sakamoto T, Yasuda J, Shiozaki H, Furukawa K, Onda S, Gocho T, Shiba H, Yanaga K. Phase II Study of Adjuvant Chemotherapy With Gemcitabine and Nafamostat Mesilate for Pancreatic Cancer. Pancreas 2021;50:313-6. [PMID: 33835961 DOI: 10.1097/MPA.0000000000001767] [Reference Citation Analysis]
532 Shen P, Huang K, Zhang C, Xiao L, Zhang T. Surgery with adjuvant or neoadjuvant treatment vs surgery alone for resectable pancreatic cancer: A network meta-analysis. WJMA 2019;7:309-22. [DOI: 10.13105/wjma.v7.i6.309] [Reference Citation Analysis]
533 Endo Y, Kitago M, Aiura K, Shinoda M, Yagi H, Abe Y, Oshima G, Hori S, Nakano Y, Itano O, Fukada J, Masugi Y, Kitagawa Y. Efficacy and safety of preoperative 5-fluorouracil, cisplatin, and mitomycin C in combination with radiotherapy in patients with resectable and borderline resectable pancreatic cancer: a long-term follow-up study. World J Surg Oncol. 2019;17:145. [PMID: 31420046 DOI: 10.1186/s12957-019-1687-4] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 5.0] [Reference Citation Analysis]
534 Grunvald MW, Jacobson RA, Kuzel TM, Pappas SG, Masood A. Current Status of Circulating Tumor DNA Liquid Biopsy in Pancreatic Cancer. Int J Mol Sci. 2020;21:7651. [PMID: 33081107 DOI: 10.3390/ijms21207651] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
535 Tani M, Iida H, Maehira H, Mori H, Miyake T, Kaida S. A High C-Reactive Protein Level on Postoperative Day 7 is Associated with Poor Survival of Patients with Pancreatic Ductal Adenocarcinoma after Resection. Am Surg 2021;:31348211023406. [PMID: 34049444 DOI: 10.1177/00031348211023406] [Reference Citation Analysis]
536 Chawla A, Ferrone CR. Neoadjuvant Therapy for Resectable Pancreatic Cancer: An Evolving Paradigm Shift. Front Oncol 2019;9:1085. [PMID: 31681614 DOI: 10.3389/fonc.2019.01085] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 8.5] [Reference Citation Analysis]
537 Hidalgo M, Álvarez R, Gallego J, Guillén-Ponce C, Laquente B, Macarulla T, Muñoz A, Salgado M, Vera R, Adeva J, Alés I, Arévalo S, Blázquez J, Calsina A, Carmona A, de Madaria E, Díaz R, Díez L, Fernández T, de Paredes BG, Gallardo ME, González I, Hernando O, Jiménez P, López A, López C, López-Ríos F, Martín E, Martínez J, Martínez A, Montans J, Pazo R, Plaza JC, Peiró I, Reina JJ, Sanjuanbenito A, Yaya R, Carrato A. Consensus guidelines for diagnosis, treatment and follow-up of patients with pancreatic cancer in Spain. Clin Transl Oncol 2017;19:667-81. [PMID: 27995549 DOI: 10.1007/s12094-016-1594-x] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 3.2] [Reference Citation Analysis]
538 Berlin JD, Feng Y, Catalano P, Abbruzzese JL, Philip PA, McWilliams RR, Lowy AM, Benson AB III, Blackstock AW. An Intergroup Randomized Phase II Study of Bevacizumab or Cetuximab in Combination with Gemcitabine and in Combination with Chemoradiation in Patients with Resected Pancreatic Carcinoma: A Trial of the ECOG-ACRIN Cancer Research Group (E2204). Oncology 2018;94:39-46. [PMID: 29040974 DOI: 10.1159/000480295] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
539 Dhara S, Chhangawala S, Chintalapudi H, Askan G, Aveson V, Massa AL, Zhang L, Torres D, Makohon-Moore AP, Lecomte N, Melchor JP, Bermeo J, Cardenas A 3rd, Sinha S, Glassman D, Nicolle R, Moffitt R, Yu KH, Leppanen S, Laderman S, Curry B, Gui J, Balachandran VP, Iacobuzio-Donahue C, Chandwani R, Leslie CS, Leach SD. Pancreatic cancer prognosis is predicted by an ATAC-array technology for assessing chromatin accessibility. Nat Commun 2021;12:3044. [PMID: 34031415 DOI: 10.1038/s41467-021-23237-2] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
540 Serrano PE, Cleary SP, Dhani N, Kim PT, Greig PD, Leung K, Moulton CA, Gallinger S, Wei AC. Improved long-term outcomes after resection of pancreatic adenocarcinoma: a comparison between two time periods. Ann Surg Oncol 2015;22:1160-7. [PMID: 25348784 DOI: 10.1245/s10434-014-4196-2] [Cited by in Crossref: 42] [Cited by in F6Publishing: 35] [Article Influence: 6.0] [Reference Citation Analysis]
541 Shaib WL, Narayan AS, Switchenko JM, Kane SR, Wu C, Akce M, Alese OB, Patel PR, Maithel SK, Sarmiento JM, Kooby DA, El-Rayes BF. Role of adjuvant therapy in resected stage IA subcentimeter (T1a/T1b) pancreatic cancer. Cancer 2019;125:57-67. [PMID: 30457666 DOI: 10.1002/cncr.31787] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
542 Koh YX, Chok AY, Zheng HL, Tan CS, Goh BK. Systematic review and meta-analysis comparing the surgical outcomes of invasive intraductal papillary mucinous neoplasms and conventional pancreatic ductal adenocarcinoma. Ann Surg Oncol. 2014;21:2782-2800. [PMID: 24687151 DOI: 10.1245/s10434-014-3639-0] [Cited by in Crossref: 33] [Cited by in F6Publishing: 25] [Article Influence: 4.7] [Reference Citation Analysis]
543 Coveler AL, Rossi GR, Vahanian NN, Link C, Chiorean EG. Algenpantucel-L immunotherapy in pancreatic adenocarcinoma. Immunotherapy. 2016;8:117-125. [PMID: 26787078 DOI: 10.2217/imt.15.113] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 3.0] [Reference Citation Analysis]
544 Maegawa FB, Ashouri Y, Bartz-Kurycki M, Ahmad M, De La Rosa E, Philipovskiy A, Riall TS, Konstantinidis IT. Impact of facility type on survival after pancreatoduodenectomy for small pancreatic adenocarcinoma (≤ 2 cm). Am J Surg 2021;222:145-52. [PMID: 33131577 DOI: 10.1016/j.amjsurg.2020.10.022] [Reference Citation Analysis]
545 Picozzi VJ, Oh SY, Edwards A, Mandelson MT, Dorer R, Rocha FG, Alseidi A, Biehl T, Traverso LW, Helton WS, Kozarek RA. Five-Year Actual Overall Survival in Resected Pancreatic Cancer: A Contemporary Single-Institution Experience from a Multidisciplinary Perspective. Ann Surg Oncol 2017;24:1722-30. [PMID: 28054192 DOI: 10.1245/s10434-016-5716-z] [Cited by in Crossref: 19] [Cited by in F6Publishing: 15] [Article Influence: 4.8] [Reference Citation Analysis]
546 Orcutt ST, Coppola D, Hodul PJ. Colloid Carcinoma of the Pancreas: Case Report and Review of the Literature. Case Rep Pancreat Cancer 2016;2:40-5. [PMID: 30631814 DOI: 10.1089/crpc.2016.0006] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
547 De Dosso S, Siebenhüner AR, Winder T, Meisel A, Fritsch R, Astaras C, Szturz P, Borner M. Treatment landscape of metastatic pancreatic cancer. Cancer Treat Rev 2021;96:102180. [PMID: 33812339 DOI: 10.1016/j.ctrv.2021.102180] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
548 Wu W, Zhao L, Yu Y, Hu H, Shi H, Jia Q, Du L. Heparanase expression in blood is sensitive to monitor response to anticancer treatment in pancreatic cancer, a pilot study. Pancreatology 2018;18:100-5. [PMID: 29153700 DOI: 10.1016/j.pan.2017.11.004] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
549 Rocha FG. Landmark Series: Immunotherapy and Targeted Therapy for Pancreatic Cancer. Ann Surg Oncol 2021;28:1400-6. [PMID: 33386541 DOI: 10.1245/s10434-020-09367-9] [Reference Citation Analysis]
550 D'Angelo FA, Antolino L, La Rocca M, Petrucciani N, Magistri P, Aurello P, Ramacciato G. Adjuvant and neoadjuvant therapies in resectable pancreatic cancer: a systematic review of randomized controlled trials. Med Oncol 2016;33:28. [PMID: 26883935 DOI: 10.1007/s12032-016-0742-z] [Cited by in Crossref: 16] [Cited by in F6Publishing: 12] [Article Influence: 3.2] [Reference Citation Analysis]
551 Ge L, Pan B, Song F, Ma J, Zeraatkar D, Zhou J, Tian J. Comparing the diagnostic accuracy of five common tumour biomarkers and CA19-9 for pancreatic cancer: a protocol for a network meta-analysis of diagnostic test accuracy. BMJ Open 2017;7:e018175. [PMID: 29282264 DOI: 10.1136/bmjopen-2017-018175] [Cited by in Crossref: 19] [Cited by in F6Publishing: 8] [Article Influence: 4.8] [Reference Citation Analysis]
552 Li X, Li T, Liu Z, Gou S, Wang C. The effect of metformin on survival of patients with pancreatic cancer: a meta-analysis. Sci Rep. 2017;7:5825. [PMID: 28724893 DOI: 10.1038/s41598-017-06207-x] [Cited by in Crossref: 37] [Cited by in F6Publishing: 31] [Article Influence: 9.3] [Reference Citation Analysis]
553 Schiffman SC, Abberbock S, Winters S, Valko C, Steve J, Zureikat AH, Zeh HJ, Hogg ME. A pancreatic cancer multidisciplinary clinic: insights and outcomes. Journal of Surgical Research 2016;202:246-52. [DOI: 10.1016/j.jss.2016.01.021] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
554 Li J, Jin L, Gao Y, Gao P, Ma L, Zhu B, Yin X, Sui S, Chen S, Jiang Z, Zhu C. Low expression of tRF-Pro-CGG predicts poor prognosis in pancreatic ductal adenocarcinoma. J Clin Lab Anal 2021;35:e23742. [PMID: 33675071 DOI: 10.1002/jcla.23742] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
555 Macías N, Sayagués JM, Esteban C, Iglesias M, González LM, Quiñones-Sampedro J, Gutiérrez ML, Corchete LA, Abad MM, Bengoechea O, Muñoz-Bellvis L. Histologic Tumor Grade and Preoperative Bilary Drainage are the Unique Independent Prognostic Factors of Survival in Pancreatic Ductal Adenocarcinoma Patients After Pancreaticoduodenectomy. J Clin Gastroenterol 2018;52:e11-7. [PMID: 28059940 DOI: 10.1097/MCG.0000000000000793] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 5.0] [Reference Citation Analysis]
556 Casolino R, Braconi C, Malleo G, Paiella S, Bassi C, Milella M, Dreyer SB, Froeling FEM, Chang DK, Biankin AV, Golan T. Reshaping preoperative treatment of pancreatic cancer in the era of precision medicine. Ann Oncol 2021;32:183-96. [PMID: 33248227 DOI: 10.1016/j.annonc.2020.11.013] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 5.0] [Reference Citation Analysis]
557 Sengul Samanci N, Çelik E, Bagcilar O, Tutar O, Samanci C, Velidedeoglu M, Yassa AE, Demirci NS, Demirelli FH. Use of volumetric CT scanning to predict tumor staging and survival in pancreatic cancer patients that are to be administered curative resection. J Surg Oncol 2021;123:1757-63. [PMID: 33684252 DOI: 10.1002/jso.26455] [Reference Citation Analysis]
558 Yang SH, Lee JC, Guo JC, Kuo SH, Tien YW, Kuo TC, Cheng AL, Yeh KH. Association of MDM2 expression with shorter progression-free survival and overall survival in patients with advanced pancreatic cancer treated with gemcitabine-based chemotherapy. PLoS One 2017;12:e0180628. [PMID: 28678832 DOI: 10.1371/journal.pone.0180628] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
559 Xu D, Wang J, Liu T, Huang Z, Luo J, Chen Y, Lu Y. Quantitative definitions of pain, CA19-9, and tumor size as high-risk features of resectable pancreatic cancer: a single-center retrospective cohort study. Gland Surg 2021;10:770-9. [PMID: 33708559 DOI: 10.21037/gs-20-877] [Reference Citation Analysis]
560 Brunetti O, Russo A, Scarpa A, Santini D, Reni M, Bittoni A, Azzariti A, Aprile G, Delcuratolo S, Signorile M, Gnoni A, Palermo L, Lorusso V, Cascinu S, Silvestris N. MicroRNA in pancreatic adenocarcinoma: predictive/prognostic biomarkers or therapeutic targets? Oncotarget 2015;6:23323-41. [PMID: 26259238 DOI: 10.18632/oncotarget.4492] [Cited by in Crossref: 43] [Cited by in F6Publishing: 45] [Article Influence: 8.6] [Reference Citation Analysis]
561 Aoki T, Matsushita H, Hoshikawa M, Hasegawa K, Kokudo N, Kakimi K. Adjuvant combination therapy with gemcitabine and autologous γδ T-cell transfer in patients with curatively resected pancreatic cancer. Cytotherapy 2017;19:473-85. [PMID: 28188072 DOI: 10.1016/j.jcyt.2017.01.002] [Cited by in Crossref: 23] [Cited by in F6Publishing: 18] [Article Influence: 5.8] [Reference Citation Analysis]
562 Guseva LN. [Nitritometric determination of allacyl]. Farmatsiia. 1969;18:43-45. [PMID: 5793409 DOI: 10.1186/s13045-017-0551-7] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 0.3] [Reference Citation Analysis]
563 Zhang X, Detering L, Sultan D, Luehmann H, Li L, Heo GS, Zhang X, Lou L, Grierson PM, Greco S, Ruzinova M, Laforest R, Dehdashti F, Lim KH, Liu Y. CC Chemokine Receptor 2-Targeting Copper Nanoparticles for Positron Emission Tomography-Guided Delivery of Gemcitabine for Pancreatic Ductal Adenocarcinoma. ACS Nano 2021;15:1186-98. [PMID: 33406361 DOI: 10.1021/acsnano.0c08185] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 5.0] [Reference Citation Analysis]
564 Hicks CW, Burkhart RA, Weiss MJ, Wolfgang CL, Cameron AM, Pawlik TM. Management of Type 9 Hepatic Arterial Anatomy at the time of Pancreaticoduodenectomy: Considerations for Preservation and Reconstruction of a Completely Replaced Common Hepatic Artery. J Gastrointest Surg 2016;20:1400-4. [PMID: 27138326 DOI: 10.1007/s11605-016-3154-7] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 1.6] [Reference Citation Analysis]
565 Turner K, Levi Sandri GB, Boucher E, Hénno S, Le Prisé E, Meunier B, Boudjema K, Sulpice L. Complete radiological response of an initially locally advanced unresectable pancreatic cancer to chemoradiotherapy using FOLFIRINOX regimen: report of a case. Clin Res Hepatol Gastroenterol 2015;39:e29-31. [PMID: 25288453 DOI: 10.1016/j.clinre.2014.08.011] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
566 Zins M, Matos C, Cassinotto C. Pancreatic Adenocarcinoma Staging in the Era of Preoperative Chemotherapy and Radiation Therapy. Radiology. 2018;287:374-390. [PMID: 29668413 DOI: 10.1148/radiol.2018171670] [Cited by in Crossref: 55] [Cited by in F6Publishing: 40] [Article Influence: 18.3] [Reference Citation Analysis]
567 Liu L, Xu HX, He M, Wang W, Wang WQ, Wu CT, Wei RQ, Liang Y, Gao HL, Liu C, Xu J, Long J, Ni QX, Shao CH, Wang J, Yu XJ. A novel scoring system predicts postsurgical survival and adjuvant chemotherapeutic benefits in patients with pancreatic adenocarcinoma: Implications for AJCC-TNM staging. Surgery 2018;163:1280-94. [PMID: 29548773 DOI: 10.1016/j.surg.2018.01.017] [Cited by in Crossref: 6] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
568 Brouwer TP, Vahrmeijer AL, de Miranda NFCC. Immunotherapy for pancreatic cancer: chasing the light at the end of the tunnel. Cell Oncol (Dordr) 2021;44:261-78. [PMID: 33710604 DOI: 10.1007/s13402-021-00587-z] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
569 Coleman O, Henry M, McVey G, Clynes M, Moriarty M, Meleady P. Proteomic strategies in the search for novel pancreatic cancer biomarkers and drug targets: recent advances and clinical impact. Expert Rev Proteomics 2016;13:383-94. [PMID: 26985644 DOI: 10.1586/14789450.2016.1167601] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
570 Liu Q, Liao Q, Zhao Y. Chemotherapy and tumor microenvironment of pancreatic cancer. Cancer Cell Int 2017;17:68. [PMID: 28694739 DOI: 10.1186/s12935-017-0437-3] [Cited by in Crossref: 44] [Cited by in F6Publishing: 41] [Article Influence: 11.0] [Reference Citation Analysis]
571 Hrebinko K, Tohme S, Hoehn RS, AlMasri S, Khan S, Kaltenmeier C, Lee KK, Paniccia A, Zureikat A, Nassour I. A National Assessment of Optimal Oncologic Surgery for Distal Pancreatic Adenocarcinomas. Pancreas 2021;50:386-92. [PMID: 33835970 DOI: 10.1097/MPA.0000000000001786] [Reference Citation Analysis]
572 Atkins JJ, Fiala MA, Wang-Gillam A, Wildes TM. Racial Disparities in the Outcomes of Patients With Stage IV Pancreatic Adenocarcinoma Are Mediated by Chemotherapy Utilization. Pancreas 2016;45:e33-4. [PMID: 27400157 DOI: 10.1097/MPA.0000000000000618] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
573 Eskander MF, Bliss LA, Tseng JF. Pancreatic adenocarcinoma. Current Problems in Surgery 2016;53:107-54. [DOI: 10.1067/j.cpsurg.2016.01.001] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
574 Nussbaum DP, Adam MA, Youngwirth LM, Ganapathi AM, Roman SA, Tyler DS, Sosa JA, Blazer DG 3rd. Minimally Invasive Pancreaticoduodenectomy Does Not Improve Use or Time to Initiation of Adjuvant Chemotherapy for Patients With Pancreatic Adenocarcinoma. Ann Surg Oncol. 2016;23:1026-1033. [PMID: 26542590 DOI: 10.1245/s10434-015-4937-x] [Cited by in Crossref: 50] [Cited by in F6Publishing: 36] [Article Influence: 8.3] [Reference Citation Analysis]
575 Khurana N, Dodhiawala PB, Bulle A, Lim KH. Deciphering the Role of Innate Immune NF-ĸB Pathway in Pancreatic Cancer. Cancers (Basel) 2020;12:E2675. [PMID: 32961746 DOI: 10.3390/cancers12092675] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
576 Olecki E, Gusani N, Shen C. ASO Author Reflections: Undertreatment of Pancreatic Cancer After Resection: Don't Get Fooled by Favorable Final Pathology. Ann Surg Oncol 2021;28:1593-4. [PMID: 32860172 DOI: 10.1245/s10434-020-09079-0] [Reference Citation Analysis]
577 Bisht S, Brossart P, Feldmann G. Current Therapeutic Options for Pancreatic Ductal Adenocarcinoma. Oncol Res Treat 2018;41:590-4. [PMID: 30286472 DOI: 10.1159/000493868] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 2.7] [Reference Citation Analysis]
578 Zheng R, Wang C, Huang X, Lin Q, Huang D, Li XB, Huang H, Xu B. Chemotherapy-based split stereotactic body radiation therapy for borderline resectable and locally advanced pancreatic cancer: study protocol of a prospective, single-arm phase II trial. BMJ Open 2020;10:e039900. [PMID: 33154057 DOI: 10.1136/bmjopen-2020-039900] [Reference Citation Analysis]
579 Brunner M, Wu Z, Krautz C, Pilarsky C, Grützmann R, Weber GF. Current Clinical Strategies of Pancreatic Cancer Treatment and Open Molecular Questions. Int J Mol Sci 2019;20:E4543. [PMID: 31540286 DOI: 10.3390/ijms20184543] [Cited by in Crossref: 19] [Cited by in F6Publishing: 15] [Article Influence: 9.5] [Reference Citation Analysis]
580 Bergquist JR, Ivanics T, Shubert CR, Habermann EB, Smoot RL, Kendrick ML, Nagorney DM, Farnell MB, Truty MJ. Type of Resection (Whipple vs. Distal) Does Not Affect the National Failure to Provide Post-resection Adjuvant Chemotherapy in Localized Pancreatic Cancer. Ann Surg Oncol 2017;24:1731-8. [DOI: 10.1245/s10434-016-5762-6] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 2.8] [Reference Citation Analysis]
581 Latchana N, Davis L, Coburn NG, Mahar A, Liu Y, Hammad A, Kagedan D, Elmi M, Siddiqui M, Earle CC, Hallet J. Population-based study of the impact of surgical and adjuvant therapy at the same or a different institution on survival of patients with pancreatic adenocarcinoma. BJS Open 2019;3:85-94. [PMID: 30734019 DOI: 10.1002/bjs5.50115] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 1.3] [Reference Citation Analysis]
582 Du L, DeFoe M, Ruzinova MB, Olsen JR, Wang-Gillam A. Perioperative Therapy for Surgically Resectable Pancreatic Adenocarcinoma. Hematol Oncol Clin North Am 2015;29:717-26. [PMID: 26226906 DOI: 10.1016/j.hoc.2015.04.011] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
583 van der Geest LGM, Besselink MGH, Busch ORC, de Hingh IHJT, van Eijck CHJ, Dejong CHC, Lemmens VEPP. Elderly Patients Strongly Benefit from Centralization of Pancreatic Cancer Surgery: A Population-Based Study. Ann Surg Oncol 2016;23:2002-9. [DOI: 10.1245/s10434-016-5089-3] [Cited by in Crossref: 29] [Cited by in F6Publishing: 12] [Article Influence: 5.8] [Reference Citation Analysis]
584 Poruk KE, Blackford AL, Weiss MJ, Cameron JL, He J, Goggins M, Rasheed ZA, Wolfgang CL, Wood LD. Circulating Tumor Cells Expressing Markers of Tumor-Initiating Cells Predict Poor Survival and Cancer Recurrence in Patients with Pancreatic Ductal Adenocarcinoma. Clin Cancer Res 2017;23:2681-90. [PMID: 27789528 DOI: 10.1158/1078-0432.CCR-16-1467] [Cited by in Crossref: 47] [Cited by in F6Publishing: 35] [Article Influence: 9.4] [Reference Citation Analysis]
585 Lagies S, Schlimpert M, Braun LM, Kather M, Plagge J, Erbes T, Wittel UA, Kammerer B. Unraveling altered RNA metabolism in pancreatic cancer cells by liquid-chromatography coupling to ion mobility mass spectrometry. Anal Bioanal Chem 2019;411:6319-28. [PMID: 31037374 DOI: 10.1007/s00216-019-01814-1] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
586 Yang Y, Tian W, Yang L, Zhang Q, Zhu M, Liu Y, Li J, Yang L, Liu J, Shen Y, Qi Z. Gemcitabine potentiates anti-tumor effect of resveratrol on pancreatic cancer via down-regulation of VEGF-B. J Cancer Res Clin Oncol 2021;147:93-103. [PMID: 32897433 DOI: 10.1007/s00432-020-03384-7] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
587 Zhang Y, Xu G, Chen M, Wei Q, Zhou T, Chen Z, Shen M, Wang P. Stage IA Patients With Pancreatic Ductal Adenocarcinoma Cannot Benefit From Chemotherapy: A Propensity Score Matching Study. Front Oncol 2020;10:1018. [PMID: 32766130 DOI: 10.3389/fonc.2020.01018] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
588 Winter JM, Jiang W, Basturk O, Mino-Kenudson M, Fong ZV, Tan WP, Lavu H, Vollmer CM, Furth EE, Haviland D, Klimstra DS, Jarnagin WR, Lillemoe KD, Yeo CJ, Fernandez-Del Castillo C, Allen PJ. Recurrence and Survival After Resection of Small Intraductal Papillary Mucinous Neoplasm-associated Carcinomas (≤20-mm Invasive Component): A Multi-institutional Analysis. Ann Surg 2016;263:793-801. [PMID: 26135696 DOI: 10.1097/SLA.0000000000001319] [Cited by in Crossref: 39] [Cited by in F6Publishing: 27] [Article Influence: 7.8] [Reference Citation Analysis]
589 Mahajan UM, Goni E, Langhoff E, Li Q, Costello E, Greenhalf W, Kruger S, Ormanns S, Halloran C, Ganeh P, Marron M, Lämmerhirt F, Zhao Y, Beyer G, Weiss FU, Sendler M, Bruns CJ, Kohlmann T, Kirchner T, Werner J, D'Haese JG, von Bergwelt-Baildon M, Heinemann V, Neoptolemos JP, Büchler MW, Belka C, Boeck S, Lerch MM, Mayerle J. Cathepsin D Expression and Gemcitabine Resistance in Pancreatic Cancer. JNCI Cancer Spectr 2020;4:pkz060. [PMID: 32296755 DOI: 10.1093/jncics/pkz060] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
590 Tsai S, Erickson BA, Dua K, Ritch PS, Tolat P, Evans DB. Evolution of the Management of Resectable Pancreatic Cancer. JOP 2016;12:772-8. [DOI: 10.1200/jop.2016.015818] [Cited by in Crossref: 18] [Cited by in F6Publishing: 7] [Article Influence: 3.6] [Reference Citation Analysis]
591 Segel JE, Hollenbeak CS, Gusani NJ. Rural‐Urban Disparities in Pancreatic Cancer Stage of Diagnosis: Understanding the Interaction With Medically Underserved Areas. The Journal of Rural Health 2020;36:476-83. [DOI: 10.1111/jrh.12498] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
592 Li Y, Tian M, Zhou Y, Tan F, Liu W, Zhao L, Perez D, Song X, Wang D, Nitschke C, Pei Q, Güngör C. A novel risk-scoring system conducing to chemotherapy decision for patients with pancreatic ductal adenocarcinoma after pancreatectomy. J Cancer 2021;12:4433-42. [PMID: 34093844 DOI: 10.7150/jca.57768] [Reference Citation Analysis]
593 Winer ES, Safran H, Karaszewska B, Richards DA, Hartner L, Forget F, Ramlau R, Kumar K, Mayer B, Johnson BM, Messam CA, Mostafa Kamel Y. Eltrombopag with gemcitabine-based chemotherapy in patients with advanced solid tumors: a randomized phase I study. Cancer Med 2015;4:16-26. [PMID: 25165041 DOI: 10.1002/cam4.326] [Cited by in Crossref: 22] [Cited by in F6Publishing: 12] [Article Influence: 3.1] [Reference Citation Analysis]
594 Kim NH, Kim HJ. Preoperative risk factors for early recurrence in patients with resectable pancreatic ductal adenocarcinoma after curative intent surgical resection. Hepatobiliary Pancreat Dis Int 2018;17:450-5. [PMID: 30237091 DOI: 10.1016/j.hbpd.2018.09.003] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
595 Chen YT, Huang ZP, Zhou ZW, He MM. Equipping the American Joint Committee on Cancer staging for resectable pancreatic ductal adenocarcinoma with tumor grade: a recursive partitioning analysis. Med Oncol 2016;33:122. [PMID: 27730526 DOI: 10.1007/s12032-016-0839-4] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.6] [Reference Citation Analysis]
596 Flaum N, Hubner RA, Valle JW, Amir E, Mcnamara MG. Adjuvant chemotherapy and outcomes in patients with nodal and resection margin‐negative pancreatic ductal adenocarcinoma: A systematic review and meta‐analysis. J Surg Oncol 2019;119:932-40. [DOI: 10.1002/jso.25440] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 3.5] [Reference Citation Analysis]
597 Kokumai T, Aoki S, Mizuma M, Maeda S, Ohtsuka H, Nakagawa K, Morikawa T, Motoi F, Kamei T, Unno M. Prognostic value of an inflammation-based nutritional score for patients with initially unresectable pancreatic adenocarcinoma undergoing conversion surgery following chemo-/radiotherapy. Surg Today 2021. [PMID: 33829334 DOI: 10.1007/s00595-021-02279-5] [Reference Citation Analysis]
598 Cerullo M, Gani F, Chen SY, Canner JK, Pawlik TM. Impact of Angiotensin Receptor Blocker Use on Overall Survival Among Patients Undergoing Resection for Pancreatic Cancer. World J Surg 2017;41:2361-70. [PMID: 28429090 DOI: 10.1007/s00268-017-4021-8] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
599 Petrucciani N, Nigri G, Debs T, Giannini G, Sborlini E, Antolino L, Aurello P, D'angelo F, Gugenheim J, Ramacciato G. Frozen section analysis of the pancreatic margin during pancreaticoduodenectomy for cancer: Does extending the resection to obtain a secondary R0 provide a survival benefit? Results of a systematic review. Pancreatology 2016;16:1037-43. [DOI: 10.1016/j.pan.2016.09.004] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 3.2] [Reference Citation Analysis]
600 Nicolle R, Gayet O, Duconseil P, Vanbrugghe C, Roques J, Bigonnet M, Blum Y, Elarouci N, Armenoult L, Ayadi M, de Reyniès A, Puleo F, Augustin J, Emile J, Svrcek M, Arsenijevic T, Hammel P, Giovannini M, Grandval P, Dahan L, Moutardier V, Gilabert M, Van Laethem J, Bachet J, Cros J, Iovanna J, Dusetti N. A transcriptomic signature to predict adjuvant gemcitabine sensitivity in pancreatic adenocarcinoma. Annals of Oncology 2021;32:250-60. [DOI: 10.1016/j.annonc.2020.10.601] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 10.0] [Reference Citation Analysis]
601 Wright GP, Chesla DW, Chung MH. Using next-generation sequencing to determine potential molecularly guided therapy options for patients with resectable pancreatic adenocarcinoma. The American Journal of Surgery 2016;211:506-11. [DOI: 10.1016/j.amjsurg.2015.11.002] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
602 Li HY, Cui ZM, Chen J, Guo XZ, Li YY. Pancreatic cancer: diagnosis and treatments. Tumour Biol. 2015;36:1375-1384. [PMID: 25680410 DOI: 10.1007/s13277-015-3223-7] [Cited by in Crossref: 23] [Cited by in F6Publishing: 21] [Article Influence: 3.8] [Reference Citation Analysis]
603 Ng KYY, Chow EWX, Jiang B, Lim C, Goh BKP, Lee SY, Teo JY, Tan DMY, Cheow PC, Ooi LLPJ, Chow PKH, Lee JJX, Kam JH, Koh YX, Jeyaraj PR, Tan EK, Choo SP, Chan CY, Chung AYF, Tai D. Resected pancreatic adenocarcinoma: An Asian institution's experience. Cancer Rep (Hoboken) 2021;:e1393. [PMID: 33939335 DOI: 10.1002/cnr2.1393] [Reference Citation Analysis]
604 Weinrich M, Bochow J, Kutsch AL, Alsfasser G, Weiss C, Klar E, Rau BM. High compliance with guideline recommendations but low completion rates of adjuvant chemotherapy in resected pancreatic cancer: A cohort study. Ann Med Surg (Lond) 2018;32:32-7. [PMID: 30034801 DOI: 10.1016/j.amsu.2018.06.004] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
605 Zhu X, Li F, Liu W, Shi D, Ju X, Cao Y, Shen Y, Cao F, Qing S, Fang F, Jia Z, Zhang H. Stereotactic body radiation therapy plus induction or adjuvant chemotherapy for early stage but medically inoperable pancreatic cancer: A propensity score-matched analysis of a prospectively collected database. Cancer Manag Res 2018;10:1295-304. [PMID: 29872342 DOI: 10.2147/CMAR.S163655] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 2.3] [Reference Citation Analysis]
606 Ge JC, Tao M, Li L, Ma ZL, Jiang B, Yuan CH, Wang HY, Peng Y, Xiu DR. Nomogram and competing risk model to predict recurrence after curative surgical resection of PDAC. Pancreatology 2021:S1424-3903(21)00149-6. [PMID: 34001437 DOI: 10.1016/j.pan.2021.04.010] [Reference Citation Analysis]
607 Lupinacci RM, Bachet JB, André T, Duval A, Svrcek M. Pancreatic ductal adenocarcinoma harboring microsatellite instability / DNA mismatch repair deficiency. Towards personalized medicine. Surg Oncol 2019;28:121-7. [PMID: 30851885 DOI: 10.1016/j.suronc.2018.11.019] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
608 Pan L, Fang J, Tong C, Chen M, Zhang B, Juengpanich S, Wang Y, Cai X. Survival benefits of neoadjuvant chemo(radio)therapy versus surgery first in patients with resectable or borderline resectable pancreatic cancer: a systematic review and meta-analysis. World J Surg Oncol. 2019;18:1. [PMID: 31892339 DOI: 10.1186/s12957-019-1767-5] [Cited by in Crossref: 20] [Cited by in F6Publishing: 12] [Article Influence: 10.0] [Reference Citation Analysis]
609 Olecki EJ, Gusani NJ. ASO Author Reflection: Adjuvant Chemotherapy After Neoadjuvant Chemotherapy in Pancreatic Adenocarcinoma Does Not Lead to Improved Survival in All Patients. Ann Surg Oncol 2021;28:3123. [PMID: 33616769 DOI: 10.1245/s10434-021-09615-6] [Reference Citation Analysis]
610 Weyhe D, Obonyo D, Uslar VN, Stricker I, Tannapfel A. Predictive factors for long-term survival after surgery for pancreatic ductal adenocarcinoma: Making a case for standardized reporting of the resection margin using certified cancer center data. PLoS One 2021;16:e0248633. [PMID: 33735191 DOI: 10.1371/journal.pone.0248633] [Reference Citation Analysis]
611 de Geus SWL, Kasumova GG, Sachs TE, Ng SC, Kent TS, Moser AJ, Vahrmeijer AL, Callery MP, Tseng JF. Neoadjuvant therapy affects margins and margins affect all: perioperative and survival outcomes in resected pancreatic adenocarcinoma. HPB (Oxford) 2018;20:573-81. [PMID: 29426635 DOI: 10.1016/j.hpb.2017.12.004] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 3.7] [Reference Citation Analysis]
612 Liu C, Cheng H, Jin K, Fan Z, Gong Y, Qian Y, Deng S, Huang Q, Ni Q, Yu X, Luo G. Resected Pancreatic Cancer With N2 Node Involvement Is Refractory to Gemcitabine-Based Adjuvant Chemotherapy. Cancer Control 2020;27:1073274820915947. [PMID: 32268796 DOI: 10.1177/1073274820915947] [Reference Citation Analysis]
613 Lee K, Yoo C, Kim KP, Park KJ, Chang HM, Kim TW, Lee JL, Lee W, Lee SS, Park DH, Song TJ, Seo DW, Lee SK, Kim MH, Shin SH, Hwang DW, Song KB, Lee JH, Kim SC, Ryoo BY. Germline BRCA mutations in Asian patients with pancreatic adenocarcinoma: a prospective study evaluating risk category for genetic testing. Invest New Drugs 2018;36:163-9. [PMID: 28782087 DOI: 10.1007/s10637-017-0497-1] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
614 Wright GP, Poruk KE, Zenati MS, Steve J, Bahary N, Hogg ME, Zuriekat AH, Wolfgang CL, Zeh HJ, Weiss MJ. Primary Tumor Resection Following Favorable Response to Systemic Chemotherapy in Stage IV Pancreatic Adenocarcinoma with Synchronous Metastases: a Bi-institutional Analysis. J Gastrointest Surg. 2016;20:1830-1835. [PMID: 27604886 DOI: 10.1007/s11605-016-3256-2] [Cited by in Crossref: 35] [Cited by in F6Publishing: 26] [Article Influence: 7.0] [Reference Citation Analysis]
615 Coveler AL, Herman JM, Simeone DM, Chiorean EG. Localized Pancreatic Cancer: Multidisciplinary Management. Am Soc Clin Oncol Educ Book 2016;35:e217-26. [PMID: 27249726 DOI: 10.1200/EDBK_160827] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
616 Dhir M, Malhotra GK, Sohal DPS, Hein NA, Smith LM, O'Reilly EM, Bahary N, Are C. Neoadjuvant treatment of pancreatic adenocarcinoma: a systematic review and meta-analysis of 5520 patients. World J Surg Oncol. 2017;15:183. [PMID: 29017581 DOI: 10.1186/s12957-017-1240-2] [Cited by in Crossref: 65] [Cited by in F6Publishing: 50] [Article Influence: 16.3] [Reference Citation Analysis]
617 Saka B, Balci S, Basturk O, Bagci P, Postlewait LM, Maithel S, Knight J, El-Rayes B, Kooby D, Sarmiento J, Muraki T, Oliva I, Bandyopadhyay S, Akkas G, Goodman M, Reid MD, Krasinskas A, Everett R, Adsay V. Pancreatic Ductal Adenocarcinoma is Spread to the Peripancreatic Soft Tissue in the Majority of Resected Cases, Rendering the AJCC T-Stage Protocol (7th Edition) Inapplicable and Insignificant: A Size-Based Staging System (pT1: ≤2, pT2: >2-≤4, pT3: >4 cm) is More Valid and Clinically Relevant. Ann Surg Oncol 2016;23:2010-8. [PMID: 26832882 DOI: 10.1245/s10434-016-5093-7] [Cited by in Crossref: 69] [Cited by in F6Publishing: 52] [Article Influence: 13.8] [Reference Citation Analysis]
618 Ma N, Wang Z, Zhao J, Long J, Xu J, Ren Z, Jiang G. Improved Survival in Patients with Resected Pancreatic Carcinoma Using Postoperative Intensity-Modulated Radiotherapy and Regional Intra-Arterial Infusion Chemotherapy. Med Sci Monit 2017;23:2315-23. [PMID: 28512284 DOI: 10.12659/msm.904393] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
619 Vitellius C, Griveaux O, Morvant B, Pedrono E, Venara A, Ingster O, Baize N, Dincuff E, Rousselet MC, Guardiola P, Caroli-Bosc FX. Impact of Driver Mutations on the Evolution of Isolated Metachronous Lung Metastasis of Pancreatic Ductal adenocarcinoma. Mol Diagn Ther 2020;24:443-9. [PMID: 32524539 DOI: 10.1007/s40291-020-00472-9] [Reference Citation Analysis]
620 Kimura N, Yamada S, Takami H, Murotani K, Yoshioka I, Shibuya K, Sonohara F, Hoshino Y, Hirano K, Watanabe T, Baba H, Mori K, Miwa T, Kanda M, Hayashi M, Matsui K, Okumura T, Kodera Y, Fujii T. Optimal Preoperative Multidisciplinary Treatment in Borderline Resectable Pancreatic Cancer. Cancers (Basel) 2020;13:E36. [PMID: 33374369 DOI: 10.3390/cancers13010036] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
621 Lessing Y, Pencovich N, Nevo N, Lubezky N, Goykhman Y, Nakache R, Lahat G, Klausner JM, Nachmany I. Early reoperation following pancreaticoduodenectomy: impact on morbidity, mortality, and long-term survival. World J Surg Oncol. 2019;17:26. [PMID: 30704497 DOI: 10.1186/s12957-019-1569-9] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 5.0] [Reference Citation Analysis]
622 Meng Q, Shi S, Liang C, Liang D, Hua J, Zhang B, Xu J, Yu X. Abrogation of glutathione peroxidase-1 drives EMT and chemoresistance in pancreatic cancer by activating ROS-mediated Akt/GSK3β/Snail signaling. Oncogene 2018;37:5843-57. [DOI: 10.1038/s41388-018-0392-z] [Cited by in Crossref: 42] [Cited by in F6Publishing: 41] [Article Influence: 14.0] [Reference Citation Analysis]
623 Tassone E, Muscolini M, van Montfoort N, Hiscott J. Oncolytic virotherapy for pancreatic ductal adenocarcinoma: A glimmer of hope after years of disappointment? Cytokine Growth Factor Rev 2020;56:141-8. [PMID: 32859494 DOI: 10.1016/j.cytogfr.2020.07.015] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
624 Chiorean EG, Coveler AL. Pancreatic cancer: optimizing treatment options, new, and emerging targeted therapies. Drug Des Devel Ther. 2015;9:3529-3545. [PMID: 26185420 DOI: 10.2147/DDDT.S60328] [Cited by in Crossref: 74] [Cited by in F6Publishing: 43] [Article Influence: 12.3] [Reference Citation Analysis]
625 Perri G, Prakash L, Qiao W, Varadhachary GR, Wolff R, Fogelman D, Overman M, Pant S, Javle M, Koay EJ, Herman J, Kim M, Ikoma N, Tzeng C, Lee JE, Katz MHG. Postoperative Chemotherapy Benefits Patients Who Received Preoperative Therapy and Pancreatectomy for Pancreatic Adenocarcinoma. Annals of Surgery 2020;271:996-1002. [DOI: 10.1097/sla.0000000000003763] [Cited by in Crossref: 11] [Cited by in F6Publishing: 3] [Article Influence: 5.5] [Reference Citation Analysis]
626 Le Large TYS, El Hassouni B, Funel N, Kok B, Piersma SR, Pham TV, Olive KP, Kazemier G, van Laarhoven HWM, Jimenez CR, Bijlsma MF, Giovannetti E. Proteomic analysis of gemcitabine-resistant pancreatic cancer cells reveals that microtubule-associated protein 2 upregulation associates with taxane treatment. Ther Adv Med Oncol 2019;11:1758835919841233. [PMID: 31205498 DOI: 10.1177/1758835919841233] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 6.5] [Reference Citation Analysis]
627 Higuera O, Ghanem I, Nasimi R, Prieto I, Koren L, Feliu J. Management of pancreatic cancer in the elderly. World J Gastroenterol 2016;22:764-75. [PMID: 26811623 DOI: 10.3748/wjg.v22.i2.764] [Cited by in CrossRef: 65] [Cited by in F6Publishing: 43] [Article Influence: 16.3] [Reference Citation Analysis]
628 Golan T, Sella T, O'Reilly EM, Katz MH, Epelbaum R, Kelsen DP, Borgida A, Maynard H, Kindler H, Friedmen E, Javle M, Gallinger S. Overall survival and clinical characteristics of BRCA mutation carriers with stage I/II pancreatic cancer. Br J Cancer 2017;116:697-702. [PMID: 28183138 DOI: 10.1038/bjc.2017.19] [Cited by in Crossref: 41] [Cited by in F6Publishing: 31] [Article Influence: 10.3] [Reference Citation Analysis]
629 Striefler JK, Sinn M, Pelzer U, Jühling A, Wislocka L, Bahra M, Sinn BV, Denkert C, Dörken B, Oettle H, Riess H, Bläker H, Lohneis P. P53 overexpression and Ki67-index are associated with outcome in ductal pancreatic adenocarcinoma with adjuvant gemcitabine treatment. Pathology - Research and Practice 2016;212:726-34. [DOI: 10.1016/j.prp.2016.06.001] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 2.2] [Reference Citation Analysis]
630 Elander NO, Aughton K, Ghaneh P, Neoptolemos JP, Palmer DH, Cox TF, Campbell F, Costello E, Halloran CM, Mackey JR, Scarfe AG, Valle JW, McDonald AC, Carter R, Tebbutt NC, Goldstein D, Shannon J, Dervenis C, Glimelius B, Deakin M, Charnley RM, Anthoney A, Lerch MM, Mayerle J, Oláh A, Büchler MW, Greenhalf W; European Study Group for Pancreatic Cancer. Expression of dihydropyrimidine dehydrogenase (DPD) and hENT1 predicts survival in pancreatic cancer. Br J Cancer 2018;118:947-54. [PMID: 29515256 DOI: 10.1038/s41416-018-0004-2] [Cited by in Crossref: 20] [Cited by in F6Publishing: 16] [Article Influence: 6.7] [Reference Citation Analysis]
631 Phua LC, Goh S, Tai DWM, Leow WQ, Alkaff SMF, Chan CY, Kam JH, Lim TKH, Chan ECY. Metabolomic prediction of treatment outcome in pancreatic ductal adenocarcinoma patients receiving gemcitabine. Cancer Chemother Pharmacol 2018;81:277-89. [PMID: 29196965 DOI: 10.1007/s00280-017-3475-6] [Cited by in Crossref: 17] [Cited by in F6Publishing: 12] [Article Influence: 4.3] [Reference Citation Analysis]
632 Sohal DPS, Willingham FF, Falconi M, Raphael KL, Crippa S. Pancreatic Adenocarcinoma: Improving Prevention and Survivorship. American Society of Clinical Oncology Educational Book 2017. [DOI: 10.1200/edbk_175222] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
633 Li D, O’Reilly EM. Adjuvant and Neoadjuvant Therapy for Pancreatic Cancer. Surg Oncol Clin N Am. 2016;25:311-326. [PMID: 27013366 DOI: 10.1016/j.soc.2015.11.010] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 3.4] [Reference Citation Analysis]
634 Razi E, Radak M, Mahjoubin-Tehran M, Talebi S, Shafiee A, Hajighadimi S, Moradizarmehri S, Sharifi H, Mousavi N, Sarvizadeh M, Nejati M, Taghizadeh M, Ghasemi F. Cancer stem cells as therapeutic targets of pancreatic cancer. Fundam Clin Pharmacol 2020;34:202-12. [PMID: 31709581 DOI: 10.1111/fcp.12521] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
635 Macarulla T, Fernández T, Gallardo ME, Hernando O, López AM, Hidalgo M. Adjuvant treatment for pancreatic ductal carcinoma. Clin Transl Oncol 2017;19:1199-204. [PMID: 28639051 DOI: 10.1007/s12094-017-1683-5] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
636 Elebro J, Heby M, Gaber A, Nodin B, Jonsson L, Fristedt R, Uhlén M, Jirström K, Eberhard J. Prognostic and treatment predictive significance of SATB1 and SATB2 expression in pancreatic and periampullary adenocarcinoma. J Transl Med 2014;12:289. [PMID: 25323550 DOI: 10.1186/s12967-014-0289-8] [Cited by in Crossref: 33] [Cited by in F6Publishing: 32] [Article Influence: 4.7] [Reference Citation Analysis]
637 Seufferlein T, Porzner M, Heinemann V, Tannapfel A, Stuschke M, Uhl W. Ductal pancreatic adenocarcinoma. Dtsch Arztebl Int 2014;111:396-402. [PMID: 24980565 DOI: 10.3238/arztebl.2014.0396] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
638 Yurttas C, Horvath P, Fischer I, Meisner C, Nadalin S, Königsrainer I, Königsrainer A, Beckert S, Löffler MW. A Prospective, Phase I/II, Open-Label Pilot Trial to Assess the Safety of Hyperthermic Intraperitoneal Chemotherapy After Oncological Resection of Pancreatic Adenocarcinoma. Ann Surg Oncol 2021. [PMID: 34131821 DOI: 10.1245/s10434-021-10187-8] [Reference Citation Analysis]
639 Karamitopoulou E. The Tumor Microenvironment of Pancreatic Cancer. Cancers (Basel) 2020;12:E3076. [PMID: 33096881 DOI: 10.3390/cancers12103076] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
640 Sakamoto T, Saito H, Amisaki M, Tokuyasu N, Honjo S, Fujiwara Y. Combined preoperative platelet-to-lymphocyte ratio and serum carbohydrate antigen 19-9 level as a prognostic factor in patients with resected pancreatic cancer. Hepatobiliary Pancreat Dis Int 2019;18:278-84. [PMID: 30987900 DOI: 10.1016/j.hbpd.2019.03.010] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
641 Okano K, Suto H, Oshima M, Ando Y, Nagao M, Kamada H, Kobara H, Masaki T, Okuyama H, Okita Y, Tsuji A, Suzuki Y. 18F-fluorodeoxyglucose positron emission tomography to indicate conversion surgery in patients with initially unresectable locally advanced pancreatic cancer. Jpn J Clin Oncol 2018;48:434-41. [PMID: 29590448 DOI: 10.1093/jjco/hyy033] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
642 Abrams RA, Winter KA, Safran H, Goodman KA, Regine WF, Berger AC, Gillin MT, Philip PA, Lowy AM, Wu A, DiPetrillo TA, Corn BW, Seaward SA, Haddock MG, Song S, Jiang Y, Fisher BJ, Katz AW, Mehta S, Willett CG, Crane CH. Results of the NRG Oncology/RTOG 0848 Adjuvant Chemotherapy Question-Erlotinib+Gemcitabine for Resected Cancer of the Pancreatic Head: A Phase II Randomized Clinical Trial. Am J Clin Oncol 2020;43:173-9. [PMID: 31985516 DOI: 10.1097/COC.0000000000000633] [Cited by in Crossref: 8] [Cited by in F6Publishing: 2] [Article Influence: 8.0] [Reference Citation Analysis]
643 Kommalapati A, Tella SH, Goyal G, Ma WW, Mahipal A. Contemporary Management of Localized Resectable Pancreatic Cancer. Cancers (Basel) 2018;10:E24. [PMID: 29361690 DOI: 10.3390/cancers10010024] [Cited by in Crossref: 25] [Cited by in F6Publishing: 23] [Article Influence: 8.3] [Reference Citation Analysis]
644 Neoptolemos JP, Kleeff J, Michl P, Costello E, Greenhalf W, Palmer DH. Therapeutic developments in pancreatic cancer: current and future perspectives. Nat Rev Gastroenterol Hepatol. 2018;15:333-348. [PMID: 29717230 DOI: 10.1038/s41575-018-0005-x] [Cited by in Crossref: 295] [Cited by in F6Publishing: 241] [Article Influence: 147.5] [Reference Citation Analysis]
645 Striefler JK, Riess H, Lohneis P, Bischoff S, Kurreck A, Modest DP, Bahra M, Oettle H, Sinn M, Bläker H, Denkert C, Stintzing S, Sinn BV, Pelzer U. Mucin-1 Protein Is a Prognostic Marker for Pancreatic Ductal Adenocarcinoma: Results From the CONKO-001 Study. Front Oncol 2021;11:670396. [PMID: 34386419 DOI: 10.3389/fonc.2021.670396] [Reference Citation Analysis]
646 Kim HW, Lee J, Paik K, Kang J, Kim YH, Yoon Y, Han H, Kim J, Hwang J. Adjunctive role of preoperative liver magnetic resonance imaging for potentially resectable pancreatic cancer. Surgery 2017;161:1579-87. [DOI: 10.1016/j.surg.2016.12.038] [Cited by in Crossref: 26] [Cited by in F6Publishing: 17] [Article Influence: 6.5] [Reference Citation Analysis]
647 Huang W, Lu J, Chen KM, Wu ZY, Wang QB, Liu JJ, Gong J, Chen ZJ, Ding XY, Wang ZM. Preliminary application of 3D-printed coplanar template for iodine-125 seed implantation therapy in patients with advanced pancreatic cancer. World J Gastroenterol 2018;24:5280-7. [PMID: 30581276 DOI: 10.3748/wjg.v24.i46.5280] [Cited by in CrossRef: 7] [Cited by in F6Publishing: 6] [Article Influence: 3.5] [Reference Citation Analysis]
648 Klaiber U, Leonhardt C, Strobel O, Tjaden C, Hackert T, Neoptolemos JP. Neoadjuvant and adjuvant chemotherapy in pancreatic cancer. Langenbecks Arch Surg 2018;403:917-32. [DOI: 10.1007/s00423-018-1724-8] [Cited by in Crossref: 31] [Cited by in F6Publishing: 24] [Article Influence: 10.3] [Reference Citation Analysis]
649 Sugumar K, Hue JJ, De La Serna S, Rothermel LD, Ocuin LM, Hardacre JM, Ammori JB, Winter JM. The importance of time-to-adjuvant treatment on survival with pancreatic cancer: A systematic review and meta-analysis. Cancer Rep (Hoboken) 2021;:e1390. [PMID: 34245139 DOI: 10.1002/cnr2.1390] [Reference Citation Analysis]
650 Tchelebi L, Zaorsky N, Mackley H. Stereotactic Body Radiation Therapy in the Management of Upper GI Malignancies. Biomedicines 2018;6:E7. [PMID: 29301352 DOI: 10.3390/biomedicines6010007] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
651 Adam MA, Nassour I, Hoehn R, Hlavin CA, Bahary N, Bartlett DL, Lee KKW, Zureikat AH, Paniccia A. Neoadjuvant Chemotherapy for Pancreatic Adenocarcinoma Lessens the Deleterious Effect of Omission of Adjuvant Chemotherapy. Ann Surg Oncol 2021;28:3800-7. [PMID: 33386547 DOI: 10.1245/s10434-020-09446-x] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
652 Kurosawa J, Tawada K, Mikata R, Ishihara T, Tsuyuguchi T, Saito M, Shimofusa R, Yoshitomi H, Ohtsuka M, Miyazaki M, Yokosuka O. Prognostic relevance of apparent diffusion coefficient obtained by diffusion-weighted MRI in pancreatic cancer: Role of DW-MRI in Pancreatic Cancer. J Magn Reson Imaging 2015;42:1532-7. [DOI: 10.1002/jmri.24939] [Cited by in Crossref: 18] [Cited by in F6Publishing: 14] [Article Influence: 3.0] [Reference Citation Analysis]
653 Okusaka T, Furuse J. Recent advances in chemotherapy for pancreatic cancer: evidence from Japan and recommendations in guidelines. J Gastroenterol. 2020;55:369-382. [PMID: 31997007 DOI: 10.1007/s00535-020-01666-y] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 4.0] [Reference Citation Analysis]
654 Hagiwara Y, Ohashi Y, Uesaka K, Boku N, Fukutomi A, Okamura Y, Konishi M, Matsumoto I, Kaneoka Y, Shimizu Y, Nakamori S, Sakamoto H, Morinaga S, Kainuma O, Imai K, Sata N, Hishinuma S, Ojima H, Yamaguchi R, Hirano S, Sudo T; JASPAC 01 Study Group. Health-related quality of life of adjuvant chemotherapy with S-1 versus gemcitabine for resected pancreatic cancer: Results from a randomised phase III trial (JASPAC 01). Eur J Cancer. 2018;93:79-88. [PMID: 29477795 DOI: 10.1016/j.ejca.2018.01.081] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 2.3] [Reference Citation Analysis]
655 Lu F, Poruk KE, Weiss MJ. Surgery for oligometastasis of pancreatic cancer. Chin J Cancer Res. 2015;27:358-367. [PMID: 26361405 DOI: 10.3978/j.issn.1000-9604.2015.05.02] [Cited by in F6Publishing: 14] [Reference Citation Analysis]
656 Kainuma O, Miura F, Furukawa D, Yamamoto H, Cho A, Sano K, Nakagohri T, Asano T. Feasibility and efficacy of gemcitabine plus cisplatin combination therapy after curative resection for biliary tract cancer. J Hepatobiliary Pancreat Sci 2015;22:789-94. [PMID: 26234468 DOI: 10.1002/jhbp.283] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.5] [Reference Citation Analysis]
657 Guarneri G, Gasparini G, Crippa S, Andreasi V, Falconi M. Diagnostic strategy with a solid pancreatic mass. La Presse Médicale 2019;48:e125-45. [DOI: 10.1016/j.lpm.2019.02.026] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 2.5] [Reference Citation Analysis]
658 Kordes M, Yu J, Malgerud O, Gustafsson Liljefors M, Löhr J-. Survival Benefits of Chemotherapy for Patients with Advanced Pancreatic Cancer in A Clinical Real-World Cohort. Cancers (Basel) 2019;11:E1326. [PMID: 31500236 DOI: 10.3390/cancers11091326] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
659 Marsh Rde W, Talamonti MS, Katz MH, Herman JM. Pancreatic cancer and FOLFIRINOX: a new era and new questions. Cancer Med 2015;4:853-63. [PMID: 25693729 DOI: 10.1002/cam4.433] [Cited by in Crossref: 29] [Cited by in F6Publishing: 26] [Article Influence: 4.8] [Reference Citation Analysis]
660 Hoshikawa M, Aoki T, Matsushita H, Karasaki T, Hosoi A, Odaira K, Fujieda N, Kobayashi Y, Kambara K, Ohara O, Arita J, Hasegawa K, Kakimi K, Kokudo N. NK cell and IFN signatures are positive prognostic biomarkers for resectable pancreatic cancer. Biochem Biophys Res Commun. 2018;495:2058-2065. [PMID: 29253566 DOI: 10.1016/j.bbrc.2017.12.083] [Cited by in Crossref: 16] [Cited by in F6Publishing: 11] [Article Influence: 4.0] [Reference Citation Analysis]
661 Palmer DH, Valle JW, Ma YT, Faluyi O, Neoptolemos JP, Jensen Gjertsen T, Iversen B, Amund Eriksen J, Møller AS, Aksnes AK, Miller R, Dueland S. TG01/GM-CSF and adjuvant gemcitabine in patients with resected RAS-mutant adenocarcinoma of the pancreas (CT TG01-01): a single-arm, phase 1/2 trial. Br J Cancer 2020;122:971-7. [PMID: 32063605 DOI: 10.1038/s41416-020-0752-7] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 9.0] [Reference Citation Analysis]
662 Macarulla T, Hendifar AE, Li CP, Reni M, Riess H, Tempero MA, Dueck AC, Botteman MF, Deshpande CG, Lucas EJ, Oh DY. Landscape of Health-Related Quality of Life in Patients With Early-Stage Pancreatic Cancer Receiving Adjuvant or Neoadjuvant Chemotherapy: A Systematic Literature Review. Pancreas 2020;49:393-407. [PMID: 32132518 DOI: 10.1097/MPA.0000000000001507] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 5.0] [Reference Citation Analysis]
663 Lee H, Heo JS, Choi SH, Choi DW. Extended versus peripancreatic lymph node dissection for the treatment of left-sided pancreatic cancer. Ann Surg Treat Res 2017;92:411-8. [PMID: 28580345 DOI: 10.4174/astr.2017.92.6.411] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.8] [Reference Citation Analysis]
664 Neuzillet C, Tijeras-Raballand A, Bourget P, Cros J, Couvelard A, Sauvanet A, Vullierme MP, Tournigand C, Hammel P. State of the art and future directions of pancreatic ductal adenocarcinoma therapy. Pharmacol Ther. 2015;155:80-104. [PMID: 26299994 DOI: 10.1016/j.pharmthera.2015.08.006] [Cited by in Crossref: 58] [Cited by in F6Publishing: 52] [Article Influence: 9.7] [Reference Citation Analysis]
665 Radi I, Samaha R, El Hajj J, Samaha H, Kourie HR. Perioperative chemotherapy with modified FOLFIRINOX for nonmetastatic pancreatic cancer: a new standard of care? Future Oncol 2021;17:229-33. [PMID: 33305614 DOI: 10.2217/fon-2020-0836] [Reference Citation Analysis]
666 Rose JB, Rocha FG, Alseidi A, Biehl T, Moonka R, Ryan JA, Lin B, Picozzi V, Helton S. Extended neoadjuvant chemotherapy for borderline resectable pancreatic cancer demonstrates pro